<html><head><meta content="text/html; charset=UTF-8" http-equiv="content-type"><style type="text/css">@import url('https://themes.googleusercontent.com/fonts/css?kit=fpjTOVmNbO4Lz34iLyptLcWpXo_CmM6erK5IinBZ-8N8u45WU12y72TEk3aAZtZE');.lst-kix_2qvefga6tw9t-5>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-5}.lst-kix_amnxd0o32wxe-4>li:before{content:"-  "}.lst-kix_amnxd0o32wxe-8>li:before{content:"-  "}ol.lst-kix_stodkckubncd-5.start{counter-reset:lst-ctn-kix_stodkckubncd-5 0}.lst-kix_9kz8bq8q3b2i-3>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-3}.lst-kix_5f9t9fms2d21-0>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-0,decimal) ". "}.lst-kix_amnxd0o32wxe-2>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-0.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-0 0}.lst-kix_5f9t9fms2d21-2>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-2,lower-roman) ". "}.lst-kix_km6c63ta0u1m-5>li:before{content:"\0025a0  "}ol.lst-kix_qgxhqyjzp80f-1.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-1 0}.lst-kix_5f9t9fms2d21-6>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-6,decimal) ". "}.lst-kix_6hpp8uicfxco-7>li:before{content:"-  "}.lst-kix_km6c63ta0u1m-1>li:before{content:"\0025cb  "}.lst-kix_km6c63ta0u1m-3>li:before{content:"\0025cf  "}.lst-kix_5f9t9fms2d21-4>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-4,lower-latin) ". "}ol.lst-kix_73zznxkq85l2-5.start{counter-reset:lst-ctn-kix_73zznxkq85l2-5 0}.lst-kix_amnxd0o32wxe-6>li:before{content:"-  "}ol.lst-kix_bz3wxvkk86wr-4.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-4 0}.lst-kix_6hpp8uicfxco-3>li:before{content:"-  "}.lst-kix_6hpp8uicfxco-5>li:before{content:"-  "}ol.lst-kix_bz3wxvkk86wr-6{list-style-type:none}ol.lst-kix_m0nrdnud90zq-1.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-1 0}ol.lst-kix_bz3wxvkk86wr-7{list-style-type:none}.lst-kix_6hpp8uicfxco-1>li:before{content:"-  "}ol.lst-kix_bz3wxvkk86wr-4{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-5{list-style-type:none}.lst-kix_5f9t9fms2d21-8>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-8,lower-roman) ". "}ol.lst-kix_bz3wxvkk86wr-8{list-style-type:none}ol.lst-kix_stodkckubncd-0.start{counter-reset:lst-ctn-kix_stodkckubncd-0 0}.lst-kix_km6c63ta0u1m-7>li:before{content:"\0025cb  "}ol.lst-kix_bz3wxvkk86wr-2{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-3{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-0{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-1{list-style-type:none}.lst-kix_h8i9ymdmzkx8-3>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-3}.lst-kix_stodkckubncd-2>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-2,lower-roman) ". "}.lst-kix_stodkckubncd-0>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-0,decimal) ". "}.lst-kix_stodkckubncd-4>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-4,lower-latin) ". "}ol.lst-kix_yhp6v7of3e00-5.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-5 0}ol.lst-kix_qgxhqyjzp80f-6.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-6 0}ol.lst-kix_m0nrdnud90zq-6.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-6 0}ol.lst-kix_yfnaf4f33kdr-6.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-6 0}ol.lst-kix_73zznxkq85l2-0.start{counter-reset:lst-ctn-kix_73zznxkq85l2-0 0}.lst-kix_8eggh954z6m1-6>li:before{content:"-  "}ol.lst-kix_69woh12i7ucg-8.start{counter-reset:lst-ctn-kix_69woh12i7ucg-8 0}.lst-kix_8eggh954z6m1-2>li:before{content:"-  "}.lst-kix_8eggh954z6m1-0>li:before{content:"-  "}.lst-kix_8eggh954z6m1-8>li:before{content:"-  "}.lst-kix_m09drfn41lbc-8>li:before{content:"\0025a0  "}.lst-kix_m09drfn41lbc-6>li:before{content:"\0025cf  "}.lst-kix_stodkckubncd-8>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-8,lower-roman) ". "}.lst-kix_stodkckubncd-6>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-6,decimal) ". "}.lst-kix_8eggh954z6m1-4>li:before{content:"-  "}.lst-kix_m09drfn41lbc-4>li:before{content:"\0025cb  "}ul.lst-kix_oj0ws47jaz7a-2{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-3{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-0{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-1{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-6{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-7{list-style-type:none}ul.lst-kix_oj0ws47jaz7a-4{list-style-type:none}ol.lst-kix_fh553kxqh3vv-4.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-4 0}ul.lst-kix_oj0ws47jaz7a-5{list-style-type:none}ol.lst-kix_2qvefga6tw9t-8{list-style-type:none}ol.lst-kix_2qvefga6tw9t-7{list-style-type:none}ol.lst-kix_2qvefga6tw9t-6{list-style-type:none}ol.lst-kix_2qvefga6tw9t-5{list-style-type:none}ol.lst-kix_b0ja666m9l9x-6.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-6 0}ol.lst-kix_5f9t9fms2d21-1{list-style-type:none}ol.lst-kix_5f9t9fms2d21-2{list-style-type:none}ol.lst-kix_5f9t9fms2d21-0{list-style-type:none}ol.lst-kix_5f9t9fms2d21-5{list-style-type:none}ol.lst-kix_5f9t9fms2d21-6{list-style-type:none}ol.lst-kix_5f9t9fms2d21-3{list-style-type:none}ol.lst-kix_5f9t9fms2d21-4{list-style-type:none}ol.lst-kix_2qvefga6tw9t-0{list-style-type:none}ul.lst-kix_bh4xapke1dje-3{list-style-type:none}ul.lst-kix_bh4xapke1dje-2{list-style-type:none}ul.lst-kix_bh4xapke1dje-1{list-style-type:none}ol.lst-kix_5f9t9fms2d21-7{list-style-type:none}.lst-kix_73zznxkq85l2-3>li{counter-increment:lst-ctn-kix_73zznxkq85l2-3}ul.lst-kix_bh4xapke1dje-0{list-style-type:none}ol.lst-kix_5f9t9fms2d21-8{list-style-type:none}ol.lst-kix_2qvefga6tw9t-4{list-style-type:none}ul.lst-kix_bh4xapke1dje-7{list-style-type:none}ol.lst-kix_2qvefga6tw9t-3{list-style-type:none}ul.lst-kix_bh4xapke1dje-6{list-style-type:none}ol.lst-kix_69woh12i7ucg-3.start{counter-reset:lst-ctn-kix_69woh12i7ucg-3 0}ol.lst-kix_2qvefga6tw9t-2{list-style-type:none}ul.lst-kix_bh4xapke1dje-5{list-style-type:none}ol.lst-kix_2qvefga6tw9t-1{list-style-type:none}ul.lst-kix_bh4xapke1dje-4{list-style-type:none}.lst-kix_h8i9ymdmzkx8-0>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-0,decimal) ". "}ul.lst-kix_bh4xapke1dje-8{list-style-type:none}ol.lst-kix_seg2qxi99oen-0.start{counter-reset:lst-ctn-kix_seg2qxi99oen-0 0}.lst-kix_stodkckubncd-5>li{counter-increment:lst-ctn-kix_stodkckubncd-5}ul.lst-kix_7hpd7l1orcn5-2{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-1{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-4{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-3{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-6{list-style-type:none}ol.lst-kix_uf4umlhhckq2-7.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-7 0}ul.lst-kix_7hpd7l1orcn5-5{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-8{list-style-type:none}ul.lst-kix_7hpd7l1orcn5-7{list-style-type:none}.lst-kix_ujrictqeu2kx-3>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-3,decimal) ". "}.lst-kix_ujrictqeu2kx-1>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-1,lower-latin) ". "}ul.lst-kix_7hpd7l1orcn5-0{list-style-type:none}ul.lst-kix_efg97u94j8hb-4{list-style-type:none}ul.lst-kix_efg97u94j8hb-3{list-style-type:none}ul.lst-kix_efg97u94j8hb-2{list-style-type:none}ul.lst-kix_efg97u94j8hb-1{list-style-type:none}ul.lst-kix_efg97u94j8hb-0{list-style-type:none}ul.lst-kix_efg97u94j8hb-8{list-style-type:none}ul.lst-kix_efg97u94j8hb-7{list-style-type:none}ul.lst-kix_efg97u94j8hb-6{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-0{list-style-type:none}.lst-kix_bh4xapke1dje-3>li:before{content:"\0025cf  "}ul.lst-kix_efg97u94j8hb-5{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-2{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-1{list-style-type:none}.lst-kix_ujrictqeu2kx-5>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-5,lower-roman) ". "}ul.lst-kix_p0rhwsmbgd7c-4{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-3{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-6{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-5{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-8{list-style-type:none}ul.lst-kix_p0rhwsmbgd7c-7{list-style-type:none}.lst-kix_seg2qxi99oen-3>li{counter-increment:lst-ctn-kix_seg2qxi99oen-3}.lst-kix_q7k3qhhwoyo7-1>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-1}.lst-kix_m0nrdnud90zq-6>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-6}.lst-kix_jrq3pc6b7fs5-8>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-8}.lst-kix_fh553kxqh3vv-1>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-1}ol.lst-kix_h8i9ymdmzkx8-4.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-4 0}.lst-kix_bh4xapke1dje-7>li:before{content:"\0025cb  "}.lst-kix_h8i9ymdmzkx8-2>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-2,lower-roman) ". "}.lst-kix_q7k3qhhwoyo7-8>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-8}.lst-kix_h8i9ymdmzkx8-6>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-6,decimal) ". "}ol.lst-kix_2qvefga6tw9t-7.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-7 0}.lst-kix_b7uuq29jz54a-0>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-0,decimal) ". "}.lst-kix_xgq4y4xln1s-4>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-4,lower-latin) ". "}ol.lst-kix_vkx5887x6ome-8.start{counter-reset:lst-ctn-kix_vkx5887x6ome-8 0}.lst-kix_xgq4y4xln1s-0>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-0,decimal) ". "}.lst-kix_fh553kxqh3vv-3>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-3}.lst-kix_jrq3pc6b7fs5-6>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-6,decimal) ". "}.lst-kix_bz3wxvkk86wr-8>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-8}.lst-kix_b0ja666m9l9x-5>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-5}.lst-kix_jrq3pc6b7fs5-3>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-3}.lst-kix_d9wep1z810b6-8>li{counter-increment:lst-ctn-kix_d9wep1z810b6-8}ol.lst-kix_xgq4y4xln1s-3.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-3 0}.lst-kix_jrq3pc6b7fs5-2>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-2,lower-roman) ". "}ul.lst-kix_33s9mn975cqx-7{list-style-type:none}ul.lst-kix_33s9mn975cqx-8{list-style-type:none}.lst-kix_73zznxkq85l2-8>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-8,lower-roman) ". "}.lst-kix_m09drfn41lbc-0>li:before{content:"\0025cf  "}.lst-kix_yhp6v7of3e00-2>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-2,lower-roman) ". "}ol.lst-kix_76cwqgc9ntcg-0.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-0 0}.lst-kix_mzqsrs9zicmn-4>li:before{content:"\0025cb  "}.lst-kix_33s9mn975cqx-6>li:before{content:"\0025cf  "}.lst-kix_yhp6v7of3e00-6>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-6,decimal) ". "}ol.lst-kix_2qvefga6tw9t-2.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-2 0}.lst-kix_yfnaf4f33kdr-6>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-6}ol.lst-kix_d9wep1z810b6-4{list-style-type:none}ol.lst-kix_d9wep1z810b6-5{list-style-type:none}ol.lst-kix_d9wep1z810b6-2{list-style-type:none}.lst-kix_73zti2swi0ua-3>li:before{content:"\0025cf  "}ol.lst-kix_d9wep1z810b6-3{list-style-type:none}ol.lst-kix_d9wep1z810b6-8{list-style-type:none}ol.lst-kix_d9wep1z810b6-6{list-style-type:none}ol.lst-kix_d9wep1z810b6-7{list-style-type:none}ol.lst-kix_b7uuq29jz54a-5.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-5 0}.lst-kix_uf4umlhhckq2-6>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-6}.lst-kix_xgq4y4xln1s-8>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-8,lower-roman) ". "}ol.lst-kix_b0ja666m9l9x-1.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-1 0}ol.lst-kix_9kz8bq8q3b2i-0.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-0 0}.lst-kix_gv17x2lsey8i-8>li:before{content:"\0025a0  "}.lst-kix_gv17x2lsey8i-0>li:before{content:"\0025cf  "}.lst-kix_1jqtmxt015qr-7>li:before{content:"-  "}ol.lst-kix_xgq4y4xln1s-8.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-8 0}.lst-kix_33s9mn975cqx-2>li:before{content:"\0025a0  "}.lst-kix_mzqsrs9zicmn-0>li:before{content:"\0025cf  "}ul.lst-kix_33s9mn975cqx-1{list-style-type:none}.lst-kix_1jqtmxt015qr-3>li:before{content:"-  "}ul.lst-kix_33s9mn975cqx-2{list-style-type:none}.lst-kix_73zti2swi0ua-7>li:before{content:"\0025cb  "}ul.lst-kix_33s9mn975cqx-0{list-style-type:none}ol.lst-kix_d9wep1z810b6-0{list-style-type:none}ul.lst-kix_33s9mn975cqx-5{list-style-type:none}ol.lst-kix_d9wep1z810b6-1{list-style-type:none}ul.lst-kix_33s9mn975cqx-6{list-style-type:none}ul.lst-kix_33s9mn975cqx-3{list-style-type:none}ul.lst-kix_33s9mn975cqx-4{list-style-type:none}.lst-kix_gv17x2lsey8i-4>li:before{content:"\0025cb  "}.lst-kix_jrq3pc6b7fs5-1>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-1}ol.lst-kix_vkx5887x6ome-7{list-style-type:none}ol.lst-kix_vkx5887x6ome-8{list-style-type:none}ol.lst-kix_vkx5887x6ome-5{list-style-type:none}ol.lst-kix_vkx5887x6ome-6{list-style-type:none}ol.lst-kix_vkx5887x6ome-3{list-style-type:none}ol.lst-kix_vkx5887x6ome-4{list-style-type:none}.lst-kix_qgxhqyjzp80f-3>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-3}ol.lst-kix_2qvefga6tw9t-4.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-4 0}.lst-kix_m0nrdnud90zq-8>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-8}.lst-kix_fh553kxqh3vv-8>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-8}.lst-kix_vfpim5mnet5b-5>li:before{content:"\0025a0  "}.lst-kix_bz3wxvkk86wr-1>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-1}ol.lst-kix_76cwqgc9ntcg-3.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-3 0}ol.lst-kix_5f9t9fms2d21-2.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-2 0}.lst-kix_mzqsrs9zicmn-8>li:before{content:"\0025a0  "}ol.lst-kix_b7uuq29jz54a-7.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-7 0}ol.lst-kix_xgq4y4xln1s-6.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-6 0}.lst-kix_amnxd0o32wxe-0>li:before{content:"-  "}ol.lst-kix_q7k3qhhwoyo7-6.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-6 0}ul.lst-kix_8eggh954z6m1-2{list-style-type:none}.lst-kix_vfpim5mnet5b-1>li:before{content:"\0025cb  "}ul.lst-kix_8eggh954z6m1-3{list-style-type:none}ul.lst-kix_8eggh954z6m1-0{list-style-type:none}ul.lst-kix_8eggh954z6m1-1{list-style-type:none}ul.lst-kix_8eggh954z6m1-6{list-style-type:none}ul.lst-kix_8eggh954z6m1-7{list-style-type:none}ul.lst-kix_8eggh954z6m1-4{list-style-type:none}ul.lst-kix_8eggh954z6m1-5{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-1{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-2{list-style-type:none}ul.lst-kix_8eggh954z6m1-8{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-0{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-5{list-style-type:none}.lst-kix_wt16kx5082x6-3>li:before{content:"\0025cf  "}ul.lst-kix_8hc53kjy1j5y-6{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-3{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-4{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-7{list-style-type:none}ul.lst-kix_8hc53kjy1j5y-8{list-style-type:none}.lst-kix_cmax3c5l3b9l-4>li:before{content:"\0025cb  "}.lst-kix_6zkl42mjxb9i-7>li:before{content:"\0025cb  "}ol.lst-kix_puq7slv7ersb-3.start{counter-reset:lst-ctn-kix_puq7slv7ersb-3 0}.lst-kix_h8i9ymdmzkx8-5>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-5}.lst-kix_73zznxkq85l2-8>li{counter-increment:lst-ctn-kix_73zznxkq85l2-8}.lst-kix_b0ja666m9l9x-0>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-0}ul.lst-kix_kn39yucmriut-8{list-style-type:none}ul.lst-kix_kn39yucmriut-7{list-style-type:none}ul.lst-kix_kn39yucmriut-6{list-style-type:none}ul.lst-kix_kn39yucmriut-5{list-style-type:none}.lst-kix_nm3lwvrsfgs8-2>li:before{content:"\0025a0  "}.lst-kix_gnt2wo6vinpb-5>li:before{content:"-  "}ul.lst-kix_kn39yucmriut-4{list-style-type:none}ul.lst-kix_kn39yucmriut-3{list-style-type:none}.lst-kix_2qvefga6tw9t-7>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-7}ul.lst-kix_kn39yucmriut-2{list-style-type:none}ul.lst-kix_kn39yucmriut-1{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-8.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-8 0}ul.lst-kix_kn39yucmriut-0{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-1.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-1 0}.lst-kix_gvdnkwhuv0x-7>li:before{content:"\0025cb  "}.lst-kix_nm3lwvrsfgs8-4>li:before{content:"\0025cb  "}ol.lst-kix_jrq3pc6b7fs5-2.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-2 0}.lst-kix_gvdnkwhuv0x-5>li:before{content:"\0025a0  "}.lst-kix_cmax3c5l3b9l-6>li:before{content:"\0025cf  "}ol.lst-kix_q7k3qhhwoyo7-8.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-8 0}.lst-kix_6zkl42mjxb9i-1>li:before{content:"\0025cb  "}ol.lst-kix_9kz8bq8q3b2i-7.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-7 0}.lst-kix_gnt2wo6vinpb-7>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-1>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-1,lower-latin) ". "}.lst-kix_y8nzqr1vapa0-3>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-3,decimal) ". "}.lst-kix_yfnaf4f33kdr-1>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-1,lower-latin) ". "}.lst-kix_yfnaf4f33kdr-8>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-8}.lst-kix_yhp6v7of3e00-4>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-4}.lst-kix_bz3wxvkk86wr-4>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-4,lower-latin) ". "}.lst-kix_yfnaf4f33kdr-3>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-3,decimal) ". "}ol.lst-kix_puq7slv7ersb-8.start{counter-reset:lst-ctn-kix_puq7slv7ersb-8 0}.lst-kix_m0nrdnud90zq-1>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-1}.lst-kix_2qvefga6tw9t-3>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-3}.lst-kix_bz3wxvkk86wr-6>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-6,decimal) ". "}ol.lst-kix_76cwqgc9ntcg-5.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-5 0}ol.lst-kix_9kz8bq8q3b2i-2.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-2 0}.lst-kix_h8i9ymdmzkx8-1>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-1}.lst-kix_kn39yucmriut-7>li:before{content:"-  "}.lst-kix_73zznxkq85l2-1>li{counter-increment:lst-ctn-kix_73zznxkq85l2-1}ol.lst-kix_jrq3pc6b7fs5-7.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-7 0}ol.lst-kix_5f9t9fms2d21-4.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-4 0}.lst-kix_n9l39mx24y7l-7>li:before{content:"\0025cb  "}.lst-kix_73zznxkq85l2-2>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-2,lower-roman) ". "}.lst-kix_73zznxkq85l2-4>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-4,lower-latin) ". "}.lst-kix_wt16kx5082x6-5>li:before{content:"\0025a0  "}.lst-kix_n9l39mx24y7l-5>li:before{content:"\0025a0  "}.lst-kix_kn39yucmriut-1>li:before{content:"-  "}.lst-kix_uf4umlhhckq2-4>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-4}.lst-kix_9kz8bq8q3b2i-2>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-2,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-3>li:before{content:"-  "}.lst-kix_p0rhwsmbgd7c-5>li:before{content:"-  "}.lst-kix_2qvefga6tw9t-8>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-8,lower-roman) ". "}.lst-kix_vkx5887x6ome-6>li{counter-increment:lst-ctn-kix_vkx5887x6ome-6}.lst-kix_9kz8bq8q3b2i-4>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-4,lower-latin) ". "}.lst-kix_76cwqgc9ntcg-0>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-0,decimal) ". "}.lst-kix_76cwqgc9ntcg-8>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-8,lower-roman) ". "}ol.lst-kix_9kz8bq8q3b2i-5.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-5 0}.lst-kix_2qvefga6tw9t-6>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-6,decimal) ". "}ol.lst-kix_y8nzqr1vapa0-6.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-6 0}.lst-kix_nyooapufejer-0>li:before{content:"-  "}.lst-kix_b0ja666m9l9x-7>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-7}ol.lst-kix_5f9t9fms2d21-7.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-7 0}.lst-kix_y8nzqr1vapa0-7>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-7}.lst-kix_yhp6v7of3e00-8>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-8}.lst-kix_4h5ayc5t6q0q-4>li:before{content:"\0025cb  "}ol.lst-kix_76cwqgc9ntcg-8.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-8 0}.lst-kix_2qvefga6tw9t-0>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-0,decimal) ". "}.lst-kix_4h5ayc5t6q0q-6>li:before{content:"\0025cf  "}.lst-kix_b7uuq29jz54a-4>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-4,lower-latin) ". "}.lst-kix_b7uuq29jz54a-6>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-6,decimal) ". "}.lst-kix_s1e4p75lcpk8-3>li:before{content:"\0025cf  "}.lst-kix_d9wep1z810b6-1>li{counter-increment:lst-ctn-kix_d9wep1z810b6-1}.lst-kix_s1e4p75lcpk8-1>li:before{content:"\0025cb  "}.lst-kix_q7k3qhhwoyo7-6>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-6}ol.lst-kix_ks1i5lssvjkg-1.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-1 0}.lst-kix_h8i9ymdmzkx8-8>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-8}ol.lst-kix_ks1i5lssvjkg-3.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-3 0}.lst-kix_xgq4y4xln1s-4>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-4}.lst-kix_7hpd7l1orcn5-4>li:before{content:"-  "}.lst-kix_nyooapufejer-8>li:before{content:"-  "}.lst-kix_7hpd7l1orcn5-6>li:before{content:"-  "}.lst-kix_76cwqgc9ntcg-6>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-6,decimal) ". "}.lst-kix_nyooapufejer-6>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-4.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-4 0}.lst-kix_oj0ws47jaz7a-2>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-8.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-8 0}.lst-kix_r1qxtw4k9pgo-1>li:before{content:"-  "}.lst-kix_xgq4y4xln1s-8>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-8}.lst-kix_yhp6v7of3e00-1>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-1}ol.lst-kix_puq7slv7ersb-0.start{counter-reset:lst-ctn-kix_puq7slv7ersb-0 0}.lst-kix_ujrictqeu2kx-7>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-7,lower-latin) ". "}.lst-kix_m0nrdnud90zq-4>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-4}ol.lst-kix_73zznxkq85l2-8{list-style-type:none}.lst-kix_y8nzqr1vapa0-0>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-0}.lst-kix_8hc53kjy1j5y-2>li:before{content:"-  "}.lst-kix_puq7slv7ersb-0>li{counter-increment:lst-ctn-kix_puq7slv7ersb-0}.lst-kix_ujrictqeu2kx-8>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-8}.lst-kix_bh4xapke1dje-5>li:before{content:"\0025a0  "}ol.lst-kix_73zznxkq85l2-1{list-style-type:none}ol.lst-kix_73zznxkq85l2-0{list-style-type:none}.lst-kix_69woh12i7ucg-3>li{counter-increment:lst-ctn-kix_69woh12i7ucg-3}.lst-kix_b7uuq29jz54a-6>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-6}ol.lst-kix_73zznxkq85l2-3{list-style-type:none}ol.lst-kix_73zznxkq85l2-2{list-style-type:none}ol.lst-kix_73zznxkq85l2-5{list-style-type:none}ol.lst-kix_73zznxkq85l2-4{list-style-type:none}.lst-kix_seg2qxi99oen-0>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-0,decimal) ". "}.lst-kix_76cwqgc9ntcg-1>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-1}ol.lst-kix_73zznxkq85l2-7{list-style-type:none}ol.lst-kix_73zznxkq85l2-6{list-style-type:none}.lst-kix_efg97u94j8hb-4>li:before{content:"-  "}.lst-kix_uf4umlhhckq2-6>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-6,decimal) ". "}.lst-kix_6l3u48hb8och-1>li:before{content:"-  "}ol.lst-kix_y8nzqr1vapa0-4.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-4 0}.lst-kix_puq7slv7ersb-7>li{counter-increment:lst-ctn-kix_puq7slv7ersb-7}.lst-kix_jrq3pc6b7fs5-8>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-8,lower-roman) ". "}.lst-kix_h8i9ymdmzkx8-8>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-8,lower-roman) ". "}.lst-kix_seg2qxi99oen-8>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-8,lower-roman) ". "}.lst-kix_xgq4y4xln1s-2>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-2,lower-roman) ". "}.lst-kix_jrq3pc6b7fs5-0>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-0,decimal) ". "}.lst-kix_ujrictqeu2kx-1>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-1}.lst-kix_5f9t9fms2d21-8>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-8}.lst-kix_76cwqgc9ntcg-8>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-8}ol.lst-kix_ks1i5lssvjkg-6.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-6 0}ul.lst-kix_oj0ws47jaz7a-8{list-style-type:none}.lst-kix_vkx5887x6ome-4>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-4,lower-latin) ". "}ol.lst-kix_yfnaf4f33kdr-1.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-1 0}.lst-kix_1jqtmxt015qr-1>li:before{content:"-  "}.lst-kix_fh553kxqh3vv-5>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-5,lower-roman) ". "}.lst-kix_2qvefga6tw9t-0>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-0}ol.lst-kix_yfnaf4f33kdr-4.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-4 0}.lst-kix_yhp6v7of3e00-4>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-4,lower-latin) ". "}.lst-kix_rjzoughkzvzw-1>li:before{content:"\0025cb  "}.lst-kix_33s9mn975cqx-8>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-4>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-4,lower-latin) ". "}.lst-kix_gv17x2lsey8i-6>li:before{content:"\0025cf  "}.lst-kix_a6itagplhb2w-4>li:before{content:"\0025cb  "}.lst-kix_c9w8l0v8vj60-1>li:before{content:"-  "}.lst-kix_mzqsrs9zicmn-2>li:before{content:"\0025a0  "}.lst-kix_5f9t9fms2d21-1>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-1}.lst-kix_s078hly7oqfy-7>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-8.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-8 0}.lst-kix_73zti2swi0ua-5>li:before{content:"\0025a0  "}.lst-kix_33s9mn975cqx-0>li:before{content:"\0025cf  "}ul.lst-kix_vfpim5mnet5b-0{list-style-type:none}ul.lst-kix_vfpim5mnet5b-1{list-style-type:none}ol.lst-kix_puq7slv7ersb-5.start{counter-reset:lst-ctn-kix_puq7slv7ersb-5 0}ul.lst-kix_vfpim5mnet5b-2{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-3.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-3 0}.lst-kix_vfpim5mnet5b-3>li:before{content:"\0025cf  "}.lst-kix_d9wep1z810b6-4>li{counter-increment:lst-ctn-kix_d9wep1z810b6-4}.lst-kix_m0nrdnud90zq-4>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-4,lower-latin) ". "}.lst-kix_q7k3qhhwoyo7-5>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-5,lower-roman) ". "}ul.lst-kix_vfpim5mnet5b-3{list-style-type:none}ul.lst-kix_vfpim5mnet5b-4{list-style-type:none}ul.lst-kix_vfpim5mnet5b-5{list-style-type:none}.lst-kix_73zznxkq85l2-5>li{counter-increment:lst-ctn-kix_73zznxkq85l2-5}ul.lst-kix_vfpim5mnet5b-6{list-style-type:none}ul.lst-kix_vfpim5mnet5b-7{list-style-type:none}ul.lst-kix_vfpim5mnet5b-8{list-style-type:none}.lst-kix_xgq4y4xln1s-1>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-1}.lst-kix_seg2qxi99oen-7>li{counter-increment:lst-ctn-kix_seg2qxi99oen-7}ol.lst-kix_y8nzqr1vapa0-1.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-1 0}.lst-kix_ks1i5lssvjkg-5>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-5}.lst-kix_vkx5887x6ome-3>li{counter-increment:lst-ctn-kix_vkx5887x6ome-3}ol.lst-kix_jrq3pc6b7fs5-4.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-4 0}.lst-kix_puq7slv7ersb-4>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-4,lower-latin) ". "}.lst-kix_uf4umlhhckq2-2>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-2}ol.lst-kix_d9wep1z810b6-6.start{counter-reset:lst-ctn-kix_d9wep1z810b6-6 0}ol.lst-kix_y8nzqr1vapa0-2.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-2 0}.lst-kix_qgxhqyjzp80f-6>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-6}.lst-kix_m0nrdnud90zq-3>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-3}.lst-kix_yhp6v7of3e00-2>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-2}ol.lst-kix_fh553kxqh3vv-2.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-2 0}.lst-kix_73zznxkq85l2-6>li{counter-increment:lst-ctn-kix_73zznxkq85l2-6}ol.lst-kix_h8i9ymdmzkx8-7.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-7 0}.lst-kix_ks1i5lssvjkg-6>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-6,decimal) ". "}.lst-kix_ks1i5lssvjkg-2>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-2,lower-roman) ". "}.lst-kix_ks1i5lssvjkg-3>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-3,decimal) ". "}.lst-kix_b0ja666m9l9x-7>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-7,lower-latin) ". "}.lst-kix_b0ja666m9l9x-8>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-8,lower-roman) ". "}.lst-kix_d9wep1z810b6-1>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-1,lower-latin) ". "}.lst-kix_d9wep1z810b6-3>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-3,decimal) ". "}.lst-kix_d9wep1z810b6-0>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-0,decimal) ". "}.lst-kix_d9wep1z810b6-4>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-4,lower-latin) ". "}.lst-kix_ks1i5lssvjkg-0>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-0,decimal) ". "}.lst-kix_vkx5887x6ome-4>li{counter-increment:lst-ctn-kix_vkx5887x6ome-4}.lst-kix_b0ja666m9l9x-1>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-1,lower-latin) ". "}.lst-kix_69woh12i7ucg-1>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-1,lower-latin) ". "}.lst-kix_d9wep1z810b6-7>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-7,lower-latin) ". "}.lst-kix_h8i9ymdmzkx8-7>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-7}ol.lst-kix_69woh12i7ucg-1.start{counter-reset:lst-ctn-kix_69woh12i7ucg-1 0}.lst-kix_zyb4ozncdg-0>li:before{content:"\0025cf  "}ol.lst-kix_fh553kxqh3vv-7.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-7 0}.lst-kix_zyb4ozncdg-1>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-4>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-4,lower-latin) ". "}.lst-kix_69woh12i7ucg-5>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-5,lower-roman) ". "}ol.lst-kix_puq7slv7ersb-2.start{counter-reset:lst-ctn-kix_puq7slv7ersb-2 0}.lst-kix_bz3wxvkk86wr-5>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-5}.lst-kix_zyb4ozncdg-3>li:before{content:"\0025cf  "}.lst-kix_zyb4ozncdg-7>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-8>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-8,lower-roman) ". "}.lst-kix_b0ja666m9l9x-4>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-4,lower-latin) ". "}.lst-kix_zyb4ozncdg-4>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-7>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-7,lower-latin) ". "}.lst-kix_b0ja666m9l9x-5>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-5,lower-roman) ". "}.lst-kix_ujrictqeu2kx-3>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-3}.lst-kix_vkx5887x6ome-3>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-3,decimal) ". "}.lst-kix_fh553kxqh3vv-4>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-4,lower-latin) ". "}ol.lst-kix_ks1i5lssvjkg-4.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-4 0}.lst-kix_qaijc6nbpdk4-2>li:before{content:"-  "}.lst-kix_qaijc6nbpdk4-6>li:before{content:"-  "}.lst-kix_fh553kxqh3vv-5>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-5}.lst-kix_a6itagplhb2w-7>li:before{content:"\0025cb  "}ol.lst-kix_yhp6v7of3e00-8{list-style-type:none}.lst-kix_qaijc6nbpdk4-8>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-4{list-style-type:none}.lst-kix_s078hly7oqfy-2>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-5{list-style-type:none}ol.lst-kix_yhp6v7of3e00-6{list-style-type:none}ol.lst-kix_yhp6v7of3e00-7{list-style-type:none}.lst-kix_yfnaf4f33kdr-3>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-3}.lst-kix_u7vldufjcii4-6>li:before{content:"\0025cf  "}ol.lst-kix_yhp6v7of3e00-0{list-style-type:none}.lst-kix_s078hly7oqfy-4>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-1{list-style-type:none}ol.lst-kix_yhp6v7of3e00-2{list-style-type:none}ol.lst-kix_yhp6v7of3e00-3{list-style-type:none}.lst-kix_jrq3pc6b7fs5-5>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-5}.lst-kix_69woh12i7ucg-6>li{counter-increment:lst-ctn-kix_69woh12i7ucg-6}.lst-kix_a6itagplhb2w-3>li:before{content:"\0025cf  "}.lst-kix_s078hly7oqfy-8>li:before{content:"-  "}.lst-kix_u7vldufjcii4-4>li:before{content:"\0025cb  "}.lst-kix_b7uuq29jz54a-3>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-3}.lst-kix_vkx5887x6ome-7>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-7,lower-latin) ". "}.lst-kix_5f9t9fms2d21-4>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-4}ol.lst-kix_69woh12i7ucg-6.start{counter-reset:lst-ctn-kix_69woh12i7ucg-6 0}.lst-kix_ks1i5lssvjkg-1>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-1}.lst-kix_76cwqgc9ntcg-4>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-4}.lst-kix_2qvefga6tw9t-8>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-8}.lst-kix_2qvefga6tw9t-2>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-2}ol.lst-kix_d9wep1z810b6-1.start{counter-reset:lst-ctn-kix_d9wep1z810b6-1 0}.lst-kix_q7k3qhhwoyo7-8>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-8,lower-roman) ". "}ol.lst-kix_ujrictqeu2kx-0.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-0 0}.lst-kix_u7vldufjcii4-0>li:before{content:"\0025cf  "}.lst-kix_q7k3qhhwoyo7-4>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-4,lower-latin) ". "}ol.lst-kix_fh553kxqh3vv-7{list-style-type:none}ol.lst-kix_fh553kxqh3vv-8{list-style-type:none}ol.lst-kix_fh553kxqh3vv-5{list-style-type:none}ol.lst-kix_fh553kxqh3vv-6{list-style-type:none}.lst-kix_puq7slv7ersb-5>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-5,lower-roman) ". "}ol.lst-kix_fh553kxqh3vv-3{list-style-type:none}ol.lst-kix_fh553kxqh3vv-4{list-style-type:none}ol.lst-kix_fh553kxqh3vv-1{list-style-type:none}ol.lst-kix_fh553kxqh3vv-2{list-style-type:none}ol.lst-kix_fh553kxqh3vv-0{list-style-type:none}.lst-kix_puq7slv7ersb-1>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-1,lower-latin) ". "}.lst-kix_fh553kxqh3vv-8>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-8,lower-roman) ". "}ol.lst-kix_y8nzqr1vapa0-7.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-7 0}ul.lst-kix_6l3u48hb8och-2{list-style-type:none}ul.lst-kix_6l3u48hb8och-1{list-style-type:none}ul.lst-kix_6l3u48hb8och-0{list-style-type:none}ul.lst-kix_6l3u48hb8och-6{list-style-type:none}ul.lst-kix_6l3u48hb8och-5{list-style-type:none}ul.lst-kix_6l3u48hb8och-4{list-style-type:none}ul.lst-kix_6l3u48hb8och-3{list-style-type:none}.lst-kix_oj0ws47jaz7a-3>li:before{content:"-  "}ul.lst-kix_6l3u48hb8och-8{list-style-type:none}ul.lst-kix_6l3u48hb8och-7{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-7.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-7 0}ol.lst-kix_ks1i5lssvjkg-0.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-0 0}.lst-kix_b0ja666m9l9x-1>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-1}.lst-kix_8hc53kjy1j5y-8>li:before{content:"-  "}.lst-kix_b0ja666m9l9x-3>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-3}.lst-kix_8hc53kjy1j5y-4>li:before{content:"-  "}ul.lst-kix_s078hly7oqfy-0{list-style-type:none}ul.lst-kix_s078hly7oqfy-1{list-style-type:none}ul.lst-kix_s078hly7oqfy-2{list-style-type:none}.lst-kix_8hc53kjy1j5y-1>li:before{content:"-  "}.lst-kix_8hc53kjy1j5y-5>li:before{content:"-  "}ul.lst-kix_s078hly7oqfy-3{list-style-type:none}.lst-kix_bz3wxvkk86wr-6>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-6}ul.lst-kix_s078hly7oqfy-4{list-style-type:none}ul.lst-kix_s078hly7oqfy-5{list-style-type:none}ul.lst-kix_s078hly7oqfy-6{list-style-type:none}ul.lst-kix_s078hly7oqfy-7{list-style-type:none}ul.lst-kix_s078hly7oqfy-8{list-style-type:none}ol.lst-kix_5f9t9fms2d21-0.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-0 0}ol.lst-kix_2qvefga6tw9t-0.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-0 0}ol.lst-kix_2qvefga6tw9t-6.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-6 0}.lst-kix_r1qxtw4k9pgo-2>li:before{content:"-  "}ol.lst-kix_5f9t9fms2d21-6.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-6 0}ol.lst-kix_76cwqgc9ntcg-1.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-1 0}.lst-kix_uf4umlhhckq2-4>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-4,lower-latin) ". "}.lst-kix_efg97u94j8hb-2>li:before{content:"-  "}.lst-kix_efg97u94j8hb-1>li:before{content:"-  "}.lst-kix_efg97u94j8hb-5>li:before{content:"-  "}ul.lst-kix_s1e4p75lcpk8-0{list-style-type:none}.lst-kix_seg2qxi99oen-1>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-1,lower-latin) ". "}ul.lst-kix_s1e4p75lcpk8-1{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-2{list-style-type:none}ol.lst-kix_fh553kxqh3vv-6.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-6 0}ul.lst-kix_s1e4p75lcpk8-3{list-style-type:none}.lst-kix_uf4umlhhckq2-0>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-0,decimal) ". "}ul.lst-kix_s1e4p75lcpk8-4{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-5{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-6{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-7{list-style-type:none}ul.lst-kix_s1e4p75lcpk8-8{list-style-type:none}.lst-kix_uf4umlhhckq2-1>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-1,lower-latin) ". "}ol.lst-kix_5f9t9fms2d21-5.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-5 0}.lst-kix_6l3u48hb8och-8>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-7{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-6{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-8{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-3{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-2{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-5{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-4{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-1{list-style-type:none}ol.lst-kix_yfnaf4f33kdr-0{list-style-type:none}.lst-kix_76cwqgc9ntcg-5>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-5}ol.lst-kix_2qvefga6tw9t-1.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-1 0}ol.lst-kix_76cwqgc9ntcg-6.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-6 0}.lst-kix_qgxhqyjzp80f-5>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-5}.lst-kix_qaijc6nbpdk4-5>li:before{content:"-  "}.lst-kix_vkx5887x6ome-6>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-6,decimal) ". "}.lst-kix_69woh12i7ucg-7>li{counter-increment:lst-ctn-kix_69woh12i7ucg-7}.lst-kix_fh553kxqh3vv-7>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-7,lower-latin) ". "}.lst-kix_q7k3qhhwoyo7-5>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-5}ul.lst-kix_rjzoughkzvzw-2{list-style-type:none}ul.lst-kix_rjzoughkzvzw-3{list-style-type:none}ul.lst-kix_rjzoughkzvzw-4{list-style-type:none}.lst-kix_nyooapufejer-1>li:before{content:"-  "}ul.lst-kix_rjzoughkzvzw-5{list-style-type:none}ul.lst-kix_rjzoughkzvzw-0{list-style-type:none}.lst-kix_a6itagplhb2w-6>li:before{content:"\0025cf  "}ul.lst-kix_rjzoughkzvzw-1{list-style-type:none}.lst-kix_s078hly7oqfy-1>li:before{content:"-  "}.lst-kix_s078hly7oqfy-5>li:before{content:"-  "}.lst-kix_qgxhqyjzp80f-2>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-2,lower-roman) ". "}.lst-kix_u7vldufjcii4-7>li:before{content:"\0025cb  "}.lst-kix_c9w8l0v8vj60-3>li:before{content:"-  "}.lst-kix_2qvefga6tw9t-1>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-1,lower-latin) ". "}ul.lst-kix_mzqsrs9zicmn-4{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-3{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-2{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-1{list-style-type:none}ul.lst-kix_rjzoughkzvzw-6{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-0{list-style-type:none}ul.lst-kix_rjzoughkzvzw-7{list-style-type:none}ul.lst-kix_rjzoughkzvzw-8{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-2{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-3{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-0{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-1{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-8{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-7{list-style-type:none}.lst-kix_seg2qxi99oen-8>li{counter-increment:lst-ctn-kix_seg2qxi99oen-8}.lst-kix_u7vldufjcii4-3>li:before{content:"\0025cf  "}ul.lst-kix_mzqsrs9zicmn-6{list-style-type:none}ul.lst-kix_mzqsrs9zicmn-5{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-8{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-6{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-7{list-style-type:none}.lst-kix_puq7slv7ersb-3>li{counter-increment:lst-ctn-kix_puq7slv7ersb-3}ul.lst-kix_qaijc6nbpdk4-4{list-style-type:none}ul.lst-kix_qaijc6nbpdk4-5{list-style-type:none}.lst-kix_xgq4y4xln1s-0>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-0}ol.lst-kix_5f9t9fms2d21-1.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-1 0}.lst-kix_q7k3qhhwoyo7-7>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-7,lower-latin) ". "}.lst-kix_m0nrdnud90zq-2>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-2,lower-roman) ". "}ol.lst-kix_76cwqgc9ntcg-2.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-2 0}ol.lst-kix_h8i9ymdmzkx8-2.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-2 0}.lst-kix_q7k3qhhwoyo7-3>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-3}.lst-kix_b7uuq29jz54a-5>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-5}.lst-kix_9kz8bq8q3b2i-0>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-0}.lst-kix_stodkckubncd-1>li{counter-increment:lst-ctn-kix_stodkckubncd-1}ol.lst-kix_ujrictqeu2kx-2{list-style-type:none}ol.lst-kix_ujrictqeu2kx-3{list-style-type:none}ol.lst-kix_ujrictqeu2kx-0{list-style-type:none}ol.lst-kix_ujrictqeu2kx-1{list-style-type:none}ol.lst-kix_ujrictqeu2kx-6{list-style-type:none}ol.lst-kix_ujrictqeu2kx-7{list-style-type:none}ol.lst-kix_ujrictqeu2kx-4{list-style-type:none}ol.lst-kix_ujrictqeu2kx-5{list-style-type:none}ol.lst-kix_ujrictqeu2kx-8{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-5{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-4{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-3{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-3.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-3 0}ul.lst-kix_c9w8l0v8vj60-2{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-1{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-0{list-style-type:none}.lst-kix_c9w8l0v8vj60-7>li:before{content:"-  "}ol.lst-kix_2qvefga6tw9t-5.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-5 0}ol.lst-kix_qgxhqyjzp80f-8{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-7{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-4{list-style-type:none}.lst-kix_oj0ws47jaz7a-0>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-3{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-6{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-5{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-0{list-style-type:none}.lst-kix_puq7slv7ersb-2>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-2,lower-roman) ". "}ol.lst-kix_qgxhqyjzp80f-2{list-style-type:none}ol.lst-kix_qgxhqyjzp80f-1{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-8{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-7{list-style-type:none}ul.lst-kix_c9w8l0v8vj60-6{list-style-type:none}ol.lst-kix_69woh12i7ucg-7.start{counter-reset:lst-ctn-kix_69woh12i7ucg-7 0}.lst-kix_wt16kx5082x6-2>li:before{content:"\0025a0  "}.lst-kix_cmax3c5l3b9l-5>li:before{content:"\0025a0  "}.lst-kix_6zkl42mjxb9i-8>li:before{content:"\0025a0  "}.lst-kix_cmax3c5l3b9l-2>li:before{content:"\0025a0  "}.lst-kix_gnt2wo6vinpb-4>li:before{content:"-  "}.lst-kix_gnt2wo6vinpb-1>li:before{content:"-  "}.lst-kix_nm3lwvrsfgs8-3>li:before{content:"\0025cf  "}.lst-kix_bz3wxvkk86wr-3>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-3}.lst-kix_seg2qxi99oen-2>li{counter-increment:lst-ctn-kix_seg2qxi99oen-2}ol.lst-kix_fh553kxqh3vv-8.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-8 0}.lst-kix_gvdnkwhuv0x-6>li:before{content:"\0025cf  "}.lst-kix_6zkl42mjxb9i-5>li:before{content:"\0025a0  "}.lst-kix_yfnaf4f33kdr-5>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-5,lower-roman) ". "}.lst-kix_cmax3c5l3b9l-8>li:before{content:"\0025a0  "}.lst-kix_gvdnkwhuv0x-3>li:before{content:"\0025cf  "}.lst-kix_nm3lwvrsfgs8-0>li:before{content:"\0025cf  "}.lst-kix_6zkl42mjxb9i-2>li:before{content:"\0025a0  "}.lst-kix_bz3wxvkk86wr-2>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-2,lower-roman) ". "}.lst-kix_y8nzqr1vapa0-2>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-2,lower-roman) ". "}.lst-kix_bz3wxvkk86wr-5>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-5,lower-roman) ". "}.lst-kix_y8nzqr1vapa0-5>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-5,lower-roman) ". "}.lst-kix_yfnaf4f33kdr-2>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-2,lower-roman) ". "}.lst-kix_69woh12i7ucg-4>li{counter-increment:lst-ctn-kix_69woh12i7ucg-4}ol.lst-kix_h8i9ymdmzkx8-6.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-6 0}.lst-kix_y8nzqr1vapa0-8>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-8,lower-roman) ". "}.lst-kix_nm3lwvrsfgs8-6>li:before{content:"\0025cf  "}ol.lst-kix_ujrictqeu2kx-4.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-4 0}ol.lst-kix_69woh12i7ucg-2.start{counter-reset:lst-ctn-kix_69woh12i7ucg-2 0}.lst-kix_bz3wxvkk86wr-8>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-8,lower-roman) ". "}.lst-kix_n9l39mx24y7l-1>li:before{content:"\0025cb  "}.lst-kix_kn39yucmriut-8>li:before{content:"-  "}.lst-kix_9kz8bq8q3b2i-5>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-5}.lst-kix_76cwqgc9ntcg-2>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-2}.lst-kix_kn39yucmriut-5>li:before{content:"-  "}.lst-kix_73zznxkq85l2-3>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-3,decimal) ". "}.lst-kix_qgxhqyjzp80f-8>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-8}.lst-kix_73zznxkq85l2-6>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-6,decimal) ". "}.lst-kix_n9l39mx24y7l-4>li:before{content:"\0025cb  "}.lst-kix_kn39yucmriut-2>li:before{content:"-  "}.lst-kix_p0rhwsmbgd7c-1>li:before{content:"-  "}.lst-kix_d9wep1z810b6-5>li{counter-increment:lst-ctn-kix_d9wep1z810b6-5}.lst-kix_qgxhqyjzp80f-0>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-0}ol.lst-kix_ujrictqeu2kx-2.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-2 0}.lst-kix_76cwqgc9ntcg-2>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-2,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-7>li:before{content:"-  "}.lst-kix_uf4umlhhckq2-8>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-8}.lst-kix_rjzoughkzvzw-2>li:before{content:"\0025a0  "}.lst-kix_2qvefga6tw9t-4>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-4,lower-latin) ". "}.lst-kix_1jqtmxt015qr-8>li:before{content:"-  "}.lst-kix_73zznxkq85l2-0>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-0,decimal) ". "}.lst-kix_5f9t9fms2d21-2>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-2}ol.lst-kix_h8i9ymdmzkx8-8.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-8 0}ol.lst-kix_fh553kxqh3vv-1.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-1 0}.lst-kix_yhp6v7of3e00-5>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-5,lower-roman) ". "}.lst-kix_gv17x2lsey8i-5>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-5>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-5,lower-roman) ". "}.lst-kix_b7uuq29jz54a-2>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-2,lower-roman) ". "}.lst-kix_c9w8l0v8vj60-0>li:before{content:"-  "}.lst-kix_mzqsrs9zicmn-3>li:before{content:"\0025cf  "}.lst-kix_4h5ayc5t6q0q-0>li:before{content:"\0025cf  "}.lst-kix_9kz8bq8q3b2i-8>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-8,lower-roman) ". "}ol.lst-kix_d9wep1z810b6-2.start{counter-reset:lst-ctn-kix_d9wep1z810b6-2 0}.lst-kix_s1e4p75lcpk8-5>li:before{content:"\0025a0  "}.lst-kix_xgq4y4xln1s-3>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-3}.lst-kix_1jqtmxt015qr-2>li:before{content:"-  "}.lst-kix_b7uuq29jz54a-8>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-8,lower-roman) ". "}ol.lst-kix_69woh12i7ucg-5.start{counter-reset:lst-ctn-kix_69woh12i7ucg-5 0}.lst-kix_m0nrdnud90zq-5>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-5,lower-roman) ". "}.lst-kix_7hpd7l1orcn5-2>li:before{content:"-  "}ol.lst-kix_d9wep1z810b6-0.start{counter-reset:lst-ctn-kix_d9wep1z810b6-0 0}ol.lst-kix_fh553kxqh3vv-3.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-3 0}ol.lst-kix_69woh12i7ucg-4.start{counter-reset:lst-ctn-kix_69woh12i7ucg-4 0}.lst-kix_nyooapufejer-4>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-2>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-2}.lst-kix_7hpd7l1orcn5-8>li:before{content:"-  "}.lst-kix_rjzoughkzvzw-8>li:before{content:"\0025a0  "}.lst-kix_oj0ws47jaz7a-6>li:before{content:"-  "}.lst-kix_ks1i5lssvjkg-7>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-7}.lst-kix_b7uuq29jz54a-8>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-8}.lst-kix_vkx5887x6ome-1>li{counter-increment:lst-ctn-kix_vkx5887x6ome-1}.lst-kix_69woh12i7ucg-1>li{counter-increment:lst-ctn-kix_69woh12i7ucg-1}ol.lst-kix_d9wep1z810b6-3.start{counter-reset:lst-ctn-kix_d9wep1z810b6-3 0}.lst-kix_ujrictqeu2kx-8>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-8,lower-roman) ". "}ol.lst-kix_ujrictqeu2kx-1.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-1 0}.lst-kix_r1qxtw4k9pgo-8>li:before{content:"-  "}.lst-kix_seg2qxi99oen-5>li{counter-increment:lst-ctn-kix_seg2qxi99oen-5}.lst-kix_yfnaf4f33kdr-0>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-0}.lst-kix_stodkckubncd-7>li{counter-increment:lst-ctn-kix_stodkckubncd-7}.lst-kix_bh4xapke1dje-6>li:before{content:"\0025cf  "}.lst-kix_r1qxtw4k9pgo-5>li:before{content:"-  "}.lst-kix_xgq4y4xln1s-6>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-6}.lst-kix_uf4umlhhckq2-7>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-7,lower-latin) ". "}.lst-kix_seg2qxi99oen-4>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-4,lower-latin) ". "}.lst-kix_6l3u48hb8och-2>li:before{content:"-  "}ol.lst-kix_puq7slv7ersb-0{list-style-type:none}.lst-kix_h8i9ymdmzkx8-4>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-4,lower-latin) ". "}ol.lst-kix_puq7slv7ersb-1{list-style-type:none}.lst-kix_6l3u48hb8och-5>li:before{content:"-  "}.lst-kix_jrq3pc6b7fs5-7>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-7,lower-latin) ". "}ol.lst-kix_puq7slv7ersb-2{list-style-type:none}ol.lst-kix_puq7slv7ersb-3{list-style-type:none}ol.lst-kix_puq7slv7ersb-4{list-style-type:none}ol.lst-kix_puq7slv7ersb-5{list-style-type:none}.lst-kix_seg2qxi99oen-7>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-7,lower-latin) ". "}.lst-kix_efg97u94j8hb-8>li:before{content:"-  "}.lst-kix_xgq4y4xln1s-6>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-6,decimal) ". "}.lst-kix_xgq4y4xln1s-3>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-3,decimal) ". "}ul.lst-kix_cmax3c5l3b9l-8{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-7{list-style-type:none}.lst-kix_d9wep1z810b6-2>li{counter-increment:lst-ctn-kix_d9wep1z810b6-2}ol.lst-kix_puq7slv7ersb-6{list-style-type:none}ol.lst-kix_puq7slv7ersb-7{list-style-type:none}ol.lst-kix_puq7slv7ersb-8{list-style-type:none}.lst-kix_9kz8bq8q3b2i-8>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-8}.lst-kix_jrq3pc6b7fs5-4>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-4,lower-latin) ". "}ul.lst-kix_cmax3c5l3b9l-0{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-2{list-style-type:none}ol.lst-kix_d9wep1z810b6-4.start{counter-reset:lst-ctn-kix_d9wep1z810b6-4 0}ul.lst-kix_cmax3c5l3b9l-1{list-style-type:none}ol.lst-kix_fh553kxqh3vv-0.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-0 1}ul.lst-kix_cmax3c5l3b9l-4{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-3{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-6{list-style-type:none}ul.lst-kix_cmax3c5l3b9l-5{list-style-type:none}ol.lst-kix_69woh12i7ucg-0.start{counter-reset:lst-ctn-kix_69woh12i7ucg-0 0}.lst-kix_fh553kxqh3vv-1>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-1,lower-latin) ". "}.lst-kix_yhp6v7of3e00-8>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-8,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-4>li:before{content:"-  "}ol.lst-kix_ujrictqeu2kx-5.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-5 0}.lst-kix_33s9mn975cqx-4>li:before{content:"\0025cb  "}.lst-kix_2qvefga6tw9t-7>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-7,lower-latin) ". "}.lst-kix_vkx5887x6ome-0>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-0,decimal) ". "}ul.lst-kix_6zkl42mjxb9i-7{list-style-type:none}ul.lst-kix_6zkl42mjxb9i-8{list-style-type:none}.lst-kix_mzqsrs9zicmn-6>li:before{content:"\0025cf  "}ul.lst-kix_6zkl42mjxb9i-0{list-style-type:none}.lst-kix_73zti2swi0ua-1>li:before{content:"\0025cb  "}ul.lst-kix_6zkl42mjxb9i-1{list-style-type:none}ol.lst-kix_d9wep1z810b6-5.start{counter-reset:lst-ctn-kix_d9wep1z810b6-5 0}ul.lst-kix_6zkl42mjxb9i-2{list-style-type:none}ol.lst-kix_ujrictqeu2kx-8.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-8 0}ul.lst-kix_6zkl42mjxb9i-3{list-style-type:none}ul.lst-kix_6zkl42mjxb9i-4{list-style-type:none}ul.lst-kix_6zkl42mjxb9i-5{list-style-type:none}.lst-kix_gv17x2lsey8i-2>li:before{content:"\0025a0  "}ul.lst-kix_6zkl42mjxb9i-6{list-style-type:none}.lst-kix_qgxhqyjzp80f-8>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-8,lower-roman) ". "}.lst-kix_bz3wxvkk86wr-0>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-0}.lst-kix_jrq3pc6b7fs5-2>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-2}.lst-kix_s1e4p75lcpk8-2>li:before{content:"\0025a0  "}.lst-kix_1jqtmxt015qr-5>li:before{content:"-  "}.lst-kix_b7uuq29jz54a-5>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-5,lower-roman) ". "}.lst-kix_h8i9ymdmzkx8-1>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-1,lower-latin) ". "}.lst-kix_73zznxkq85l2-0>li{counter-increment:lst-ctn-kix_73zznxkq85l2-0}.lst-kix_a6itagplhb2w-0>li:before{content:"\0025cf  "}.lst-kix_uf4umlhhckq2-5>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-5}.lst-kix_ujrictqeu2kx-6>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-6}ol.lst-kix_ujrictqeu2kx-7.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-7 0}.lst-kix_fh553kxqh3vv-2>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-2}.lst-kix_vfpim5mnet5b-7>li:before{content:"\0025cb  "}.lst-kix_q7k3qhhwoyo7-1>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-1,lower-latin) ". "}.lst-kix_m0nrdnud90zq-8>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-8,lower-roman) ". "}ol.lst-kix_d9wep1z810b6-8.start{counter-reset:lst-ctn-kix_d9wep1z810b6-8 0}ul.lst-kix_n9l39mx24y7l-7{list-style-type:none}ul.lst-kix_n9l39mx24y7l-8{list-style-type:none}ul.lst-kix_n9l39mx24y7l-3{list-style-type:none}ul.lst-kix_n9l39mx24y7l-4{list-style-type:none}.lst-kix_puq7slv7ersb-8>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-8,lower-roman) ". "}ul.lst-kix_n9l39mx24y7l-5{list-style-type:none}ul.lst-kix_n9l39mx24y7l-6{list-style-type:none}ul.lst-kix_n9l39mx24y7l-0{list-style-type:none}ul.lst-kix_n9l39mx24y7l-1{list-style-type:none}ul.lst-kix_n9l39mx24y7l-2{list-style-type:none}ol.lst-kix_ujrictqeu2kx-6.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-6 0}.lst-kix_7hpd7l1orcn5-5>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-5>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-5}.lst-kix_rjzoughkzvzw-5>li:before{content:"\0025a0  "}ol.lst-kix_d9wep1z810b6-7.start{counter-reset:lst-ctn-kix_d9wep1z810b6-7 0}.lst-kix_nyooapufejer-7>li:before{content:"-  "}ul.lst-kix_amnxd0o32wxe-1{list-style-type:none}ul.lst-kix_amnxd0o32wxe-2{list-style-type:none}ul.lst-kix_amnxd0o32wxe-3{list-style-type:none}.lst-kix_amnxd0o32wxe-3>li:before{content:"-  "}ul.lst-kix_amnxd0o32wxe-4{list-style-type:none}.lst-kix_amnxd0o32wxe-5>li:before{content:"-  "}ol.lst-kix_jrq3pc6b7fs5-8.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-8 0}ol.lst-kix_5f9t9fms2d21-3.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-3 0}ul.lst-kix_amnxd0o32wxe-5{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-4.start{counter-reset:lst-ctn-kix_76cwqgc9ntcg-4 0}ul.lst-kix_amnxd0o32wxe-6{list-style-type:none}ul.lst-kix_amnxd0o32wxe-7{list-style-type:none}.lst-kix_km6c63ta0u1m-0>li:before{content:"\0025cf  "}ul.lst-kix_amnxd0o32wxe-8{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-1.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-1 0}.lst-kix_amnxd0o32wxe-1>li:before{content:"-  "}ol.lst-kix_b7uuq29jz54a-6.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-6 0}.lst-kix_5f9t9fms2d21-1>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-1,lower-latin) ". "}.lst-kix_q7k3qhhwoyo7-0>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-0}.lst-kix_km6c63ta0u1m-6>li:before{content:"\0025cf  "}ul.lst-kix_amnxd0o32wxe-0{list-style-type:none}.lst-kix_d9wep1z810b6-7>li{counter-increment:lst-ctn-kix_d9wep1z810b6-7}.lst-kix_69woh12i7ucg-2>li{counter-increment:lst-ctn-kix_69woh12i7ucg-2}.lst-kix_b7uuq29jz54a-7>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-7}.lst-kix_5f9t9fms2d21-3>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-3,decimal) ". "}.lst-kix_km6c63ta0u1m-4>li:before{content:"\0025cb  "}.lst-kix_y8nzqr1vapa0-1>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-1}.lst-kix_6hpp8uicfxco-8>li:before{content:"-  "}.lst-kix_amnxd0o32wxe-7>li:before{content:"-  "}.lst-kix_6hpp8uicfxco-6>li:before{content:"-  "}.lst-kix_5f9t9fms2d21-5>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-5,lower-roman) ". "}.lst-kix_km6c63ta0u1m-2>li:before{content:"\0025a0  "}.lst-kix_6hpp8uicfxco-4>li:before{content:"-  "}ol.lst-kix_2qvefga6tw9t-3.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-3 0}.lst-kix_5f9t9fms2d21-7>li:before{content:"" counter(lst-ctn-kix_5f9t9fms2d21-7,lower-latin) ". "}.lst-kix_6hpp8uicfxco-2>li:before{content:"-  "}.lst-kix_km6c63ta0u1m-8>li:before{content:"\0025a0  "}.lst-kix_6hpp8uicfxco-0>li:before{content:"-  "}.lst-kix_5f9t9fms2d21-7>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-7}.lst-kix_stodkckubncd-1>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-1,lower-latin) ". "}.lst-kix_stodkckubncd-3>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-3,decimal) ". "}.lst-kix_ks1i5lssvjkg-4>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-4}.lst-kix_xgq4y4xln1s-5>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-5}ol.lst-kix_q7k3qhhwoyo7-1{list-style-type:none}.lst-kix_ujrictqeu2kx-7>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-7}ol.lst-kix_q7k3qhhwoyo7-2{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-3{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-4{list-style-type:none}.lst-kix_m0nrdnud90zq-7>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-7}ol.lst-kix_q7k3qhhwoyo7-5{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-2.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-2 0}ol.lst-kix_q7k3qhhwoyo7-6{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-7{list-style-type:none}ol.lst-kix_q7k3qhhwoyo7-8{list-style-type:none}.lst-kix_8eggh954z6m1-7>li:before{content:"-  "}ol.lst-kix_2qvefga6tw9t-8.start{counter-reset:lst-ctn-kix_2qvefga6tw9t-8 0}ol.lst-kix_q7k3qhhwoyo7-0{list-style-type:none}.lst-kix_8eggh954z6m1-1>li:before{content:"-  "}.lst-kix_m09drfn41lbc-5>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-2>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-2}.lst-kix_m09drfn41lbc-3>li:before{content:"\0025cf  "}.lst-kix_m09drfn41lbc-7>li:before{content:"\0025cb  "}.lst-kix_8eggh954z6m1-3>li:before{content:"-  "}.lst-kix_stodkckubncd-5>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-5,lower-roman) ". "}.lst-kix_stodkckubncd-7>li:before{content:"" counter(lst-ctn-kix_stodkckubncd-7,lower-latin) ". "}.lst-kix_8eggh954z6m1-5>li:before{content:"-  "}ol.lst-kix_ujrictqeu2kx-3.start{counter-reset:lst-ctn-kix_ujrictqeu2kx-3 0}ul.lst-kix_73zti2swi0ua-7{list-style-type:none}ul.lst-kix_73zti2swi0ua-8{list-style-type:none}ul.lst-kix_73zti2swi0ua-3{list-style-type:none}ul.lst-kix_73zti2swi0ua-4{list-style-type:none}ul.lst-kix_73zti2swi0ua-5{list-style-type:none}ul.lst-kix_73zti2swi0ua-6{list-style-type:none}ul.lst-kix_73zti2swi0ua-0{list-style-type:none}.lst-kix_33s9mn975cqx-5>li:before{content:"\0025a0  "}ul.lst-kix_73zti2swi0ua-1{list-style-type:none}ul.lst-kix_73zti2swi0ua-2{list-style-type:none}.lst-kix_m09drfn41lbc-1>li:before{content:"\0025cb  "}.lst-kix_stodkckubncd-4>li{counter-increment:lst-ctn-kix_stodkckubncd-4}ol.lst-kix_xgq4y4xln1s-2.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-2 0}.lst-kix_73zznxkq85l2-2>li{counter-increment:lst-ctn-kix_73zznxkq85l2-2}.lst-kix_33s9mn975cqx-7>li:before{content:"\0025cb  "}.lst-kix_d9wep1z810b6-0>li{counter-increment:lst-ctn-kix_d9wep1z810b6-0}.lst-kix_73zti2swi0ua-2>li:before{content:"\0025a0  "}.lst-kix_b0ja666m9l9x-6>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-6}.lst-kix_73zti2swi0ua-0>li:before{content:"\0025cf  "}.lst-kix_73zti2swi0ua-4>li:before{content:"\0025cb  "}.lst-kix_xgq4y4xln1s-7>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-7,lower-latin) ". "}.lst-kix_m0nrdnud90zq-0>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-0}.lst-kix_33s9mn975cqx-1>li:before{content:"\0025cb  "}.lst-kix_33s9mn975cqx-3>li:before{content:"\0025cf  "}.lst-kix_73zti2swi0ua-8>li:before{content:"\0025a0  "}.lst-kix_vkx5887x6ome-7>li{counter-increment:lst-ctn-kix_vkx5887x6ome-7}.lst-kix_73zti2swi0ua-6>li:before{content:"\0025cf  "}.lst-kix_puq7slv7ersb-6>li{counter-increment:lst-ctn-kix_puq7slv7ersb-6}ol.lst-kix_5f9t9fms2d21-8.start{counter-reset:lst-ctn-kix_5f9t9fms2d21-8 0}.lst-kix_vfpim5mnet5b-2>li:before{content:"\0025a0  "}ol.lst-kix_ks1i5lssvjkg-2.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-2 0}.lst-kix_vfpim5mnet5b-4>li:before{content:"\0025cb  "}ol.lst-kix_9kz8bq8q3b2i-6.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-6 0}.lst-kix_vfpim5mnet5b-6>li:before{content:"\0025cf  "}.lst-kix_vfpim5mnet5b-8>li:before{content:"\0025a0  "}.lst-kix_q7k3qhhwoyo7-7>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-7}ol.lst-kix_b7uuq29jz54a-1.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-1 0}ol.lst-kix_vkx5887x6ome-4.start{counter-reset:lst-ctn-kix_vkx5887x6ome-4 0}.lst-kix_vkx5887x6ome-0>li{counter-increment:lst-ctn-kix_vkx5887x6ome-0}.lst-kix_y8nzqr1vapa0-8>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-8}.lst-kix_seg2qxi99oen-4>li{counter-increment:lst-ctn-kix_seg2qxi99oen-4}.lst-kix_vfpim5mnet5b-0>li:before{content:"\0025cf  "}.lst-kix_bh4xapke1dje-0>li:before{content:"\0025cf  "}ol.lst-kix_b0ja666m9l9x-2.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-2 0}.lst-kix_bh4xapke1dje-4>li:before{content:"\0025cb  "}.lst-kix_ujrictqeu2kx-6>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-6,decimal) ". "}.lst-kix_2qvefga6tw9t-6>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-6}ol.lst-kix_fh553kxqh3vv-5.start{counter-reset:lst-ctn-kix_fh553kxqh3vv-5 0}.lst-kix_2qvefga6tw9t-4>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-4}.lst-kix_bh4xapke1dje-8>li:before{content:"\0025a0  "}ol.lst-kix_b0ja666m9l9x-7.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-7 0}.lst-kix_h8i9ymdmzkx8-3>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-3,decimal) ". "}.lst-kix_xgq4y4xln1s-5>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-5,lower-roman) ". "}.lst-kix_h8i9ymdmzkx8-7>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-7,lower-latin) ". "}ul.lst-kix_wt16kx5082x6-8{list-style-type:none}.lst-kix_jrq3pc6b7fs5-1>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-1,lower-latin) ". "}ul.lst-kix_wt16kx5082x6-7{list-style-type:none}ul.lst-kix_wt16kx5082x6-4{list-style-type:none}ul.lst-kix_wt16kx5082x6-3{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-5.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-5 0}ul.lst-kix_wt16kx5082x6-6{list-style-type:none}ul.lst-kix_wt16kx5082x6-5{list-style-type:none}ul.lst-kix_wt16kx5082x6-0{list-style-type:none}.lst-kix_xgq4y4xln1s-1>li:before{content:"" counter(lst-ctn-kix_xgq4y4xln1s-1,lower-latin) ". "}ul.lst-kix_wt16kx5082x6-2{list-style-type:none}.lst-kix_h8i9ymdmzkx8-4>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-4}ol.lst-kix_m0nrdnud90zq-5.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-5 0}ul.lst-kix_wt16kx5082x6-1{list-style-type:none}.lst-kix_jrq3pc6b7fs5-5>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-5,lower-roman) ". "}.lst-kix_9kz8bq8q3b2i-2>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-2}.lst-kix_76cwqgc9ntcg-1>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-1,lower-latin) ". "}.lst-kix_76cwqgc9ntcg-7>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-7}.lst-kix_yhp6v7of3e00-7>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-7}.lst-kix_9kz8bq8q3b2i-5>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-5,lower-roman) ". "}.lst-kix_p0rhwsmbgd7c-6>li:before{content:"-  "}ol.lst-kix_h8i9ymdmzkx8-0.start{counter-reset:lst-ctn-kix_h8i9ymdmzkx8-0 0}ol.lst-kix_q7k3qhhwoyo7-7.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-7 0}ol.lst-kix_b0ja666m9l9x-0{list-style-type:none}ol.lst-kix_b0ja666m9l9x-3{list-style-type:none}ol.lst-kix_b0ja666m9l9x-4{list-style-type:none}ol.lst-kix_b0ja666m9l9x-1{list-style-type:none}ol.lst-kix_b0ja666m9l9x-2{list-style-type:none}ol.lst-kix_b0ja666m9l9x-7{list-style-type:none}ol.lst-kix_b0ja666m9l9x-8{list-style-type:none}ol.lst-kix_b0ja666m9l9x-5{list-style-type:none}.lst-kix_9kz8bq8q3b2i-1>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-1,lower-latin) ". "}ol.lst-kix_b0ja666m9l9x-6{list-style-type:none}.lst-kix_yhp6v7of3e00-5>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-5}.lst-kix_s1e4p75lcpk8-8>li:before{content:"\0025a0  "}.lst-kix_4h5ayc5t6q0q-7>li:before{content:"\0025cb  "}.lst-kix_b7uuq29jz54a-3>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-3,decimal) ". "}.lst-kix_b7uuq29jz54a-0>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-0}ol.lst-kix_73zznxkq85l2-4.start{counter-reset:lst-ctn-kix_73zznxkq85l2-4 0}.lst-kix_s1e4p75lcpk8-0>li:before{content:"\0025cf  "}.lst-kix_s1e4p75lcpk8-4>li:before{content:"\0025cb  "}.lst-kix_4h5ayc5t6q0q-3>li:before{content:"\0025cf  "}ol.lst-kix_73zznxkq85l2-1.start{counter-reset:lst-ctn-kix_73zznxkq85l2-1 0}.lst-kix_b7uuq29jz54a-7>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-7,lower-latin) ". "}.lst-kix_ujrictqeu2kx-0>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-0}.lst-kix_5f9t9fms2d21-0>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-0}ol.lst-kix_xgq4y4xln1s-7.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-7 0}.lst-kix_puq7slv7ersb-8>li{counter-increment:lst-ctn-kix_puq7slv7ersb-8}.lst-kix_xgq4y4xln1s-7>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-7}.lst-kix_76cwqgc9ntcg-0>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-0}.lst-kix_ujrictqeu2kx-2>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-2,lower-roman) ". "}.lst-kix_yhp6v7of3e00-0>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-0}.lst-kix_76cwqgc9ntcg-5>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-5,lower-roman) ". "}.lst-kix_wt16kx5082x6-0>li:before{content:"\0025cf  "}ol.lst-kix_qgxhqyjzp80f-7.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-7 0}.lst-kix_cmax3c5l3b9l-1>li:before{content:"\0025cb  "}.lst-kix_gnt2wo6vinpb-0>li:before{content:"-  "}ol.lst-kix_ks1i5lssvjkg-6{list-style-type:none}.lst-kix_y8nzqr1vapa0-3>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-3}ol.lst-kix_ks1i5lssvjkg-7{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-4{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-5{list-style-type:none}.lst-kix_gnt2wo6vinpb-2>li:before{content:"-  "}ol.lst-kix_ks1i5lssvjkg-2{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-3{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-0{list-style-type:none}ol.lst-kix_ks1i5lssvjkg-1{list-style-type:none}.lst-kix_gvdnkwhuv0x-8>li:before{content:"\0025a0  "}.lst-kix_uf4umlhhckq2-0>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-0}ol.lst-kix_ks1i5lssvjkg-8{list-style-type:none}.lst-kix_6zkl42mjxb9i-6>li:before{content:"\0025cf  "}.lst-kix_yfnaf4f33kdr-6>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-6,decimal) ". "}.lst-kix_yfnaf4f33kdr-8>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-8,lower-roman) ". "}ol.lst-kix_yfnaf4f33kdr-5.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-5 0}.lst-kix_cmax3c5l3b9l-7>li:before{content:"\0025cb  "}.lst-kix_6zkl42mjxb9i-4>li:before{content:"\0025cb  "}ol.lst-kix_m0nrdnud90zq-7.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-7 0}.lst-kix_gvdnkwhuv0x-2>li:before{content:"\0025a0  "}.lst-kix_gnt2wo6vinpb-8>li:before{content:"-  "}.lst-kix_nm3lwvrsfgs8-1>li:before{content:"\0025cb  "}.lst-kix_69woh12i7ucg-0>li{counter-increment:lst-ctn-kix_69woh12i7ucg-0}.lst-kix_yfnaf4f33kdr-0>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-0,decimal) ". "}.lst-kix_stodkckubncd-6>li{counter-increment:lst-ctn-kix_stodkckubncd-6}.lst-kix_bz3wxvkk86wr-1>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-1,lower-latin) ". "}.lst-kix_gvdnkwhuv0x-0>li:before{content:"\0025cf  "}.lst-kix_y8nzqr1vapa0-4>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-4,lower-latin) ". "}.lst-kix_y8nzqr1vapa0-6>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-6,decimal) ". "}ol.lst-kix_b0ja666m9l9x-0.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-0 0}.lst-kix_n9l39mx24y7l-8>li:before{content:"\0025a0  "}.lst-kix_nm3lwvrsfgs8-7>li:before{content:"\0025cb  "}.lst-kix_puq7slv7ersb-1>li{counter-increment:lst-ctn-kix_puq7slv7ersb-1}.lst-kix_bz3wxvkk86wr-7>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-7,lower-latin) ". "}.lst-kix_n9l39mx24y7l-0>li:before{content:"\0025cf  "}.lst-kix_n9l39mx24y7l-2>li:before{content:"\0025a0  "}.lst-kix_kn39yucmriut-6>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-0.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-0 0}.lst-kix_kn39yucmriut-4>li:before{content:"-  "}.lst-kix_5f9t9fms2d21-5>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-5}.lst-kix_fh553kxqh3vv-0>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-0}.lst-kix_wt16kx5082x6-8>li:before{content:"\0025a0  "}.lst-kix_jrq3pc6b7fs5-0>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-0}.lst-kix_q7k3qhhwoyo7-2>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-2}.lst-kix_p0rhwsmbgd7c-0>li:before{content:"-  "}.lst-kix_73zznxkq85l2-7>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-7,lower-latin) ". "}ol.lst-kix_yhp6v7of3e00-6.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-6 0}.lst-kix_73zznxkq85l2-5>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-5,lower-roman) ". "}.lst-kix_wt16kx5082x6-6>li:before{content:"\0025cf  "}.lst-kix_p0rhwsmbgd7c-2>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-0.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-0 2}.lst-kix_b7uuq29jz54a-2>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-2}.lst-kix_yhp6v7of3e00-7>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-7,lower-latin) ". "}.lst-kix_jrq3pc6b7fs5-4>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-4}.lst-kix_yfnaf4f33kdr-5>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-5}ol.lst-kix_yhp6v7of3e00-4.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-4 0}.lst-kix_ks1i5lssvjkg-2>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-2}.lst-kix_puq7slv7ersb-4>li{counter-increment:lst-ctn-kix_puq7slv7ersb-4}ol.lst-kix_m0nrdnud90zq-0.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-0 0}.lst-kix_mzqsrs9zicmn-5>li:before{content:"\0025a0  "}.lst-kix_c9w8l0v8vj60-4>li:before{content:"-  "}.lst-kix_gv17x2lsey8i-3>li:before{content:"\0025cf  "}ol.lst-kix_yhp6v7of3e00-1.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-1 0}.lst-kix_qgxhqyjzp80f-1>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-1,lower-latin) ". "}.lst-kix_qgxhqyjzp80f-7>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-7,lower-latin) ". "}.lst-kix_gv17x2lsey8i-1>li:before{content:"\0025cb  "}.lst-kix_yhp6v7of3e00-1>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-1,lower-latin) ". "}ol.lst-kix_stodkckubncd-5{list-style-type:none}ol.lst-kix_stodkckubncd-4{list-style-type:none}ol.lst-kix_stodkckubncd-3{list-style-type:none}.lst-kix_1jqtmxt015qr-6>li:before{content:"-  "}ol.lst-kix_stodkckubncd-2{list-style-type:none}ol.lst-kix_puq7slv7ersb-1.start{counter-reset:lst-ctn-kix_puq7slv7ersb-1 0}ol.lst-kix_stodkckubncd-8{list-style-type:none}ol.lst-kix_stodkckubncd-7{list-style-type:none}ol.lst-kix_stodkckubncd-6{list-style-type:none}.lst-kix_1jqtmxt015qr-4>li:before{content:"-  "}ol.lst-kix_qgxhqyjzp80f-5.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-5 0}.lst-kix_fh553kxqh3vv-4>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-4}ol.lst-kix_m0nrdnud90zq-2.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-2 0}ol.lst-kix_qgxhqyjzp80f-2.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-2 0}ol.lst-kix_9kz8bq8q3b2i-5{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-6{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-7{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-8{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-1{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-2{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-3{list-style-type:none}.lst-kix_h8i9ymdmzkx8-2>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-2}ol.lst-kix_9kz8bq8q3b2i-4{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-8.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-8 0}ol.lst-kix_9kz8bq8q3b2i-0{list-style-type:none}.lst-kix_m0nrdnud90zq-7>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-7,lower-latin) ". "}.lst-kix_c9w8l0v8vj60-6>li:before{content:"-  "}ul.lst-kix_gnt2wo6vinpb-0{list-style-type:none}.lst-kix_mzqsrs9zicmn-7>li:before{content:"\0025cb  "}ul.lst-kix_gnt2wo6vinpb-1{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-2{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-3{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-4{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-5{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-6{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-7{list-style-type:none}ul.lst-kix_gnt2wo6vinpb-8{list-style-type:none}.lst-kix_rjzoughkzvzw-4>li:before{content:"\0025cb  "}ol.lst-kix_m0nrdnud90zq-6{list-style-type:none}ol.lst-kix_m0nrdnud90zq-5{list-style-type:none}ol.lst-kix_m0nrdnud90zq-8{list-style-type:none}ol.lst-kix_m0nrdnud90zq-7{list-style-type:none}ol.lst-kix_m0nrdnud90zq-2{list-style-type:none}ol.lst-kix_m0nrdnud90zq-1{list-style-type:none}ol.lst-kix_m0nrdnud90zq-4{list-style-type:none}ol.lst-kix_m0nrdnud90zq-3{list-style-type:none}.lst-kix_rjzoughkzvzw-6>li:before{content:"\0025cf  "}ol.lst-kix_m0nrdnud90zq-0{list-style-type:none}.lst-kix_bh4xapke1dje-2>li:before{content:"\0025a0  "}.lst-kix_oj0ws47jaz7a-5>li:before{content:"-  "}ol.lst-kix_jrq3pc6b7fs5-5.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-5 0}.lst-kix_8hc53kjy1j5y-7>li:before{content:"-  "}.lst-kix_7hpd7l1orcn5-1>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-2.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-2 0}ol.lst-kix_y8nzqr1vapa0-5.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-5 0}.lst-kix_uf4umlhhckq2-3>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-3}ul.lst-kix_6hpp8uicfxco-7{list-style-type:none}ul.lst-kix_6hpp8uicfxco-6{list-style-type:none}ul.lst-kix_6hpp8uicfxco-8{list-style-type:none}ul.lst-kix_6hpp8uicfxco-3{list-style-type:none}ul.lst-kix_6hpp8uicfxco-2{list-style-type:none}ul.lst-kix_6hpp8uicfxco-5{list-style-type:none}ul.lst-kix_6hpp8uicfxco-4{list-style-type:none}.lst-kix_m0nrdnud90zq-1>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-1,lower-latin) ". "}ul.lst-kix_6hpp8uicfxco-1{list-style-type:none}.lst-kix_r1qxtw4k9pgo-4>li:before{content:"-  "}ul.lst-kix_6hpp8uicfxco-0{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-7{list-style-type:none}ul.lst-kix_zyb4ozncdg-8{list-style-type:none}.lst-kix_seg2qxi99oen-3>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-3,decimal) ". "}ul.lst-kix_4h5ayc5t6q0q-6{list-style-type:none}ul.lst-kix_zyb4ozncdg-7{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-5{list-style-type:none}ul.lst-kix_zyb4ozncdg-6{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-4{list-style-type:none}ul.lst-kix_zyb4ozncdg-5{list-style-type:none}.lst-kix_uf4umlhhckq2-3>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-3,decimal) ". "}ul.lst-kix_4h5ayc5t6q0q-8{list-style-type:none}ul.lst-kix_zyb4ozncdg-0{list-style-type:none}.lst-kix_yfnaf4f33kdr-2>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-2}ol.lst-kix_stodkckubncd-1{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-3{list-style-type:none}ul.lst-kix_zyb4ozncdg-4{list-style-type:none}ol.lst-kix_stodkckubncd-0{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-2{list-style-type:none}ul.lst-kix_zyb4ozncdg-3{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-6.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-6 0}ul.lst-kix_4h5ayc5t6q0q-1{list-style-type:none}ul.lst-kix_zyb4ozncdg-2{list-style-type:none}ul.lst-kix_4h5ayc5t6q0q-0{list-style-type:none}ul.lst-kix_zyb4ozncdg-1{list-style-type:none}.lst-kix_h8i9ymdmzkx8-5>li:before{content:"" counter(lst-ctn-kix_h8i9ymdmzkx8-5,lower-roman) ". "}.lst-kix_efg97u94j8hb-7>li:before{content:"-  "}ol.lst-kix_jrq3pc6b7fs5-0.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-0 0}ol.lst-kix_ks1i5lssvjkg-5.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-5 0}.lst-kix_6l3u48hb8och-6>li:before{content:"-  "}ol.lst-kix_yfnaf4f33kdr-7.start{counter-reset:lst-ctn-kix_yfnaf4f33kdr-7 0}ul.lst-kix_gvdnkwhuv0x-0{list-style-type:none}.lst-kix_bz3wxvkk86wr-2>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-2}ul.lst-kix_gvdnkwhuv0x-4{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-3{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-2{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-1{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-8{list-style-type:none}.lst-kix_jrq3pc6b7fs5-3>li:before{content:"" counter(lst-ctn-kix_jrq3pc6b7fs5-3,decimal) ". "}ul.lst-kix_gvdnkwhuv0x-7{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-6{list-style-type:none}ul.lst-kix_gvdnkwhuv0x-5{list-style-type:none}.lst-kix_uf4umlhhckq2-7>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-7}ul.lst-kix_a6itagplhb2w-1{list-style-type:none}ul.lst-kix_a6itagplhb2w-0{list-style-type:none}ul.lst-kix_a6itagplhb2w-3{list-style-type:none}ul.lst-kix_a6itagplhb2w-2{list-style-type:none}ul.lst-kix_a6itagplhb2w-5{list-style-type:none}ul.lst-kix_a6itagplhb2w-4{list-style-type:none}ul.lst-kix_a6itagplhb2w-7{list-style-type:none}ul.lst-kix_a6itagplhb2w-6{list-style-type:none}.lst-kix_p0rhwsmbgd7c-8>li:before{content:"-  "}ul.lst-kix_a6itagplhb2w-8{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-1.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-1 0}ol.lst-kix_ks1i5lssvjkg-7.start{counter-reset:lst-ctn-kix_ks1i5lssvjkg-7 0}.lst-kix_qaijc6nbpdk4-3>li:before{content:"-  "}ol.lst-kix_76cwqgc9ntcg-8{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-7{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-6{list-style-type:none}ol.lst-kix_69woh12i7ucg-0{list-style-type:none}.lst-kix_2qvefga6tw9t-3>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-3,decimal) ". "}ol.lst-kix_69woh12i7ucg-1{list-style-type:none}ol.lst-kix_69woh12i7ucg-4{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-1{list-style-type:none}ol.lst-kix_69woh12i7ucg-5{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-0{list-style-type:none}ol.lst-kix_69woh12i7ucg-2{list-style-type:none}ol.lst-kix_69woh12i7ucg-3{list-style-type:none}ol.lst-kix_69woh12i7ucg-8{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-5{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-4{list-style-type:none}ol.lst-kix_69woh12i7ucg-6{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-3{list-style-type:none}ol.lst-kix_69woh12i7ucg-7{list-style-type:none}ol.lst-kix_76cwqgc9ntcg-2{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-3.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-3 0}.lst-kix_b7uuq29jz54a-1>li:before{content:"" counter(lst-ctn-kix_b7uuq29jz54a-1,lower-latin) ". "}.lst-kix_s1e4p75lcpk8-6>li:before{content:"\0025cf  "}.lst-kix_stodkckubncd-2>li{counter-increment:lst-ctn-kix_stodkckubncd-2}.lst-kix_u7vldufjcii4-1>li:before{content:"\0025cb  "}.lst-kix_fh553kxqh3vv-7>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-7}ol.lst-kix_puq7slv7ersb-7.start{counter-reset:lst-ctn-kix_puq7slv7ersb-7 0}.lst-kix_9kz8bq8q3b2i-7>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-7,lower-latin) ". "}.lst-kix_4h5ayc5t6q0q-1>li:before{content:"\0025cb  "}ol.lst-kix_puq7slv7ersb-4.start{counter-reset:lst-ctn-kix_puq7slv7ersb-4 0}.lst-kix_jrq3pc6b7fs5-7>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-7}.lst-kix_9kz8bq8q3b2i-6>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-6}ol.lst-kix_jrq3pc6b7fs5-3.start{counter-reset:lst-ctn-kix_jrq3pc6b7fs5-3 0}ol.lst-kix_y8nzqr1vapa0-0.start{counter-reset:lst-ctn-kix_y8nzqr1vapa0-0 0}.lst-kix_b0ja666m9l9x-4>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-4}ol.lst-kix_h8i9ymdmzkx8-4{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-3{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-2{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-1{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-8{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-7{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-6{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-5{list-style-type:none}ol.lst-kix_h8i9ymdmzkx8-0{list-style-type:none}ol.lst-kix_puq7slv7ersb-6.start{counter-reset:lst-ctn-kix_puq7slv7ersb-6 0}.lst-kix_ujrictqeu2kx-4>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-4,lower-latin) ". "}.lst-kix_nyooapufejer-3>li:before{content:"-  "}.lst-kix_76cwqgc9ntcg-3>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-3,decimal) ". "}ul.lst-kix_gv17x2lsey8i-0{list-style-type:none}ul.lst-kix_gv17x2lsey8i-1{list-style-type:none}ul.lst-kix_gv17x2lsey8i-2{list-style-type:none}ul.lst-kix_gv17x2lsey8i-3{list-style-type:none}ul.lst-kix_gv17x2lsey8i-4{list-style-type:none}ul.lst-kix_gv17x2lsey8i-5{list-style-type:none}.lst-kix_stodkckubncd-8>li{counter-increment:lst-ctn-kix_stodkckubncd-8}ol.lst-kix_vkx5887x6ome-6.start{counter-reset:lst-ctn-kix_vkx5887x6ome-6 0}.lst-kix_ks1i5lssvjkg-8>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-8,lower-roman) ". "}ul.lst-kix_gv17x2lsey8i-6{list-style-type:none}.lst-kix_ks1i5lssvjkg-7>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-7,lower-latin) ". "}ul.lst-kix_gv17x2lsey8i-7{list-style-type:none}ul.lst-kix_gv17x2lsey8i-8{list-style-type:none}.lst-kix_ks1i5lssvjkg-5>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-5,lower-roman) ". "}.lst-kix_d9wep1z810b6-2>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-2,lower-roman) ". "}.lst-kix_ks1i5lssvjkg-4>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-4,lower-latin) ". "}.lst-kix_b0ja666m9l9x-6>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-6,decimal) ". "}ol.lst-kix_seg2qxi99oen-3.start{counter-reset:lst-ctn-kix_seg2qxi99oen-3 0}.lst-kix_seg2qxi99oen-0>li{counter-increment:lst-ctn-kix_seg2qxi99oen-0}.lst-kix_zyb4ozncdg-8>li:before{content:"\0025a0  "}.lst-kix_69woh12i7ucg-3>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-3,decimal) ". "}.lst-kix_ks1i5lssvjkg-1>li:before{content:"" counter(lst-ctn-kix_ks1i5lssvjkg-1,lower-latin) ". "}.lst-kix_b0ja666m9l9x-0>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-0,decimal) ". "}.lst-kix_d9wep1z810b6-8>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-8,lower-roman) ". "}.lst-kix_69woh12i7ucg-2>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-2,lower-roman) ". "}.lst-kix_d9wep1z810b6-6>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-6,decimal) ". "}.lst-kix_69woh12i7ucg-0>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-0,decimal) ". "}.lst-kix_d9wep1z810b6-5>li:before{content:"" counter(lst-ctn-kix_d9wep1z810b6-5,lower-roman) ". "}ol.lst-kix_vkx5887x6ome-1.start{counter-reset:lst-ctn-kix_vkx5887x6ome-1 0}.lst-kix_zyb4ozncdg-2>li:before{content:"\0025a0  "}ol.lst-kix_seg2qxi99oen-3{list-style-type:none}ol.lst-kix_seg2qxi99oen-2{list-style-type:none}ol.lst-kix_seg2qxi99oen-1{list-style-type:none}ol.lst-kix_seg2qxi99oen-0{list-style-type:none}ol.lst-kix_seg2qxi99oen-7{list-style-type:none}.lst-kix_zyb4ozncdg-6>li:before{content:"\0025cf  "}ol.lst-kix_seg2qxi99oen-6{list-style-type:none}ol.lst-kix_seg2qxi99oen-5{list-style-type:none}ol.lst-kix_seg2qxi99oen-4{list-style-type:none}.lst-kix_69woh12i7ucg-6>li:before{content:"" counter(lst-ctn-kix_69woh12i7ucg-6,decimal) ". "}.lst-kix_b0ja666m9l9x-2>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-2,lower-roman) ". "}ol.lst-kix_seg2qxi99oen-8{list-style-type:none}.lst-kix_b0ja666m9l9x-3>li:before{content:"" counter(lst-ctn-kix_b0ja666m9l9x-3,decimal) ". "}.lst-kix_b0ja666m9l9x-2>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-2}.lst-kix_zyb4ozncdg-5>li:before{content:"\0025a0  "}.lst-kix_fh553kxqh3vv-2>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-2,lower-roman) ". "}ul.lst-kix_1jqtmxt015qr-2{list-style-type:none}ol.lst-kix_9kz8bq8q3b2i-8.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-8 0}ul.lst-kix_1jqtmxt015qr-1{list-style-type:none}.lst-kix_vkx5887x6ome-5>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-5,lower-roman) ". "}ul.lst-kix_1jqtmxt015qr-4{list-style-type:none}.lst-kix_5f9t9fms2d21-3>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-3}ul.lst-kix_1jqtmxt015qr-3{list-style-type:none}.lst-kix_fh553kxqh3vv-0>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-0,decimal) ". "}ul.lst-kix_1jqtmxt015qr-6{list-style-type:none}ul.lst-kix_1jqtmxt015qr-5{list-style-type:none}ul.lst-kix_1jqtmxt015qr-8{list-style-type:none}ul.lst-kix_1jqtmxt015qr-7{list-style-type:none}.lst-kix_fh553kxqh3vv-6>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-6,decimal) ". "}.lst-kix_qaijc6nbpdk4-4>li:before{content:"-  "}ul.lst-kix_1jqtmxt015qr-0{list-style-type:none}ol.lst-kix_uf4umlhhckq2-5.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-5 0}.lst-kix_ujrictqeu2kx-4>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-4}.lst-kix_vkx5887x6ome-1>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-1,lower-latin) ". "}.lst-kix_s078hly7oqfy-0>li:before{content:"-  "}ol.lst-kix_m0nrdnud90zq-3.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-3 0}.lst-kix_a6itagplhb2w-1>li:before{content:"\0025cb  "}.lst-kix_u7vldufjcii4-8>li:before{content:"\0025a0  "}.lst-kix_a6itagplhb2w-5>li:before{content:"\0025a0  "}.lst-kix_2qvefga6tw9t-1>li{counter-increment:lst-ctn-kix_2qvefga6tw9t-1}ol.lst-kix_73zznxkq85l2-7.start{counter-reset:lst-ctn-kix_73zznxkq85l2-7 0}.lst-kix_u7vldufjcii4-2>li:before{content:"\0025a0  "}.lst-kix_s078hly7oqfy-6>li:before{content:"-  "}.lst-kix_qaijc6nbpdk4-0>li:before{content:"-  "}ol.lst-kix_yhp6v7of3e00-2.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-2 0}ol.lst-kix_stodkckubncd-3.start{counter-reset:lst-ctn-kix_stodkckubncd-3 0}.lst-kix_q7k3qhhwoyo7-6>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-6,decimal) ". "}.lst-kix_76cwqgc9ntcg-3>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-3}.lst-kix_69woh12i7ucg-5>li{counter-increment:lst-ctn-kix_69woh12i7ucg-5}.lst-kix_q7k3qhhwoyo7-2>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-2,lower-roman) ". "}.lst-kix_puq7slv7ersb-7>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-7,lower-latin) ". "}ol.lst-kix_qgxhqyjzp80f-3.start{counter-reset:lst-ctn-kix_qgxhqyjzp80f-3 0}ol.lst-kix_b7uuq29jz54a-8{list-style-type:none}.lst-kix_q7k3qhhwoyo7-0>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-0,decimal) ". "}ol.lst-kix_xgq4y4xln1s-0.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-0 0}ol.lst-kix_q7k3qhhwoyo7-0.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-0 0}.lst-kix_ks1i5lssvjkg-8>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-8}ul.lst-kix_m09drfn41lbc-8{list-style-type:none}.lst-kix_oj0ws47jaz7a-1>li:before{content:"-  "}ul.lst-kix_m09drfn41lbc-7{list-style-type:none}ul.lst-kix_m09drfn41lbc-6{list-style-type:none}ul.lst-kix_m09drfn41lbc-5{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-6.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-6 0}.lst-kix_puq7slv7ersb-3>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-3,decimal) ". "}ul.lst-kix_m09drfn41lbc-4{list-style-type:none}ol.lst-kix_b7uuq29jz54a-5{list-style-type:none}ol.lst-kix_stodkckubncd-2.start{counter-reset:lst-ctn-kix_stodkckubncd-2 0}ol.lst-kix_yhp6v7of3e00-3.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-3 0}ul.lst-kix_m09drfn41lbc-3{list-style-type:none}ol.lst-kix_b7uuq29jz54a-4{list-style-type:none}ul.lst-kix_m09drfn41lbc-2{list-style-type:none}ol.lst-kix_b7uuq29jz54a-7{list-style-type:none}ul.lst-kix_m09drfn41lbc-1{list-style-type:none}ol.lst-kix_b7uuq29jz54a-6{list-style-type:none}ul.lst-kix_m09drfn41lbc-0{list-style-type:none}ol.lst-kix_b7uuq29jz54a-1{list-style-type:none}ol.lst-kix_b7uuq29jz54a-0{list-style-type:none}ol.lst-kix_b7uuq29jz54a-3{list-style-type:none}ol.lst-kix_b7uuq29jz54a-2{list-style-type:none}.lst-kix_oj0ws47jaz7a-7>li:before{content:"-  "}.lst-kix_oj0ws47jaz7a-4>li:before{content:"-  "}.lst-kix_oj0ws47jaz7a-8>li:before{content:"-  "}ol.lst-kix_73zznxkq85l2-8.start{counter-reset:lst-ctn-kix_73zznxkq85l2-8 0}ol.lst-kix_bz3wxvkk86wr-7.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-7 0}.lst-kix_7hpd7l1orcn5-0>li:before{content:"-  "}.lst-kix_bz3wxvkk86wr-4>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-4}ol.lst-kix_yhp6v7of3e00-8.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-8 0}ol.lst-kix_q7k3qhhwoyo7-5.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-5 0}ol.lst-kix_b7uuq29jz54a-3.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-3 0}.lst-kix_r1qxtw4k9pgo-7>li:before{content:"-  "}ol.lst-kix_9kz8bq8q3b2i-4.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-4 0}.lst-kix_r1qxtw4k9pgo-3>li:before{content:"-  "}.lst-kix_h8i9ymdmzkx8-6>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-6}ol.lst-kix_m0nrdnud90zq-4.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-4 0}.lst-kix_8hc53kjy1j5y-0>li:before{content:"-  "}.lst-kix_r1qxtw4k9pgo-6>li:before{content:"-  "}.lst-kix_seg2qxi99oen-2>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-2,lower-roman) ". "}.lst-kix_seg2qxi99oen-5>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-5,lower-roman) ". "}.lst-kix_6l3u48hb8och-0>li:before{content:"-  "}ol.lst-kix_xgq4y4xln1s-4.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-4 0}.lst-kix_uf4umlhhckq2-8>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-8,lower-roman) ". "}.lst-kix_6l3u48hb8och-3>li:before{content:"-  "}.lst-kix_6l3u48hb8och-7>li:before{content:"-  "}.lst-kix_6l3u48hb8och-4>li:before{content:"-  "}.lst-kix_seg2qxi99oen-6>li:before{content:"" counter(lst-ctn-kix_seg2qxi99oen-6,decimal) ". "}.lst-kix_efg97u94j8hb-6>li:before{content:"-  "}.lst-kix_y8nzqr1vapa0-4>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-4}ol.lst-kix_9kz8bq8q3b2i-3.start{counter-reset:lst-ctn-kix_9kz8bq8q3b2i-3 0}.lst-kix_uf4umlhhckq2-5>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-5,lower-roman) ". "}.lst-kix_fh553kxqh3vv-6>li{counter-increment:lst-ctn-kix_fh553kxqh3vv-6}.lst-kix_b0ja666m9l9x-8>li{counter-increment:lst-ctn-kix_b0ja666m9l9x-8}.lst-kix_uf4umlhhckq2-1>li{counter-increment:lst-ctn-kix_uf4umlhhckq2-1}ol.lst-kix_b7uuq29jz54a-4.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-4 0}.lst-kix_jrq3pc6b7fs5-6>li{counter-increment:lst-ctn-kix_jrq3pc6b7fs5-6}.lst-kix_fh553kxqh3vv-3>li:before{content:"" counter(lst-ctn-kix_fh553kxqh3vv-3,decimal) ". "}ol.lst-kix_q7k3qhhwoyo7-4.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-4 0}.lst-kix_vkx5887x6ome-2>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-2,lower-roman) ". "}.lst-kix_xgq4y4xln1s-2>li{counter-increment:lst-ctn-kix_xgq4y4xln1s-2}.lst-kix_2qvefga6tw9t-5>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-5,lower-roman) ". "}ol.lst-kix_yhp6v7of3e00-7.start{counter-reset:lst-ctn-kix_yhp6v7of3e00-7 0}ol.lst-kix_uf4umlhhckq2-6{list-style-type:none}ol.lst-kix_uf4umlhhckq2-5{list-style-type:none}ol.lst-kix_uf4umlhhckq2-8{list-style-type:none}.lst-kix_y8nzqr1vapa0-6>li{counter-increment:lst-ctn-kix_y8nzqr1vapa0-6}ol.lst-kix_uf4umlhhckq2-7{list-style-type:none}.lst-kix_qgxhqyjzp80f-6>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-6,decimal) ". "}.lst-kix_a6itagplhb2w-2>li:before{content:"\0025a0  "}ol.lst-kix_uf4umlhhckq2-0{list-style-type:none}ol.lst-kix_uf4umlhhckq2-2{list-style-type:none}ol.lst-kix_xgq4y4xln1s-5.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-5 0}ol.lst-kix_uf4umlhhckq2-1{list-style-type:none}ol.lst-kix_uf4umlhhckq2-4{list-style-type:none}ol.lst-kix_uf4umlhhckq2-3{list-style-type:none}ol.lst-kix_b0ja666m9l9x-4.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-4 0}.lst-kix_qaijc6nbpdk4-1>li:before{content:"-  "}.lst-kix_ujrictqeu2kx-5>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-5}ul.lst-kix_nm3lwvrsfgs8-7{list-style-type:none}.lst-kix_y8nzqr1vapa0-0>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-0,decimal) ". "}ul.lst-kix_nm3lwvrsfgs8-8{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-5{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-6{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-3{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-4{list-style-type:none}.lst-kix_q7k3qhhwoyo7-3>li:before{content:"" counter(lst-ctn-kix_q7k3qhhwoyo7-3,decimal) ". "}.lst-kix_m0nrdnud90zq-6>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-6,decimal) ". "}ol.lst-kix_73zznxkq85l2-2.start{counter-reset:lst-ctn-kix_73zznxkq85l2-2 0}.lst-kix_d9wep1z810b6-3>li{counter-increment:lst-ctn-kix_d9wep1z810b6-3}.lst-kix_9kz8bq8q3b2i-7>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-7}ol.lst-kix_b0ja666m9l9x-3.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-3 0}ol.lst-kix_b7uuq29jz54a-8.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-8 0}.lst-kix_puq7slv7ersb-6>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-6,decimal) ". "}ol.lst-kix_m0nrdnud90zq-8.start{counter-reset:lst-ctn-kix_m0nrdnud90zq-8 0}.lst-kix_7hpd7l1orcn5-3>li:before{content:"-  "}.lst-kix_rjzoughkzvzw-3>li:before{content:"\0025cf  "}ol.lst-kix_73zznxkq85l2-3.start{counter-reset:lst-ctn-kix_73zznxkq85l2-3 0}.lst-kix_yfnaf4f33kdr-1>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-1}.lst-kix_seg2qxi99oen-1>li{counter-increment:lst-ctn-kix_seg2qxi99oen-1}.lst-kix_7hpd7l1orcn5-7>li:before{content:"-  "}.lst-kix_nyooapufejer-5>li:before{content:"-  "}.lst-kix_rjzoughkzvzw-7>li:before{content:"\0025cb  "}.lst-kix_wt16kx5082x6-1>li:before{content:"\0025cb  "}.lst-kix_m0nrdnud90zq-5>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-5}.lst-kix_wt16kx5082x6-4>li:before{content:"\0025cb  "}ol.lst-kix_uf4umlhhckq2-1.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-1 0}ul.lst-kix_nyooapufejer-7{list-style-type:none}ul.lst-kix_nyooapufejer-6{list-style-type:none}ul.lst-kix_nyooapufejer-5{list-style-type:none}ul.lst-kix_nyooapufejer-4{list-style-type:none}.lst-kix_cmax3c5l3b9l-3>li:before{content:"\0025cf  "}ul.lst-kix_nyooapufejer-8{list-style-type:none}.lst-kix_ks1i5lssvjkg-6>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-6}ol.lst-kix_vkx5887x6ome-0.start{counter-reset:lst-ctn-kix_vkx5887x6ome-0 0}.lst-kix_cmax3c5l3b9l-0>li:before{content:"\0025cf  "}ul.lst-kix_r1qxtw4k9pgo-5{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-4{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-3{list-style-type:none}.lst-kix_vkx5887x6ome-2>li{counter-increment:lst-ctn-kix_vkx5887x6ome-2}ul.lst-kix_r1qxtw4k9pgo-2{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-8{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-7{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-6{list-style-type:none}.lst-kix_6zkl42mjxb9i-0>li:before{content:"\0025cf  "}.lst-kix_qgxhqyjzp80f-4>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-4}ul.lst-kix_nyooapufejer-3{list-style-type:none}.lst-kix_nm3lwvrsfgs8-5>li:before{content:"\0025a0  "}ul.lst-kix_nyooapufejer-2{list-style-type:none}ul.lst-kix_nyooapufejer-1{list-style-type:none}ol.lst-kix_seg2qxi99oen-4.start{counter-reset:lst-ctn-kix_seg2qxi99oen-4 0}ul.lst-kix_nyooapufejer-0{list-style-type:none}.lst-kix_gnt2wo6vinpb-3>li:before{content:"-  "}ol.lst-kix_xgq4y4xln1s-1.start{counter-reset:lst-ctn-kix_xgq4y4xln1s-1 0}.lst-kix_gvdnkwhuv0x-4>li:before{content:"\0025cb  "}ol.lst-kix_vkx5887x6ome-1{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-1{list-style-type:none}ol.lst-kix_vkx5887x6ome-2{list-style-type:none}ul.lst-kix_nm3lwvrsfgs8-2{list-style-type:none}ol.lst-kix_vkx5887x6ome-0{list-style-type:none}.lst-kix_6zkl42mjxb9i-3>li:before{content:"\0025cf  "}.lst-kix_gnt2wo6vinpb-6>li:before{content:"-  "}ul.lst-kix_nm3lwvrsfgs8-0{list-style-type:none}.lst-kix_yfnaf4f33kdr-7>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-7,lower-latin) ". "}ol.lst-kix_73zznxkq85l2-6.start{counter-reset:lst-ctn-kix_73zznxkq85l2-6 0}.lst-kix_gvdnkwhuv0x-1>li:before{content:"\0025cb  "}.lst-kix_yfnaf4f33kdr-4>li:before{content:"" counter(lst-ctn-kix_yfnaf4f33kdr-4,lower-latin) ". "}.lst-kix_bz3wxvkk86wr-3>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-3,decimal) ". "}.lst-kix_y8nzqr1vapa0-7>li:before{content:"" counter(lst-ctn-kix_y8nzqr1vapa0-7,lower-latin) ". "}ol.lst-kix_stodkckubncd-6.start{counter-reset:lst-ctn-kix_stodkckubncd-6 0}.lst-kix_seg2qxi99oen-6>li{counter-increment:lst-ctn-kix_seg2qxi99oen-6}.lst-kix_nm3lwvrsfgs8-8>li:before{content:"\0025a0  "}ol.lst-kix_xgq4y4xln1s-8{list-style-type:none}ol.lst-kix_xgq4y4xln1s-5{list-style-type:none}ol.lst-kix_xgq4y4xln1s-4{list-style-type:none}ol.lst-kix_xgq4y4xln1s-7{list-style-type:none}ol.lst-kix_xgq4y4xln1s-6{list-style-type:none}.lst-kix_kn39yucmriut-3>li:before{content:"-  "}.lst-kix_n9l39mx24y7l-6>li:before{content:"\0025cf  "}.lst-kix_73zznxkq85l2-1>li:before{content:"" counter(lst-ctn-kix_73zznxkq85l2-1,lower-latin) ". "}.lst-kix_73zznxkq85l2-4>li{counter-increment:lst-ctn-kix_73zznxkq85l2-4}ol.lst-kix_b0ja666m9l9x-5.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-5 0}.lst-kix_wt16kx5082x6-7>li:before{content:"\0025cb  "}.lst-kix_kn39yucmriut-0>li:before{content:"-  "}ol.lst-kix_q7k3qhhwoyo7-3.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-3 0}.lst-kix_stodkckubncd-3>li{counter-increment:lst-ctn-kix_stodkckubncd-3}.lst-kix_n9l39mx24y7l-3>li:before{content:"\0025cf  "}.lst-kix_bz3wxvkk86wr-0>li:before{content:"" counter(lst-ctn-kix_bz3wxvkk86wr-0,decimal) ". "}ol.lst-kix_bz3wxvkk86wr-3.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-3 0}ol.lst-kix_y8nzqr1vapa0-0{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-1{list-style-type:none}.lst-kix_1jqtmxt015qr-0>li:before{content:"-  "}ol.lst-kix_y8nzqr1vapa0-2{list-style-type:none}.lst-kix_9kz8bq8q3b2i-0>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-0,decimal) ". "}ol.lst-kix_y8nzqr1vapa0-3{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-4{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-5{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-6{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-7{list-style-type:none}.lst-kix_9kz8bq8q3b2i-6>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-6,decimal) ". "}ol.lst-kix_b7uuq29jz54a-2.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-2 0}ol.lst-kix_vkx5887x6ome-7.start{counter-reset:lst-ctn-kix_vkx5887x6ome-7 0}.lst-kix_nyooapufejer-2>li:before{content:"-  "}ol.lst-kix_stodkckubncd-1.start{counter-reset:lst-ctn-kix_stodkckubncd-1 0}.lst-kix_yhp6v7of3e00-3>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-3,decimal) ". "}ol.lst-kix_xgq4y4xln1s-1{list-style-type:none}ol.lst-kix_y8nzqr1vapa0-8{list-style-type:none}ol.lst-kix_xgq4y4xln1s-0{list-style-type:none}ol.lst-kix_xgq4y4xln1s-3{list-style-type:none}ol.lst-kix_xgq4y4xln1s-2{list-style-type:none}.lst-kix_rjzoughkzvzw-0>li:before{content:"\0025cf  "}.lst-kix_b7uuq29jz54a-1>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-1}ol.lst-kix_seg2qxi99oen-2.start{counter-reset:lst-ctn-kix_seg2qxi99oen-2 0}ol.lst-kix_uf4umlhhckq2-8.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-8 0}.lst-kix_4h5ayc5t6q0q-8>li:before{content:"\0025a0  "}.lst-kix_qgxhqyjzp80f-3>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-3,decimal) ". "}.lst-kix_gv17x2lsey8i-7>li:before{content:"\0025cb  "}.lst-kix_qgxhqyjzp80f-1>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-1}.lst-kix_s1e4p75lcpk8-7>li:before{content:"\0025cb  "}.lst-kix_2qvefga6tw9t-2>li:before{content:"" counter(lst-ctn-kix_2qvefga6tw9t-2,lower-roman) ". "}.lst-kix_c9w8l0v8vj60-2>li:before{content:"-  "}ol.lst-kix_stodkckubncd-4.start{counter-reset:lst-ctn-kix_stodkckubncd-4 0}.lst-kix_mzqsrs9zicmn-1>li:before{content:"\0025cb  "}ol.lst-kix_bz3wxvkk86wr-8.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-8 0}ol.lst-kix_q7k3qhhwoyo7-1.start{counter-reset:lst-ctn-kix_q7k3qhhwoyo7-1 0}.lst-kix_ujrictqeu2kx-2>li{counter-increment:lst-ctn-kix_ujrictqeu2kx-2}.lst-kix_4h5ayc5t6q0q-2>li:before{content:"\0025a0  "}ol.lst-kix_uf4umlhhckq2-6.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-6 0}.lst-kix_m0nrdnud90zq-3>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-3,decimal) ". "}ol.lst-kix_bz3wxvkk86wr-5.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-5 0}ol.lst-kix_b7uuq29jz54a-0.start{counter-reset:lst-ctn-kix_b7uuq29jz54a-0 0}ol.lst-kix_vkx5887x6ome-5.start{counter-reset:lst-ctn-kix_vkx5887x6ome-5 0}ul.lst-kix_r1qxtw4k9pgo-1{list-style-type:none}ul.lst-kix_r1qxtw4k9pgo-0{list-style-type:none}ol.lst-kix_b0ja666m9l9x-8.start{counter-reset:lst-ctn-kix_b0ja666m9l9x-8 0}.lst-kix_puq7slv7ersb-5>li{counter-increment:lst-ctn-kix_puq7slv7ersb-5}.lst-kix_c9w8l0v8vj60-8>li:before{content:"-  "}.lst-kix_yfnaf4f33kdr-4>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-4}.lst-kix_yhp6v7of3e00-3>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-3}.lst-kix_76cwqgc9ntcg-4>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-4,lower-latin) ". "}.lst-kix_d9wep1z810b6-6>li{counter-increment:lst-ctn-kix_d9wep1z810b6-6}.lst-kix_bh4xapke1dje-1>li:before{content:"\0025cb  "}ol.lst-kix_stodkckubncd-8.start{counter-reset:lst-ctn-kix_stodkckubncd-8 0}ul.lst-kix_u7vldufjcii4-0{list-style-type:none}ul.lst-kix_u7vldufjcii4-1{list-style-type:none}.lst-kix_r1qxtw4k9pgo-0>li:before{content:"-  "}ul.lst-kix_u7vldufjcii4-2{list-style-type:none}.lst-kix_8hc53kjy1j5y-6>li:before{content:"-  "}.lst-kix_9kz8bq8q3b2i-4>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-4}.lst-kix_qgxhqyjzp80f-7>li{counter-increment:lst-ctn-kix_qgxhqyjzp80f-7}ul.lst-kix_u7vldufjcii4-7{list-style-type:none}ol.lst-kix_vkx5887x6ome-3.start{counter-reset:lst-ctn-kix_vkx5887x6ome-3 0}ul.lst-kix_u7vldufjcii4-8{list-style-type:none}ul.lst-kix_u7vldufjcii4-3{list-style-type:none}ul.lst-kix_u7vldufjcii4-4{list-style-type:none}ul.lst-kix_u7vldufjcii4-5{list-style-type:none}.lst-kix_8hc53kjy1j5y-3>li:before{content:"-  "}ul.lst-kix_u7vldufjcii4-6{list-style-type:none}ol.lst-kix_bz3wxvkk86wr-1.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-1 0}ol.lst-kix_seg2qxi99oen-1.start{counter-reset:lst-ctn-kix_seg2qxi99oen-1 0}.lst-kix_m0nrdnud90zq-0>li:before{content:"" counter(lst-ctn-kix_m0nrdnud90zq-0,decimal) ". "}ul.lst-kix_km6c63ta0u1m-8{list-style-type:none}ul.lst-kix_km6c63ta0u1m-7{list-style-type:none}.lst-kix_efg97u94j8hb-3>li:before{content:"-  "}ol.lst-kix_vkx5887x6ome-2.start{counter-reset:lst-ctn-kix_vkx5887x6ome-2 0}.lst-kix_uf4umlhhckq2-2>li:before{content:"" counter(lst-ctn-kix_uf4umlhhckq2-2,lower-roman) ". "}.lst-kix_b7uuq29jz54a-4>li{counter-increment:lst-ctn-kix_b7uuq29jz54a-4}ol.lst-kix_uf4umlhhckq2-3.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-3 0}.lst-kix_ks1i5lssvjkg-3>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-3}ol.lst-kix_bz3wxvkk86wr-2.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-2 0}.lst-kix_vkx5887x6ome-5>li{counter-increment:lst-ctn-kix_vkx5887x6ome-5}.lst-kix_vkx5887x6ome-8>li{counter-increment:lst-ctn-kix_vkx5887x6ome-8}.lst-kix_ks1i5lssvjkg-0>li{counter-increment:lst-ctn-kix_ks1i5lssvjkg-0}.lst-kix_73zznxkq85l2-7>li{counter-increment:lst-ctn-kix_73zznxkq85l2-7}ol.lst-kix_uf4umlhhckq2-4.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-4 0}.lst-kix_stodkckubncd-0>li{counter-increment:lst-ctn-kix_stodkckubncd-0}.lst-kix_9kz8bq8q3b2i-3>li:before{content:"" counter(lst-ctn-kix_9kz8bq8q3b2i-3,decimal) ". "}.lst-kix_m09drfn41lbc-2>li:before{content:"\0025a0  "}ol.lst-kix_bz3wxvkk86wr-0.start{counter-reset:lst-ctn-kix_bz3wxvkk86wr-0 0}ol.lst-kix_seg2qxi99oen-8.start{counter-reset:lst-ctn-kix_seg2qxi99oen-8 0}.lst-kix_76cwqgc9ntcg-7>li:before{content:"" counter(lst-ctn-kix_76cwqgc9ntcg-7,lower-latin) ". "}.lst-kix_76cwqgc9ntcg-6>li{counter-increment:lst-ctn-kix_76cwqgc9ntcg-6}ol.lst-kix_seg2qxi99oen-5.start{counter-reset:lst-ctn-kix_seg2qxi99oen-5 0}.lst-kix_69woh12i7ucg-8>li{counter-increment:lst-ctn-kix_69woh12i7ucg-8}.lst-kix_qaijc6nbpdk4-7>li:before{content:"-  "}.lst-kix_a6itagplhb2w-8>li:before{content:"\0025a0  "}.lst-kix_q7k3qhhwoyo7-4>li{counter-increment:lst-ctn-kix_q7k3qhhwoyo7-4}.lst-kix_s078hly7oqfy-3>li:before{content:"-  "}ol.lst-kix_uf4umlhhckq2-2.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-2 0}.lst-kix_qgxhqyjzp80f-0>li:before{content:"" counter(lst-ctn-kix_qgxhqyjzp80f-0,decimal) ". "}.lst-kix_4h5ayc5t6q0q-5>li:before{content:"\0025a0  "}.lst-kix_yhp6v7of3e00-0>li:before{content:"" counter(lst-ctn-kix_yhp6v7of3e00-0,decimal) ". "}ol.lst-kix_stodkckubncd-7.start{counter-reset:lst-ctn-kix_stodkckubncd-7 0}.lst-kix_vkx5887x6ome-8>li:before{content:"" counter(lst-ctn-kix_vkx5887x6ome-8,lower-roman) ". "}.lst-kix_efg97u94j8hb-0>li:before{content:"-  "}.lst-kix_u7vldufjcii4-5>li:before{content:"\0025a0  "}.lst-kix_h8i9ymdmzkx8-0>li{counter-increment:lst-ctn-kix_h8i9ymdmzkx8-0}ul.lst-kix_km6c63ta0u1m-4{list-style-type:none}.lst-kix_5f9t9fms2d21-6>li{counter-increment:lst-ctn-kix_5f9t9fms2d21-6}ul.lst-kix_km6c63ta0u1m-3{list-style-type:none}ul.lst-kix_km6c63ta0u1m-6{list-style-type:none}ul.lst-kix_km6c63ta0u1m-5{list-style-type:none}.lst-kix_bz3wxvkk86wr-7>li{counter-increment:lst-ctn-kix_bz3wxvkk86wr-7}ul.lst-kix_km6c63ta0u1m-0{list-style-type:none}ul.lst-kix_km6c63ta0u1m-2{list-style-type:none}.lst-kix_m0nrdnud90zq-2>li{counter-increment:lst-ctn-kix_m0nrdnud90zq-2}ul.lst-kix_km6c63ta0u1m-1{list-style-type:none}.lst-kix_9kz8bq8q3b2i-1>li{counter-increment:lst-ctn-kix_9kz8bq8q3b2i-1}ol.lst-kix_uf4umlhhckq2-0.start{counter-reset:lst-ctn-kix_uf4umlhhckq2-0 0}ol.lst-kix_seg2qxi99oen-7.start{counter-reset:lst-ctn-kix_seg2qxi99oen-7 0}.lst-kix_c9w8l0v8vj60-5>li:before{content:"-  "}.lst-kix_puq7slv7ersb-2>li{counter-increment:lst-ctn-kix_puq7slv7ersb-2}.lst-kix_puq7slv7ersb-0>li:before{content:"" counter(lst-ctn-kix_puq7slv7ersb-0,decimal) ". "}ol.lst-kix_jrq3pc6b7fs5-7{list-style-type:none}.lst-kix_yfnaf4f33kdr-7>li{counter-increment:lst-ctn-kix_yfnaf4f33kdr-7}ol.lst-kix_jrq3pc6b7fs5-8{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-5{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-6{list-style-type:none}.lst-kix_ujrictqeu2kx-0>li:before{content:"" counter(lst-ctn-kix_ujrictqeu2kx-0,decimal) ". "}ol.lst-kix_jrq3pc6b7fs5-3{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-4{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-1{list-style-type:none}ol.lst-kix_jrq3pc6b7fs5-2{list-style-type:none}.lst-kix_yhp6v7of3e00-6>li{counter-increment:lst-ctn-kix_yhp6v7of3e00-6}ol.lst-kix_jrq3pc6b7fs5-0{list-style-type:none}ol.lst-kix_seg2qxi99oen-6.start{counter-reset:lst-ctn-kix_seg2qxi99oen-6 0}ol{margin:0;padding:0}table td,table th{padding:0}.c46{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:106.5pt;border-top-color:#000000;border-bottom-style:solid}.c69{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:79.5pt;border-top-color:#000000;border-bottom-style:solid}.c61{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:60.8pt;border-top-color:#000000;border-bottom-style:solid}.c21{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:65.2pt;border-top-color:#000000;border-bottom-style:solid}.c73{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:98.2pt;border-top-color:#000000;border-bottom-style:solid}.c60{border-right-style:solid;padding:5pt 5pt 5pt 5pt;border-bottom-color:#000000;border-top-width:1pt;border-right-width:1pt;border-left-color:#000000;vertical-align:top;border-right-color:#000000;border-left-width:1pt;border-top-style:solid;border-left-style:solid;border-bottom-width:1pt;width:73.5pt;border-top-color:#000000;border-bottom-style:solid}.c52{margin-left:0pt;padding-top:18pt;list-style-position:inside;text-indent:45pt;padding-bottom:6pt;line-height:1.1500022727272727;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c41{-webkit-text-decoration-skip:none;color:#000000;font-weight:400;text-decoration:underline;vertical-align:baseline;text-decoration-skip-ink:none;font-size:11pt;font-family:"Arial";font-style:normal}.c6{-webkit-text-decoration-skip:none;color:#1155cc;font-weight:400;text-decoration:underline;vertical-align:baseline;text-decoration-skip-ink:none;font-size:11pt;font-family:"Arial";font-style:normal}.c5{margin-left:144pt;padding-top:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c2{margin-left:108pt;padding-top:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c53{padding-top:18pt;padding-bottom:6pt;line-height:1.1500022727272727;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c17{color:#000000;font-weight:700;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c8{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c44{padding-top:20pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c28{padding-top:18pt;padding-bottom:6pt;line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c54{padding-top:18pt;padding-bottom:6pt;line-height:1.0;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c4{margin-left:18pt;padding-top:3pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c11{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-size:16pt;font-family:"Arial";font-style:normal}.c39{padding-top:20pt;padding-bottom:6pt;line-height:1.1500022727272727;page-break-after:avoid;orphans:2;widows:2;text-align:left}.c48{padding-top:10pt;padding-bottom:0pt;line-height:1.0;orphans:2;widows:2;text-align:left}.c65{color:#000000;font-weight:400;text-decoration:none;font-size:11pt;font-family:"Arial";font-style:normal}.c9{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:left}.c50{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:right}.c43{margin-left:108pt;padding-top:0pt;padding-left:0pt;padding-bottom:0pt;line-height:1.15;text-align:left}.c23{color:#000000;font-weight:400;text-decoration:none;vertical-align:baseline;font-family:"Arial";font-style:normal}.c24{color:#000000;font-weight:700;text-decoration:none;vertical-align:baseline;font-size:11pt;font-family:"Arial"}.c40{padding-top:0pt;padding-bottom:0pt;line-height:1.15;orphans:2;widows:2;text-align:center}.c29{font-weight:700;vertical-align:baseline;font-size:11pt;font-family:"Arial";font-style:normal}.c94{color:#3c4043;font-weight:400;vertical-align:baseline;font-family:"Roboto";font-style:normal}.c14{text-decoration-skip-ink:none;-webkit-text-decoration-skip:none;font-style:italic;color:#1155cc;text-decoration:underline}.c19{margin-left:144pt;padding-left:0pt;orphans:2;widows:2}.c37{padding-top:0pt;padding-bottom:0pt;line-height:1.07;text-align:left}.c36{padding-top:0pt;padding-bottom:0pt;line-height:1.1500022727272727;text-align:left}.c30{margin-left:180pt;padding-left:0pt;orphans:2;widows:2}.c7{margin-left:108pt;padding-left:0pt;orphans:2;widows:2}.c76{padding-top:0pt;padding-bottom:0pt;line-height:1.15;text-align:left}.c90{margin-left:-15.8pt;border-spacing:0;border-collapse:collapse;margin-right:auto}.c13{margin-left:72pt;padding-left:0pt;orphans:2;widows:2}.c12{margin-left:117pt;padding-left:-9pt;orphans:2;widows:2}.c74{padding-top:10pt;padding-bottom:4pt;line-height:1.0;text-align:left}.c71{padding-top:4pt;padding-bottom:0pt;line-height:1.0;text-align:left}.c1{padding-top:0pt;padding-bottom:0pt;line-height:1.0;text-align:left}.c16{text-decoration-skip-ink:none;-webkit-text-decoration-skip:none;color:#1155cc;text-decoration:underline}.c20{orphans:2;widows:2;height:11pt}.c85{vertical-align:baseline;font-family:"Calibri";font-style:normal}.c59{vertical-align:baseline;font-family:"Arial";font-style:normal}.c62{color:#000000;text-decoration:none;font-size:18pt}.c42{text-decoration-skip-ink:none;-webkit-text-decoration-skip:none;text-decoration:underline}.c45{color:#ff0000;text-decoration:none}.c25{border:1px solid black;margin:5px}.c18{margin-left:72pt;padding-left:0pt}.c58{margin-left:117pt;padding-left:-9pt}.c15{color:inherit;text-decoration:inherit}.c67{orphans:2;widows:2}.c51{max-width:468pt;padding:72pt 72pt 72pt 72pt}.c75{font-weight:400;font-size:11pt}.c93{color:#222222;font-weight:400}.c81{vertical-align:baseline;font-family:"Arial"}.c26{margin-left:36pt;padding-left:0pt}.c3{padding:0;margin:0}.c38{margin-left:225pt;padding-left:-9pt}.c31{font-weight:700;font-size:14pt}.c64{vertical-align:super}.c47{padding-left:0pt}.c63{margin-left:108pt}.c79{height:20pt}.c98{font-size:14pt}.c84{color:#0000ff}.c68{height:0pt}.c72{color:#1155cc}.c10{font-size:10pt}.c33{font-weight:700}.c34{margin-left:180pt}.c0{background-color:#ffffff}.c96{font-size:12pt}.c49{font-size:20pt}.c87{color:#333333}.c82{page-break-after:avoid}.c22{font-style:italic}.c89{font-family:"Times New Roman"}.c32{margin-left:144pt}.c83{font-size:11pt}.c92{margin-left:216pt}.c27{height:11pt}.c66{color:#000000}.c35{font-size:10.5pt}.c95{font-size:16pt}.c77{font-size:18pt}.c55{height:59.2pt}.c80{text-decoration:none}.c78{margin-left:72pt}.c56{margin-left:36pt}.c86{font-size:7pt}.c97{font-weight:400}.c88{font-size:8pt}.c91{background-color:#ffff00}.c70{vertical-align:sub}.c57{color:#ff0000}.title{padding-top:0pt;color:#000000;font-size:26pt;padding-bottom:3pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}.subtitle{padding-top:0pt;color:#666666;font-size:15pt;padding-bottom:16pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}li{color:#000000;font-size:11pt;font-family:"Arial"}p{margin:0;color:#000000;font-size:11pt;font-family:"Arial"}h1{padding-top:20pt;color:#000000;font-size:20pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h2{padding-top:18pt;color:#000000;font-size:16pt;padding-bottom:6pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h3{padding-top:16pt;color:#434343;font-size:14pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h4{padding-top:14pt;color:#666666;font-size:12pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h5{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;orphans:2;widows:2;text-align:left}h6{padding-top:12pt;color:#666666;font-size:11pt;padding-bottom:4pt;font-family:"Arial";line-height:1.15;page-break-after:avoid;font-style:italic;orphans:2;widows:2;text-align:left}</style></head><body class="c0 c51"><div><p class="c50"><span class="c8">Version 3.23.20</span></p></div><p class="c1 c20"><span class="c75 c81 c22 c66 c80"></span></p><p class="c40 c0 c27"><span class="c59 c42 c33 c66 c77"></span></p><p class="c40 c0"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 468.50px; height: 93.85px;"><img alt="" src="media/image6.jpg" style="width: 468.50px; height: 93.85px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c0 c40"><span class="c59 c33 c62">Brigham and Women&rsquo;s Hospital</span></p><p class="c40 c0"><span class="c33 c77">COVID-19 Critical Care Clinical Guidelines </span></p><p class="c40 c0 c27"><span class="c59 c42 c33 c66 c77"></span></p><p class="c40 c0"><span class="c23 c77">Updated: 3/23/2020</span></p><p class="c9 c0 c27"><span class="c59 c62 c33"></span></p><p class="c40 c0"><span class="c59 c45 c31">This document is a work in progress. We have much to learn. </span></p><p class="c40 c0"><span class="c45 c31 c59">This is updated daily with evolving information; do not print.</span></p><p class="c40 c0 c27"><span class="c59 c45 c31"></span></p><p class="c40 c0"><span class="c16 c31"><a class="c15" href="https://www.google.com/url?q=https://sccm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf?lang%3Den-US%26_zs%3DWSjjd1%26_zl%3Dj1cc6&amp;sa=D&amp;ust=1585016770800000">SCCM Guidelines</a></span><span class="c59 c45 c31">&nbsp;are being reviewed and incorporated but are not yet reflected in this document</span></p><p class="c40 c0 c27"><span class="c59 c31 c66 c80"></span></p><p class="c40 c0"><span class="c31 c57">Please send suggestions:</span><span class="c31">&nbsp;</span><span class="c16 c98"><a class="c15" href="mailto:BWHCOVIDGuidelines@gmail.com">BWHCOVIDGuidelines@gmail.com</a></span><span class="c59 c31 c66 c80">&nbsp;</span></p><p class="c9 c0 c27"><span class="c59 c42 c33 c66 c77"></span></p><p class="c9"><span class="c10 c33">Disclaimer: </span><span class="c10">This document is intended as a resource for clinicians caring for critically-ill COVID-19 patients, based on available evidence and recommendations of governing bodies. The recommendations do not replace clinical judgment or the need for individualized patient care plans. While we attempt to keep this document up-to-date, the literature on COVID-19 is rapidly evolving, and we suggest that practitioners search for the most up-to-date literature on any specific topic. These guidelines will also rapidly evolve as they are implemented into clinical practice and we receive feedback from practitioners. Finally, these guidelines were developed based on practice patterns and infrastructure at Brigham and Women&rsquo;s Hospital in Boston, MA; local factors should be taken into account if utilized at other hospitals.</span></p><h1 class="c44" id="h.7amkd6138bxo"><span class="c23 c49">COVID-19 one page Quick Guides:</span></h1><p class="c9"><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.dropbox.com/s/th0vxif5x3hoejs/INITIAL%2520WORKUP-%2520covid%2520quick%2520guide.pdf?dl%3D0&amp;sa=D&amp;ust=1585016770801000">COVID-19 Initial work-up QUICK GUIDE</a></span></p><p class="c9"><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.dropbox.com/s/1na1vj0kq7dt0ys/RESP%2520FAILURE-%2520covid%2520quick%2520guide.pdf?dl%3D0&amp;sa=D&amp;ust=1585016770801000">COVID-19 Respiratory Failure management QUICK GUIDE</a></span></p><p class="c9"><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.dropbox.com/s/9ff4h4a8wea35oq/ICU%2520CARE-%2520covid%2520quick%2520guide.pdf?dl%3D0&amp;sa=D&amp;ust=1585016770801000">COVID-19 ICU care QUICK GUIDE</a></span></p><p class="c9 c0"><span class="c85 c42 c33 c66 c96">&nbsp;</span></p><hr style="page-break-before:always;display:none;"><p class="c9 c0 c27"><span class="c59 c42 c33 c66 c77"></span></p><p class="c40 c0"><span class="c59 c42 c33 c66 c77">Table of Contents</span></p><p class="c9 c0 c27"><span class="c59 c42 c31 c66"></span></p><p class="c67 c71"><span class="c29 c16"><a class="c15" href="#h.7amkd6138bxo">COVID-19 one page Quick Guides:</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.7amkd6138bxo">1</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.vpxc3qksjzgk">Chapter 1: Non-ICU Management, Triage, Transfers</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.vpxc3qksjzgk">3</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.a8294aye0lbq">Clinical Course of COVID-19</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.a8294aye0lbq">3</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.ymvixg917k3e">Non-ICU Management Principles</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.ymvixg917k3e">4</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.tsr53lmedjah">Chest Imaging and Point of Care Lung Ultrasound</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.tsr53lmedjah">6</a></span></p><p class="c4"><span class="c16"><a class="c15" href="#h.apqxkxatnuu">Triage to ICU</a></span><span class="c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c16"><a class="c15" href="#h.apqxkxatnuu">6</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.32yrxx2cn5j">Transfer Process</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.32yrxx2cn5j">6</a></span></p><p class="c48"><span class="c16 c29"><a class="c15" href="#h.hu2czim2nti8">Chapter 2: Respiratory Support for COVID-19 Patients</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.hu2czim2nti8">7</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.5z5wj4l0ghah">Respiratory Failure and ARDS</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.5z5wj4l0ghah">7</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.z178d8l3t5u1">Management of Hypoxemia</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.z178d8l3t5u1">7</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.welz4k559gib">Initial Mechanical Ventilation</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.welz4k559gib">9</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.mcb6j64zp5u6">PEEP and Mechanics</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.mcb6j64zp5u6">10</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.nhqe52dtgmrn">Targeting Sedation for Ventilator Synchrony</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.nhqe52dtgmrn">11</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.f3ug6fi0aj01">General Management of Ventilated ARDS Patients</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.f3ug6fi0aj01">12</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.qrh9t96165ug">Managing Ventilation</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.qrh9t96165ug">13</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.4wvmhdtgo9di">Managing Oxygenation</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.4wvmhdtgo9di">13</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.wgrateeto9z4">Proning and Pulmonary Vasodilators</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.wgrateeto9z4">15</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.24j39tc7pjup">ECMO consultation</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.24j39tc7pjup">16</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.kx686gedgtzg">Chapter 3: COVID-19 Therapies and Clinical Trials</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.kx686gedgtzg">17</a></span></p><p class="c4"><span class="c16"><a class="c15" href="#h.cjp7h4q36i0a">Note:</a></span><span class="c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c16"><a class="c15" href="#h.cjp7h4q36i0a">17</a></span></p><p class="c4"><span class="c16"><a class="c15" href="#h.hf0jef6dlsvm">Clinical trials</a></span><span class="c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c16"><a class="c15" href="#h.hf0jef6dlsvm">17</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.8vhrbtln428m">Antibiotic stewardship</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.8vhrbtln428m">17</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.eudti5z0ojjo">Metered-dose inhalers (MDIs) vs. nebulizers</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.eudti5z0ojjo">18</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.8pktimpr5u6o">Airway Clearance</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.8pktimpr5u6o">19</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.ym3ao1e1uli3">Inhaled Pulmonary Vasodilators</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.ym3ao1e1uli3">19</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.x05c129ivxrw">Systemic Corticosteroids</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.x05c129ivxrw">20</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.m6l0vgre9d0s">Anti-IL6 Agents (Tocilizumab, Siltuximab)</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.m6l0vgre9d0s">21</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.wr1agkjgho7b">Hydroxychloroquine and Chloroquine</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.wr1agkjgho7b">22</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.uebugzw0ifj">Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.uebugzw0ifj">23</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.msot2gdaj2bg">Non-steroidal anti-inflammatory drugs (NSAIDs)</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.msot2gdaj2bg">24</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.p7atxkt2b3sh">Blood Products</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.p7atxkt2b3sh">24</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.6zfga8b63w2s">Chapter 4: Cardiac Complications of COVID-19</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.6zfga8b63w2s">25</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.sxzvrsrmkd1g">Acute Cardiac Injury</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.sxzvrsrmkd1g">25</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.es6b8f4xqski">Cardiovascular Testing</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.es6b8f4xqski">26</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.rm4wr985h2i8">Arrhythmias</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.rm4wr985h2i8">26</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.13b1uhteftcc">Acute Coronary Syndromes</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.13b1uhteftcc">27</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.txp16938ptwl">Pericarditis and Myocarditis</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.txp16938ptwl">28</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.dpe5gr1hwjp">Chapter 5: Shock: Septic, Cardiogenic, and Cytokine Storm</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.dpe5gr1hwjp">29</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.bdbn9kepy2bs">Undifferentiated Shock in COVID</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.bdbn9kepy2bs">29</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.ebuidko2u3iz">Differentiating Shock</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.ebuidko2u3iz">30</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.lydcfzsuv4hc">Septic Shock and Secondary Infections</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.lydcfzsuv4hc">31</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.ftupyxepmedz">Cardiogenic Shock</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.ftupyxepmedz">33</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.7i62kagnynf0">Cytokine Activation Syndrome</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.7i62kagnynf0">35</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.5s70bzlr4ojz">Chapter 6: Thrombotic and Coagulation Manifestations</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.5s70bzlr4ojz">36</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.9wzf9ick65rt">Thrombotic Disease</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.9wzf9ick65rt">36</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.vpg0k312hzmd">Disseminated Intravascular Coagulation (DIC)</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.vpg0k312hzmd">37</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.9jn4ulxubc3h">Chapter 7: Renal Manifestations</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.9jn4ulxubc3h">38</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.fj20lj7bpd6o">Acute Kidney Injury</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.fj20lj7bpd6o">38</a></span></p><p class="c48"><span class="c29 c16"><a class="c15" href="#h.l3i6lcz3jr27">Chapter 8: Other Guidance</a></span><span class="c29 c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c29 c16"><a class="c15" href="#h.l3i6lcz3jr27">39</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.fg1hqkm6u1r8">Liver Disease</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.fg1hqkm6u1r8">39</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.aayfijcxre19">Considerations for Oncology Patients</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.aayfijcxre19">40</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.t1khoickfgoo">Goals of Care</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.t1khoickfgoo">43</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.ipfys4gecnv0">Management of Cardiac Arrest</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.ipfys4gecnv0">43</a></span></p><p class="c4"><span class="c6"><a class="c15" href="#h.6ogwg6sl9a40">The Role of Palliative Care</a></span><span class="c6">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c6"><a class="c15" href="#h.6ogwg6sl9a40">44</a></span></p><p class="c4"><span class="c16"><a class="c15" href="#h.foc01qidskrl">Ethical Considerations and Resource Allocation</a></span><span class="c16">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c16"><a class="c15" href="#h.foc01qidskrl">44</a></span></p><p class="c48"><span class="c33 c72"><a class="c15" href="#h.24n5wzicja05">REFERENCES</a></span><span class="c72 c33">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c72 c33"><a class="c15" href="#h.24n5wzicja05">46</a></span></p><p class="c67 c74"><span class="c72 c33"><a class="c15" href="#h.9um4ryva0zlb">ADDENDUM: COVID ICU Bundle Checklist</a></span><span class="c72 c33">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span class="c72 c33"><a class="c15" href="#h.9um4ryva0zlb">50</a></span></p><hr style="page-break-before:always;display:none;"><h1 class="c44 c79" id="h.vpxc3qksjzgk"><span class="c23 c49"></span></h1><h1 class="c44" id="h.d36vdx67mxka"><span class="c23 c49">Chapter 1: Non-ICU Management, Triage, Transfers</span></h1><ol class="c3 lst-kix_seg2qxi99oen-0 start" start="1"><li class="c28 c26"><h2 id="h.a8294aye0lbq" style="display:inline"><span>Clinical Course of </span><span>COVID-19</span><span class="c11">&nbsp;</span></h2></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c13 c1"><span class="c33">Clinical presentation: </span><span>non-specific, flu-like illness</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c43"><span class="c8">Fever (44-98%) </span></li><li class="c43"><span class="c8">Cough (46-82%)</span></li><li class="c43"><span class="c8">Shortness of breath (20-64%)</span></li><li class="c43"><span class="c8">Upper respiratory symptoms, nasal / sinus congestion &nbsp;(5-25%)</span></li><li class="c43"><span class="c8 c0">GI symptoms (10%; usually before respiratory symptoms)</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="2"><li class="c18 c76"><span class="c17 c0">Transmission:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c43"><span class="c8 c0">Large droplets and fomites</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c76 c47 c32"><span class="c0">Viral particles survive &lt; 24h on cardboard, &lt; 72h on plastic or steel (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32182409&amp;sa=D&amp;ust=1585016770824000">van Dorelmalen et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32182409&amp;sa=D&amp;ust=1585016770824000">New Engl J Med, </a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32182409&amp;sa=D&amp;ust=1585016770824000">2020</a></span><span class="c8 c0">)</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="2"><li class="c43"><span class="c8 c0">Aerosols (droplet nuclei, &lt; 5 &micro;m), estimated &lt; 4h </span></li><li class="c43"><span class="c8 c0">Incubation period: median 4 days, common range 2-7 days, up to 24 days</span></li><li class="c43"><span class="c0">Symptomatic and asymptomatic patients can transmit the virus</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="3"><li class="c13 c1"><span class="c33">Disease Course</span><span class="c8">: </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c7 c1"><span class="c8">~ 80% do not require critical care</span></li><li class="c7 c1"><span>~ 10-20% develop bacterial </span><span>superinfection</span><span class="c8">&nbsp;</span></li><li class="c7 c1"><span>~ 2-25% have respiratory viral co-infection (Qingdao, China: </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2&amp;sa=D&amp;ust=1585016770826000">Xing et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2&amp;sa=D&amp;ust=1585016770826000">medRxiv, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.29.20027698v2&amp;sa=D&amp;ust=1585016770827000">2020 preprint</a></span><span>; Stanford, CA, USA: </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333&amp;sa=D&amp;ust=1585016770827000">Shah N, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333&amp;sa=D&amp;ust=1585016770827000">Medium</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333&amp;sa=D&amp;ust=1585016770827000">, 2020 unpublished data</a></span><span>)</span></li><li class="c7 c1"><span>~ 20% develop </span><span>ARDS</span></li><li class="c7 c1"><span class="c8">~ 5% develop renal injury requiring renal replacement therapy </span></li><li class="c7 c1"><span class="c8">Elevated AST / ALT (~200s) is common; fulminant hepatitis not reported</span></li><li class="c7 c1"><span>Cardiomyopathy in critically ill patients; some progress to cardiogenic shock late in course (anecdotal reports)</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="4"><li class="c13 c1"><span class="c17">Reasons for ICU admission:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c7 c1"><span class="c8">Hypoxemic respiratory failure is the most common indication for ICU.</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c19 c1"><span class="c8">Reports of rapid progression to intubation within 12-24h</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="2"><li class="c7 c1"><span class="c8">Few patients with shock, can develop late in course</span></li><li class="c7 c1"><span class="c8">Median time from symptom onset to ICU transfer is ~10 days</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="5"><li class="c13 c1"><span class="c17">Poor prognostic indicators:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c7 c1"><span class="c8">Demographics: Age &gt; 65, male</span></li><li class="c7 c1"><span class="c8">Comorbidities: cardiovascular disease (includes hypertension), pulmonary disease, diabetes, malignancy, immunosuppression</span></li><li class="c7 c1"><span>Lab findings: severe lymphopenia, elevated troponin, elevated creatinine, elevated LDH, elevated CRP, elevated D-dimer</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="6"><li class="c9 c18"><span class="c17">Cause of death:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c2"><span class="c8">~53% respiratory failure</span></li><li class="c2"><span class="c8">~33% concomitant respiratory and heart failure</span></li><li class="c2"><span>~7% cardiac or heart failure alone</span></li><li class="c2"><span>Mortality rate appears to correlate with age and availability of medical resources </span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770831000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770831000">Intensive Care Med,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770831000">&nbsp;2020</a></span><span>)</span></li></ol><p class="c9 c27"><span class="c8"></span></p><ol class="c3 lst-kix_seg2qxi99oen-0" start="2"><li class="c54 c26"><h2 id="h.ymvixg917k3e" style="display:inline"><span>Non-ICU Management Principles</span></h2></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c9 c18"><span class="c17">Diagnostic studies: </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c2"><span class="c8">Labs &amp; EKG: </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c5"><span class="c8">On admission: CBC with differential, BMP, LFTs, LDH, CRP, D-dimer, Troponin / CPK, PTT / INR, Procalcitonin, baseline EKG</span></li><li class="c5"><span class="c8">Daily: CBC with differential, BMP</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-4 start" start="1"><li class="c9 c47 c34"><span class="c8">For stable floor patients, consider every other day</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3" start="3"><li class="c5"><span class="c8">Every other day: LFTs, LDH, CRP, D-dimer, Troponin / CPK (if in ICU), Triglycerides (if on propofol) </span></li><li class="c5"><span class="c8">If clinical worsening: LFTs, LDH, CRP, D-dimer, Troponin, CPK, PTT / INR, Procalcitonin, Ferritin, Fibrinogen, EKG </span></li><li class="c5"><span class="c8">Expert opinion does not recommend routine pro-BNP. </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="2"><li class="c2"><span class="c8">Chest imaging: Portable CXR is sufficient in most cases. Avoid routine daily CXR (unlikely to change management, evaluate case-by-case).</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c19 c1"><span class="c8">Chest imaging variable; bilateral patchy opacities most common</span></li><li class="c19 c1"><span class="c8">Chest CT often will not change treatment; obtain only if necessary (risk of transmission, time associated with transport / decontamination of equipment)</span></li><li class="c19 c1"><span>Point of Care Ultrasound of the lungs can be used but </span><span class="c8">by experienced providers only</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="3"><li class="c2"><span class="c8">Obtain additional studies only if necessary</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c5"><span>Avoid routine TTEs (for cardiac studies, see: </span><span class="c16"><a class="c15" href="#h.6zfga8b63w2s">&ldquo;Cardiac Complications of COVID&rdquo; chapter</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="2"><li class="c9 c18"><span class="c17">Medical management:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c2"><span>Further details in </span><span class="c16"><a class="c15" href="#h.kx686gedgtzg">&ldquo;COVID Therapies and Clinical Trials&rdquo; chapter</a></span></li><li class="c2"><span class="c8">Management is largely supportive</span></li><li class="c2"><span class="c8">Fluid management should be conservative due to risk of hypoxia/CHF</span></li><li class="c2"><span class="c8">Antiviral and immune-modulating therapies are investigational </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="3"><li class="c9 c18"><span class="c17">Early Advance Care Planning:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c2"><span class="c8">In conscious patients, review or sign Health Care Proxy form </span></li><li class="c2"><span class="c8">Discuss and document goals of care on admission</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c5"><span class="c8">Educate patient and family on disease course </span></li><li class="c19 c1"><span class="c8">Focus on desired quality of life and tolerance for ICU measures</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-4 start" start="1"><li class="c30 c1"><span>Avoid implying availability of ICU measures if unknown (refer to local ethics guidance)</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="4"><li class="c9 c18"><span class="c33">Avoid increasing risk of transmission: </span><span class="c8">Generally avoid transport if possible.</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c2"><span>Further details in </span><span class="c16"><a class="c15" href="#h.kx686gedgtzg">&ldquo;COVID Therapies and Clinical Trials&rdquo; chapter</a></span></li><li class="c2"><span class="c8">Non-Invasive Positive Pressure Ventilation (NIPPV: BiPAP, CPAP), High Flow Nasal Cannula (HFNC), Humidified Venturi Face Masks, Nebulizers increase aerosolization. </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c5"><span class="c41">Any aerosol-generating intervention must be performed under Strict (Airborne) Isolation Precautions, in a negative pressure room. </span></li><li class="c5"><span>In current policy, patients with </span><span class="c42">severe OSA</span><span>&nbsp;may continue nocturnal CPAP / BiPAP</span><span>&nbsp;but </span><span class="c42">must use a BWH</span><span>&nbsp;NIPPV </span><span class="c42">mask</span><span>&nbsp;and </span><span class="c42">machine</span><span class="c8">, not their home mask or nasal pillows which have elevated aerosol risk. BWH machines have dual limb (with HEPA filter); in contrast, home machines have a single limb so they have an anti-asphyxiation (pop-off) valve that increases aerosol risk. </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Transition back to home machine if COVID-19 ruled out</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3" start="3"><li class="c5"><span>Use m</span><span class="c8">etered dose inhalers instead of nebulizers. </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Transition back to nebs if COVID-19 ruled out</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3" start="4"><li class="c5"><span class="c8">If patient already on BiPAP / CPAP / HFNC becomes COVID-suspected, transition to non-rebreather followed by intubation.</span></li><li class="c5"><span class="c8">NIPPV* is not used for ARDS; early intubation is preferred. </span></li></ol><p class="c9 c32"><span>*Can be considered on a case-by-case basis for highly reversible indications (</span><span class="c22">e.g.</span><span>, </span><span class="c8">flash pulmonary edema with rapid resolution). </span></p><ol class="c3 lst-kix_seg2qxi99oen-3" start="6"><li class="c5"><span class="c8">Similar to many U.S. medical centers, our current default is to avoid HFNC in DNI patients and to use NRB, although exceptions can be considered on a case-by-case basis. </span></li></ol><p class="c9 c32 c27"><span class="c8"></span></p><ol class="c3 lst-kix_seg2qxi99oen-0" start="3"><li class="c28 c26"><h2 id="h.tsr53lmedjah" style="display:inline"><span class="c11">Chest Imaging and Point of Care Lung Ultrasound</span></h2></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c9 c18"><span class="c75 c81 c22 c66 c80">This section is in progress</span></li></ol><p class="c9 c27 c78"><span class="c8"></span></p><ol class="c3 lst-kix_seg2qxi99oen-0" start="4"><li class="c28 c26"><h2 id="h.apqxkxatnuu" style="display:inline"><span class="c11">Triage to ICU</span></h2></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c13 c1"><span class="c33">Consult the ICU triage team EARLY for:</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c7 c1"><span class="c8">Provider concern</span></li><li class="c7 c1"><span>Respiratory distress</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c1 c19"><span class="c8">Need O2 &gt; 6 LPM to maintain SpO2 &gt; 92 or PaO2 &gt; 65.</span></li><li class="c19 c1"><span class="c8">Rapid escalation of oxygen requirement.</span></li><li class="c19 c1"><span class="c8">Significant work of breathing.</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="3"><li class="c7 c1"><span>Hemodynamic instability after initial </span><span>conservative</span><span class="c8">&nbsp;fluid resuscitation </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c19 c1"><span class="c8">SBP &lt; 90, Mean arterial pressure &lt; 65, or Heart rate &gt; 120.</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="4"><li class="c7 c1"><span class="c8">Acidosis</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-3 start" start="1"><li class="c19 c1"><span class="c8">ABG with pH &lt; 7.3 or PCO2 &gt; 50 or above patient&rsquo;s baseline.</span></li><li class="c19 c1"><span class="c8">Lactate &gt; 2.</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2" start="5"><li class="c7 c1"><span class="c8">Need for intensive nursing care or frequent laboratory draws requiring arterial line.</span></li><li class="c7 c1"><span class="c8">Severe comorbid illness / high risk for deterioration.</span></li></ol><p class="c1 c20 c63"><span class="c8"></span></p><ol class="c3 lst-kix_seg2qxi99oen-0" start="5"><li class="c28 c26"><h2 id="h.32yrxx2cn5j" style="display:inline"><span class="c11">Transfer Process </span></h2></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1 start" start="1"><li class="c13 c1"><span class="c17">Additional details in Strict Isolation Procedures Manual.</span></li><li class="c13 c1"><span class="c33">Floor / ED to ICU:</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c7 c1"><span class="c8">ICU RN brings ICU bed to the floor for transfer (to avoid bed transfer in COVID precautions room and subsequent bed cleaning).</span></li><li class="c7 c1"><span class="c8">Patient wears surgical mask, with an extra clean gown and sheet on top. &nbsp; </span></li><li class="c7 c1"><span class="c8">Providers wear standard PPE during transport.</span></li><li class="c7 c1"><span class="c8">Security facilitates the shortest and fastest transfer route, walks 6 ft away from patient and providers, not required to wear PPE</span></li><li class="c7 c1"><span>Necessary tests (</span><span class="c22">e.g.</span><span class="c8">&nbsp;CT), should be obtained during transfer if possible.</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="3"><li class="c13 c1"><span class="c17">ICU to floor: </span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-2 start" start="1"><li class="c7 c1"><span class="c8">RN wears standard PPE</span></li><li class="c7 c1"><span class="c8">Patient travels in wheelchair or stretcher</span></li><li class="c7 c1"><span class="c8">Security facilitates the shortest and fastest transfer route, walks 6 ft away from patient and providers, not required to wear PPE</span></li></ol><ol class="c3 lst-kix_seg2qxi99oen-1" start="4"><li class="c13 c1"><span class="c33">Floor to discharge: s</span><span class="c33">ee separate documentation of discharge criteria/planning</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_5f9t9fms2d21-2 start" start="1"><li class="c7 c1"><span class="c8">RN wears standard PPE</span></li><li class="c7 c1"><span class="c8">Patient travels in wheelchair </span></li><li class="c7 c1"><span class="c8">Security facilitates the shortest and fastest transfer route, walks 6 ft away from patient and providers, not required to wear PPE</span></li><li class="c7 c1"><span class="c8">Patient is escorted directly into vehicle; contact care management if patient does not have access to a personal vehicle</span></li></ol><h1 class="c44" id="h.hu2czim2nti8"><span class="c23 c49">Chapter 2: Respiratory Support for COVID-19 Patients</span></h1><ol class="c3 lst-kix_uf4umlhhckq2-0 start" start="1"><li class="c28 c26"><h2 id="h.5z5wj4l0ghah" style="display:inline"><span class="c11">Respiratory Failure and ARDS </span></h2></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-1 start" start="1"><li class="c9 c18"><span class="c17">Pathophysiology: </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c2"><span>Histology shows </span><span class="c0">bilateral diffuse alveolar damage with cellular fibromyxoid exudates, desquamation of pneumocytes, pulmonary edema, and hyaline membrane formation (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770844000">Xu et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770844000">Lancet Respir Med</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770845000">, </a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770845000">2020</a></span><span class="c0">)</span></li><li class="c2"><span>Some evidence of direct viral injury to lung tissue, rather than purely hyperinflammatory process</span><span class="c0">&nbsp;(</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770845000">Xu et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770846000">Lancet Respir Med,</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32085846&amp;sa=D&amp;ust=1585016770846000">&nbsp;2020</a></span><span class="c0">)</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-1" start="2"><li class="c9 c18"><span class="c17">Time course:</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c2"><span class="c8">Anecdotal reports that progression of hypoxemic respiratory failure occurs rapidly (within ~12-24 hours)</span></li><li class="c2"><span class="c8">From onset of symptoms, median time to: </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c5"><span>D</span><span>evelopment of ARDS:</span><span>&nbsp;</span><span class="c0">8-12 days (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770847000">Wang et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770847000">JAMA</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770848000">, 2020</a></span><span class="c0">; </span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770848000">Zhou et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770848000">Lancet</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770848000">, 2020</a></span><span class="c0">; </span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&amp;sa=D&amp;ust=1585016770849000">Huang et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&amp;sa=D&amp;ust=1585016770849000">Lancet</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&amp;sa=D&amp;ust=1585016770849000">, 2020</a></span><span class="c8 c0">)</span></li><li class="c5"><span>M</span><span>echanical ventilation:</span><span>&nbsp;10.5-14.5 days (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&amp;sa=D&amp;ust=1585016770850000">Huang et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&amp;sa=D&amp;ust=1585016770850000">Lancet</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31986264&amp;sa=D&amp;ust=1585016770850000">, 2020</a></span><span class="c0">; </span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770851000">Zhou et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770851000">Lancet</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770851000">, 2020</a></span><span class="c8 c0">)</span></li></ol><p class="c9 c32 c27"><span class="c8 c0"></span></p><ol class="c3 lst-kix_uf4umlhhckq2-0" start="2"><li class="c28 c26"><h2 id="h.z178d8l3t5u1" style="display:inline"><span class="c11">Management of Hypoxemia</span></h2></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-1 start" start="1"><li class="c13 c1"><span class="c17">Supplemental Oxygen:</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c7 c1"><span>Humidified n</span><span>asal cannula (NC) 1 to 8 LPM for target SpO2 92-96%</span></li><li class="c2"><span>If a patient requires &gt; 8 LPM NC, initiate </span><span>dry</span><span class="c8">&nbsp;Venturi mask (non-humidified to reduce aerosolization risk) </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c5"><span class="c8">Start Venturi mask at 9 LPM and FiO2 28%</span></li><li class="c5"><span class="c8">Up-titrate FiO2 to goal SpO2 of 92-96% (not exceeding FiO2 35%)</span></li><li class="c5"><span class="c8">If FiO2 &gt; 35% then increase flow to 12 LPM</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2" start="3"><li class="c2"><span class="c8">Notify ICU triage pager</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-1" start="2"><li class="c13 c1"><span class="c33">Avoid </span><span class="c33">high-flow nasal cannula (HFNC) </span><span class="c33">and non-invasive positive pressure ventilation (NIPPV; </span><span class="c33">i.e.</span><span class="c17">&nbsp;CPAP/BiPAP) for ARDS.</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c7 c1"><span>Patients on nocturnal NIPPV at home should continue their nocturnal NIPPV. However, patient must use BWH NIPPV </span><span class="c42">mask</span><span>&nbsp;and </span><span class="c42">machine</span><span class="c8">&nbsp;(not home mask/nasal pillow or machine due to increased aerosol risk with home pillows/mask/machine) under strict airborne precautions. &nbsp; </span></li><li class="c7 c1"><span class="c8">If a patient already on HFNC or NIPPV becomes a COVID-19 PUI, transition to non-rebreather if safe</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c19 c1"><span class="c8">Recommend that the patient be off an aerosol generating device like &nbsp;HFNC or NIPPV for 45 minutes prior to intubation if clinically feasible</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2" start="3"><li class="c7 c1"><span>If a patient is </span><span>DNR/DNI</span><span>&nbsp;or </span><span>otherwise</span><span class="c8">&nbsp;is not eligible for intubation: </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c19 c1"><span class="c17">Current policy advises avoiding HFNC or NIPPV in DNI/DNR patients. However, neither HFNC nor NIPPV is prohibited and case-by-case exceptions could apply. </span></li><li class="c19 c1"><span>T</span><span class="c8">his is an evolving area without definitive evidence or uniform policy that underwent multi-disciplinary discussion. </span></li><li class="c19 c1"><span class="c8">Considerations include: </span></li></ol><ul class="c3 lst-kix_cmax3c5l3b9l-0 start"><li class="c30 c1"><span class="c8">Safety of staff (particularly respiratory therapy and nursing);</span></li><li class="c30 c1"><span>Paucity of data on the increased aerosol risk;</span><span>&nbsp;</span></li><li class="c30 c1"><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770855000">WHO interim guidance (published March 13, 2020)</a></span><span>&nbsp;on COVID-19 are more liberal about the usage of HFNC and NIPPV, stating that systems with </span><span>&ldquo;good interface fitting [i.e., good seal, no air leak]</span><span class="c0">&nbsp;do not create widespread dispersion of exhaled air and therefore should be associated with low risk of airborne transmission.&rdquo;</span><sup><a href="#cmnt1" id="cmnt_ref1">[a]</a></sup><span class="c8 c0">&nbsp;</span></li><li class="c30 c1"><span class="c8">Difficulty in assessing how many patients failing NRB would survive on HFNC. </span></li><li class="c30 c1"><span class="c8">Pro-active treatment of air hunger through other means.</span></li><li class="c30 c1"><span class="c8">HFNC has been utilized in lieu of ventilation of both full code and DNI/DNR patients in the setting of limited resources. </span></li></ul><p class="c1 c67 c32"><span class="c75 c81 c0 c22 c66 c80">If HFNC or NIPPV used</span></p><ol class="c3 lst-kix_uf4umlhhckq2-4 start" start="1"><li class="c30 c1"><span>For HFNC, recommend patient wear surgical mask and </span><span class="c8">limit flow rate to &lt; 30 L/min</span></li><li class="c30 c1"><span class="c8">For BiPAP, use an in-line viral filter.</span></li><li class="c30 c1"><span class="c8">Ensure masks/devices fit well and there is minimal air leak (as leaks propel potentially infected air significant distances - see &ldquo;Rationale&rdquo; below)</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2" start="4"><li class="c7 c1"><span class="c22">Rationale</span><span class="c8">: General consensus suggests that HFNC and NIPPV increase the risk of viral transmission. Given the rapid progression of disease, we do not expect many patients can be salvaged/avoid intubation using HFNC/NIPPV, but this is unknown</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c19 c1"><span>A systematic review on SARS found that NIPPV was associated with increased risk of viral transmission to healthcare workers (n=2 studies), but HFNC was not (n=1) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&amp;sa=D&amp;ust=1585016770857000">Tran et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&amp;sa=D&amp;ust=1585016770858000">PLoS One</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&amp;sa=D&amp;ust=1585016770858000">, 2012</a></span><span class="c8">)</span></li><li class="c19 c1"><span>Other studies with very limited power exist, such as a post-hoc analysis that found no secondary infections in medical staff from patients with influenza H1N1 treated with HFNC but was limited to only n=20 (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&amp;sa=D&amp;ust=1585016770858000">Rello </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&amp;sa=D&amp;ust=1585016770859000">et al</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&amp;sa=D&amp;ust=1585016770859000">, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&amp;sa=D&amp;ust=1585016770859000">J Crit Care, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22762937&amp;sa=D&amp;ust=1585016770860000">2012</a></span><sup><a href="#cmnt2" id="cmnt_ref2">[b]</a></sup><span>); </span><span class="c22">&nbsp;</span><span>&nbsp;</span></li><li class="c19 c1"><span class="c0">Exhaled air distances are minimally increased with CPAP pressures up to 20 cm H2O and HFNC up to 60 LPM; device/interface leaks cause significant lateral air travel (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&amp;sa=D&amp;ust=1585016770860000">Hui et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&amp;sa=D&amp;ust=1585016770861000">Eur Respir J,</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&amp;sa=D&amp;ust=1585016770861000">&nbsp;2019</a></span><span class="c0">)</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-1" start="3"><li class="c9 c18"><span class="c17">Early intubation: </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2 start" start="1"><li class="c2"><span>W</span><span>e recommend </span><span class="c8">early consultation with anesthesia for possible intubation in the setting of rapidly progressive hypoxia. </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c5"><span>Case reports from China suggest high failure rates for non-invasive ventilation, including high-flow nasal oxygen (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32102726&amp;sa=D&amp;ust=1585016770862000">Zuo et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32102726&amp;sa=D&amp;ust=1585016770862000">Chin Med Sci J</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32102726&amp;sa=D&amp;ust=1585016770862000">, 2020</a></span><span>)</span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2" start="2"><li class="c2"><span>For patients maintained on Venturi mask, o</span><span class="c8">nce FiO2 = 60% and SpO2 &lt; 92%, call for intubation if patient is a candidate for mechanical ventilation </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-3 start" start="1"><li class="c19 c1"><span>There is a </span><span>COVID Airway Code Team</span><span class="c8">&nbsp;with specific protocols for avoiding aerosolization.</span></li><li class="c19 c1"><span>Many centers suggest Rapid Sequence Intubation when fully paralyzed, without ambu-bag (which generates aerosols) and highly experienced operators (</span><span class="c22">e.g.</span><span class="c8">, anesthesia attending). </span></li></ol><ol class="c3 lst-kix_uf4umlhhckq2-2" start="3"><li class="c2"><span>Consider additional</span><span>&nbsp;indications for intubation (tachypnea, work of breathing).</span></li></ol><p class="c9 c63"><span>&nbsp;</span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0 start" start="3"><li class="c28 c26"><h2 id="h.welz4k559gib" style="display:inline"><span class="c11">Initial Mechanical Ventilation</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c17">Intubations outside of ICU:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>S</span><span class="c8">hould be attended by the Resource RT, who can facilitate early and appropriate ventilator settings with non-intensivists.</span></li><li class="c2"><span class="c8">Use &ldquo;Mechanical Ventilation with Sedation&rdquo; orderset.</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c17">Initiate Volume Control (AC/VC) mode </span></li><li class="c9 c18"><span class="c33">Initial tidal volume (Vt):</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Vt = 6 ml/kg (based on ideal body weight [IBW] from ARDSnet table, see table below)</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">IBW men (kg) = 50 + 2.3 (height in inches &ndash; 60)</span></li><li class="c5"><span class="c8">IBW women (kg) = 45.5 + 2.3 (height in inches &ndash; 60)</span></li></ol><p class="c9 c78"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 487.00px; height: 346.50px;"><img alt="" src="media/image4.png" style="width: 487.00px; height: 353.00px; margin-left: 0.00px; margin-top: -6.50px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c9 c18"><span class="c17">Initial respiratory rate 16-24, higher if acidosis present.</span></li><li class="c9 c18"><span class="c17">Initial PEEP based on BMI:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">BMI &lt; 35: PEEP 10</span></li><li class="c2"><span class="c8">BMI 35 to 50: PEEP 12</span></li><li class="c2"><span class="c8">BMI &gt; 50: PEEP 15</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="6"><li class="c9 c18"><span class="c17">Initial FiO2: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>100% on intubation then rapidly wean to SpO2 92-96% (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770866000">Barrot et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770867000">N Engl J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770867000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770867000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770867000">2020</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="7"><li class="c9 c18"><span class="c33">Obtain STAT portable CXR to confirm endotracheal tube location:</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Order and page radiology at time of intubation </span></li><li class="c2"><span class="c8">Prioritize CXR and vent titration over procedures (such as central venous catheter placement) if possible. </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="8"><li class="c9 c18"><span class="c33">Within 30 minutes of intubation, obtain an ABG</span><span class="c17">&nbsp;(preferred) or a VBG and adjust ventilation and oxygenation as needed</span></li></ol><p class="c9 c27 c78"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="4"><li class="c28 c26"><h2 id="h.mcb6j64zp5u6" style="display:inline"><span class="c11">PEEP and Mechanics</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c17">If patients supported by Hamilton G5 Ventilator (most common), perform the following within 10 minutes of intubation:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>Determine best PEEP following intubation </span><span>while paralyzed</span><span class="c8">&nbsp;using Pressure-Volume (PV) tool</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span>This is a departure from use of Best PEEP Trials.</span><span class="c8">&nbsp;PV tool is the preferred method due to widespread familiarity with RT staff, institutional experience, time constraints, and minimizing provider exposure</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2" start="2"><li class="c2"><span>Recommend maintaining this PEEP for initial care unless titration is required based on clinical parameters (</span><span class="c22">e.g.</span><span class="c8">, hypoxia, elevated Ppl, etc)</span></li><li class="c2"><span class="c8">If PEEP titration is required based on change in clinical status, recommend using PV tool to assess new PEEP. If this is not possible (no knowledgeable user available or patient inadequately sedated) then recommend PEEP titration by the Lower PEEP ARDSnet table (see below)</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c33">If patients </span><span class="c33 c22 c42">not</span><span class="c33">&nbsp;supported by Hamilton G5 Ventilator, perform the following within 10 minutes of intubation</span><span class="c8">:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Initiate PEEP based on BMI </span></li><li class="c2"><span>If there are changes in clinical parameters (</span><span class="c22">e.g.,</span><span class="c8">&nbsp;hypoxia), titrate PEEP according to ARDSnet Lower PEEP table (below).</span></li><li class="c2"><span>Current recommendations are to use ARDSnet Lower PEEP table. This table is selected primarily to avoid doing initial harm to patients with poor lung compliance and was chosen following joint MGH and BWH discussion.</span><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 495.50px; height: 126.21px;"><img alt="" src="media/image3.png" style="width: 495.50px; height: 126.21px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></li></ol><p class="c40 c27 c56"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c9 c18"><span class="c33">After best PEEP determined, obtain</span><span>&nbsp;</span><span class="c33">respiratory mechanics</span><span class="c8">:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>Plateau pressure (with goal &lt; 30, management below)</span></li><li class="c2"><span class="c8">Static compliance</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c9 c18"><span class="c17">Obtain arterial blood gas: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>G</span><span>oal pH 7.25 to 7.45 </span></li><li class="c2"><span class="c8">Calculate P/F ratio from initial post-intubation ABG</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="5"><li class="c9 c18"><span class="c17">Routine esophageal balloon use is not recommended</span></li></ol><p class="c9 c27"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="5"><li class="c28 c26"><h2 id="h.nhqe52dtgmrn" style="display:inline"><span class="c11">Targeting Sedation for Ventilator Synchrony</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c33">Initially target </span><span class="c33">RASS -2 to -3 (see table below)</span><span class="c33">:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Maintain deep sedation immediately post-intubation while paralyzed (assume 60 minutes for Rocuronium, 10 minutes for succinylcholine)</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c42">Preferred initial sedation regimen</span><span>:</span><span class="c0 c35 c80 c94">&nbsp;</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c9 c47 c34"><span>Fentanyl/Hydromorphone (boluses +/- infusion) + Propofol: target analgosedation and optimize analgesia first while decreasing sedative requirements</span></li><li class="c9 c47 c34"><span class="c8">Measure triglycerides and lipase every third day on propofol or earlier if other reasons for hypertriglyceridemia</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3" start="2"><li class="c5"><span class="c42">Adjunct agent:</span><span class="c8">&nbsp;Midazolam</span></li><li class="c5"><span class="c41">Use dexmedetomidine only when nearing extubation</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c33">Target ventilator synchrony: </span><span>Ventilator-induced lung injury (VILI) is common in patients who are not synchronous with the ventilator and can cause significant lasting damage</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>Once at target RASS after paralytics have worn off, assess patient synchrony with the ventilator (</span><span class="c22">e.g.</span><span class="c8">, signs of breath-stacking, double triggering, other ventilator alarms).</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span>Titrate sedatives/analgesics to ventilator synchrony allowing for deeper RASS.</span></li><li class="c5"><span>If patient remains dyssynchronous despite deep sedation (RASS -5), initiate continuous paralytics </span><span>(ensure BIS 40 to 60 prior to initiating and during paralysis)</span><span class="c8">.</span></li></ol><p class="c40 c56"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 314.51px; height: 337.50px;"><img alt="" src="media/image5.png" style="width: 314.51px; height: 337.50px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p><p class="c9 c27 c78"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="6"><li class="c28 c26"><h2 id="h.f3ug6fi0aj01" style="display:inline"><span class="c11">General Management of Ventilated ARDS Patients</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c17">Consider whether patient requires daily CXR: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">CXR clearly indicated for: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">Clinical change </span></li><li class="c5"><span class="c8">Concern for displaced ET tube:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Sudden increase in peak inspiratory pressure or resistance</span></li><li class="c9 c47 c34"><span class="c8">Decreased, unilateral breath sounds (usually on the right)</span></li><li class="c9 c47 c34"><span class="c8">RN or RT concern for change in depth of ET tube at teeth </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c17">COVID-19 ICU Bundle:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>Ventilated patients should all have a daily ICU &ldquo;Bundle&rdquo; of best practices. See </span><span class="c16"><a class="c15" href="#h.9um4ryva0zlb">Addendum 1</a></span><span>&nbsp;for a proposed </span><span>&ldquo;</span><span class="c8">COVID-19 ICU Bundle&rdquo;.</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c9 c18"><span class="c17">Ventilator consults:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">If you need additional assistance managing ventilator choices, you can request a pulmonary phone/in-person consult (pager 11957).</span></li></ol><p class="c9 c63 c27"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="7"><li class="c28 c26"><h2 id="h.qrh9t96165ug" style="display:inline"><span class="c11">Managing Ventilation</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c33">Follow ARDSnet ventilation where possible:</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Tidal volumes should be 4-6 cc/kg using IBW (see table above) to minimize volumes (and thus ventilator injury).</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c17">Minute ventilation (respiratory rate x tidal volume) typically drives pH and PCO2:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Titrate ventilatory parameters to pH, not PCO2.</span></li><li class="c2"><span class="c8">To achieve low tidal volumes, we tolerate hypercapnia (functionally no limitation unless clinical sequelae) and acidemia (pH &gt; 7.2).</span></li><li class="c2"><span class="c8">Because tidal volumes are low, the respiratory rate often has to be high to accommodate; typical RR is 20-35 breaths/minute.</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c9 c18"><span class="c17">pH goal is normally 7.25-7.45:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">If pH &gt; 7.45, decrease respiratory rate</span></li><li class="c2"><span class="c8">If pH 7.15-7.30, then increase respiratory rate until pH &gt; 7.30, or PaCO2 &lt; 25 (maximum RR= 35 breaths/minute)</span></li><li class="c2"><span class="c8">If pH &lt; 7.15, then increase respiratory rate to 35 breaths/minute</span></li><li class="c2"><span class="c8">If pH still &lt; 7.15, then perform the following:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">Tidal volume may be increased by 1 mL/kg until pH &gt; 7.15 (until plateau pressure reaches 30 cm H2O or tidal volume reaches 8 cc/kg)</span></li><li class="c5"><span class="c8">Deep sedation advancing to RASS -5 if needed</span></li><li class="c5"><span class="c8">If no improvement, initiate continuous paralysis</span></li><li class="c5"><span class="c8">If still no improvement, initiate prone ventilation (may improve V/Q matching and better ventilation)</span></li></ol><p class="c9 c32 c27"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="8"><li class="c28 c26"><h2 id="h.4wvmhdtgo9di" style="display:inline"><span class="c11">Managing Oxygenation</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c17">Minimizing oxygen toxicity: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">PEEP and Fi02 drive oxygenation </span></li><li class="c2"><span>The goal is to deliver a partial pressure of oxygen to perfuse tissues (PaO2 &gt; 75, Sp02 &gt;92%) while limiting lung injury from high distending pressures (Ppl &lt; 30) and hyperoxia (</span><span class="c33">FiO2 &lt; 75</span><span>, SpO2 &lt; 96%)</span><span class="c8">.</span></li><li class="c2"><span>Lower limit goals for PaO2 / SpO2 are widely debated (and discussed in </span><span class="c22">Rationale</span><span>);</span><span class="c8">&nbsp;PaO2 &gt; 55 and SpO2 &gt;88% are also commonly used at BWH. </span></li></ol><p class="c9 c63 c27"><span class="c8"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c17">PEEP management:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Initial PEEP should be set as explained in section 4 above. </span></li><li class="c2"><span class="c8">If patient is hypoxic on Vt = 6 ml/kg and ideal PEEP from PV tool (or PEEP determination from ARDSnet table for non-Hamilton G5 ventilators), perform the following:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span>Deep sedation,</span><span class="c33">&nbsp;</span><span class="c8">advancing to RASS -5 if needed; if no improvement then:</span></li><li class="c5"><span>Initiate continuous paralysis</span><span class="c33">&nbsp;</span><span class="c8">(cisatracurium bolus 0.2mg/kg followed by infusion at 0-5 mcg/kg/min titrated to patient-ventilator synchrony); if no improvement then:</span></li><li class="c5"><span>Initiate prone</span><span class="c33">&nbsp;</span><span>ventilation (see below); high consideration for use </span><span>early</span><span class="c8">&nbsp;in severe ARDS (&lt;36 hours from ARDS onset, start discussion of proning when P:F &lt; 150, prone within 12 hours of FiO2 &gt; 75%)</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c9 c18"><span class="c17">Checking plateau pressure:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Check plateau pressure with every change in tidal volume, PEEP, or clinical deterioration (worsening oxygenation) but not as part of routine practice</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">If plateau pressure is &gt; 30 cm H20, then decrease tidal volume by 1 ml/kg (minimum 4 mL/kg)</span></li><li class="c5"><span class="c8">If plateau pressure is &lt; 25 H20 and tidal volume &lt; 6 mL/kg, then increase tidal volume by 1 mL/kg until plateau pressure is &gt; 25 cm H2O or tidal volume = 6 mL/kg</span></li><li class="c5"><span class="c8">If plateau pressure is &lt; 30 cm H20 and patient is breath stacking or dyssynchronous, then increase tidal volume in mL/kg increments to 7 mL/kg or 8 mL/kg so long as plateau pressure is &lt; 30 cm H20</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c9 c18"><span class="c17">Adjusting Fi02:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Adjust Fi02 after optimizing PEEP &nbsp;</span></li><li class="c2"><span class="c8">Goal FiO2 &lt; 75%; if FiO2 &gt; 75%; patient requires ventilator optimization. If you need assistance, pulmonary consultation is available (pager 11957)</span></li><li class="c2"><span class="c8">It is reasonable to put a desaturating patient temporarily on 100% Fi02, but remember to wean oxygen as rapidly as possible</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="5"><li class="c9 c18"><span class="c33 c22">Rationale</span><span class="c8">: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c22">Avoiding hyperoxia: </span><span>Extensive mammalian animal data demonstrates that hyperoxic injury occurs at an FiO2 &ge; 75% (at sea level) with the rate of injury increasing as FiO2 exceeds that threshold. In multiple mammalian models, an FiO2 of 100% for 48 to 72 hours is associated with nearly 100% mortality rate. In lung injury models, the time to death is markedly attenuated. In an effort to reduce the potential for hyperoxic injury, the threshold of FiO2 &ge; 75% triggers progressive intervention throughout this protocol: increased sedation, paralysis, proning and ECMO consultation. For a review of hyperoxic acute lung injury, see </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&amp;sa=D&amp;ust=1585016770883000">Kallet and Matthay, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&amp;sa=D&amp;ust=1585016770883000">Respir Care</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&amp;sa=D&amp;ust=1585016770884000">, 2013</a></span><span>.</span><span class="c8">&nbsp;</span></li><li class="c2"><span class="c22">Setting the lower oxygen limits: </span><span>There is debate on the proper PaO2 goal, and our rationale relies on evidence for lack of benefit from conservative PaO2 goals in clinical trials (</span><span class="c22">i.e.</span><span>, PaO2 &gt; 55) and past association between lower PaO2 and cognitive impairment, although the evidence is certainly not definitive (mean PaO2 71 [IQR 67-80] for cognitively impaired survivors versus mean PaO2 86 [IQR, 70-98] in non-impaired survivors of ARDS (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&amp;sa=D&amp;ust=1585016770884000">Mikkelsen et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&amp;sa=D&amp;ust=1585016770885000">Am J Respir Crit Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&amp;sa=D&amp;ust=1585016770885000">, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22492988&amp;sa=D&amp;ust=1585016770885000">2012</a></span><sup><a href="#cmnt3" id="cmnt_ref3">[c]</a></sup><span>). In the LOCO</span><span class="c70">2</span><span>&nbsp;multi-center, randomized clinical trial, patients with ARDS were randomized to their PaO2 55-70, SpO2 88-92%; or PaO2 90-105, SpO2 &gt;95%); the trial was stopped after enrollment of 205 patients due to futility and safety concerns (44% mortality in conservative oxygen group versus 30%; (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770886000">Barrot et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770886000">New Eng J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770886000">, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32160661&amp;sa=D&amp;ust=1585016770886000">2020</a></span><sup><a href="#cmnt4" id="cmnt_ref4">[d]</a></sup><span>).</span></li></ol><p class="c9 c27"><span class="c85 c45 c75"></span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="9"><li class="c28 c26"><h2 id="h.wgrateeto9z4" style="display:inline"><span class="c11">Proning and Pulmonary Vasodilators</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c17">Prone early:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>We recommend </span><span>early</span><span>&nbsp;proning in severe ARDS without vasodilator trial (a departure from our typical practice for ARDS not due to COVID-19): &lt; 36 hours from ARDS onset, start discussion of prone when P:F &lt; 150, prone within 12 hours of FiO2 &gt; 75% (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&amp;sa=D&amp;ust=1585016770888000">Gu&eacute;rin et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&amp;sa=D&amp;ust=1585016770888000">N Engl J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&amp;sa=D&amp;ust=1585016770888000">, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&amp;sa=D&amp;ust=1585016770888000">2013</a></span><span>)</span><span>.</span><span class="c87">&nbsp;</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c17">Eligibility criteria for proning:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Eligibility may vary depending on resources and staffing. Currently we recommend: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">Age &lt; 75</span></li><li class="c5"><span>No high grade shock (either single agent norepinephrine </span><span>20 mcg/min or norepinephrine &lt; 15 mcg/min</span><span class="c8">&nbsp;and vasopressin)</span></li><li class="c5"><span class="c8">Not on CRRT or at risk of impending renal failure (due to difficulties in maintaining dialysis access while proned)</span></li><li class="c5"><span>The o</span><span class="c8">nly absolute contraindications to proned ventilation are spinal cord injury and open chest; BMI and patient size are not contraindications</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="3"><li class="c9 c18"><span class="c17">To initiate prone ventilation outside of MICU and 11C:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span class="c8">Discuss with the PCCM Consultation team assigned to that unit</span></li><li class="c2"><span class="c8">ICU charge nurse to contact MICU charge nurse for nursing assistance</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="4"><li class="c9 c18"><span class="c17">Managing a proned patient: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>Proning protocol is available at the MICU sharepoint</span></li><li class="c2"><span class="c8">Maintain deep sedation with target RASS -4 to -5 while proned.</span></li><li class="c2"><span class="c8">1 hour post-initiation of prone ventilation:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span>Adjust oxygen parameters: re-assess lung mechanics (plateau pressure and P-V tool to determine optimal PEEP) and adjust PEEP and titrate FiO2 as in </span><span class="c16"><a class="c15" href="#h.qrh9t96165ug">&ldquo;Managing Ventilation&rdquo; section</a></span><span class="c8">&nbsp;of this chapter.</span></li><li class="c5"><span class="c8">Assess tidal volume and adjust ventilation parameters as in section 6</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c9 c47 c34"><span>If Vt &lt; 6 ml/kg, may increase to maximum limit o</span><span>f 8 ml/kg while Ppl &lt; 30</span><span class="c8">&nbsp;(preferred maximum is 6 ml/kg)</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2" start="4"><li class="c2"><span class="c8">If patient demonstrates improvement on proning then recommend:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">Discontinuing of continuous neuromuscular blockade and re-assess ventilator dyssynchrony; re-institute if dyssynchronous</span></li><li class="c5"><span class="c8">Return to supine ventilation when following criteria are met:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Ppl &lt; 25</span></li><li class="c9 c47 c34"><span class="c8">FiO2 &lt; 50%</span></li><li class="c9 c47 c34"><span class="c8">pH &gt; 7.3</span></li><li class="c9 c47 c34"><span class="c8">P:F &gt; 200</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2" start="5"><li class="c2"><span class="c8">Repositioning and skin care while proned: </span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">Currently we recommend continuing proning as per the MICU proning protocol. This may change in the future depending on availability of PPE and staffing.</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="5"><li class="c9 c18"><span class="c17">Escalation if still hypoxic:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>If hypoxia (PaO2 &lt; 55 with FiO2 &gt; 75%) persists after proning; then initiate continuous inhaled epoprostenol (see </span><span class="c16"><a class="c15" href="#h.kx686gedgtzg">&ldquo;COVID-19 Therapies and Clinical Trials&rdquo; chapter</a></span><span class="c8">).</span></li><li class="c2"><span>If FiO2 &gt; 75% despite above, recommend consultation with ECMO team (see </span><span class="c16"><a class="c15" href="#h.24j39tc7pjup">&ldquo;ECMO consultation&rdquo; section</a></span><span class="c8">&nbsp;of this chapter).</span></li></ol><p class="c9 c78"><span class="c8">&nbsp;</span></p><ol class="c3 lst-kix_qgxhqyjzp80f-0" start="10"><li class="c28 c26"><h2 id="h.24j39tc7pjup" style="display:inline"><span class="c11">ECMO consultation</span></h2></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1 start" start="1"><li class="c9 c18"><span class="c17">Refractory Hypoxemia:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>If despite PEEP optimization, paralysis, prone ventilation, optimizing volume status, pulmonary vasodilators (when available) the patient meets the following criteria, then consider ECMO consult (</span><span>pager 35010</span><span class="c8">):</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Ppl &gt; 30</span></li><li class="c9 c47 c34"><span class="c8">FiO2 &gt; 75%</span></li><li class="c9 c47 c34"><span class="c8">P:F &lt; 80</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-1" start="2"><li class="c9 c18"><span class="c17">Candidacy:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-2 start" start="1"><li class="c2"><span>Final ECMO guidelines for COVID-19 patients remain </span><span>under development</span><sup><a href="#cmnt5" id="cmnt_ref5">[e]</a></sup><span>. Examples of common considerations include:</span></li></ol><ol class="c3 lst-kix_qgxhqyjzp80f-3 start" start="1"><li class="c5"><span class="c8">Patient age &lt; 65</span></li><li class="c5"><span class="c8">Mechanical ventilation duration &lt; 7 days</span></li><li class="c5"><span class="c8">BMI &lt; 35 and patient body weight &lt; 150 kg</span></li><li class="c5"><span class="c8">CrCl &gt; 30</span></li><li class="c5"><span class="c8">No multiorgan failure or high grade shock (can be on single pressor; norepinephrine &lt; 15 mcg/min)</span></li><li class="c5"><span class="c8">No active solid or liquid malignancy</span></li><li class="c5"><span class="c8">Absolute neutrophil count &gt; 500</span></li><li class="c5"><span class="c8">Platelets &gt; 50,000</span></li><li class="c5"><span class="c8">Able to tolerate anticoagulation on initiation (no active hemorrhage)</span></li><li class="c5"><span class="c8">No evidence of irreversible neurological injury</span></li><li class="c5"><span class="c8">Able to perform ADLs at baseline prior to illness</span></li></ol><p class="c9 c63 c27"><span class="c8"></span></p><h1 class="c44" id="h.kx686gedgtzg"><span class="c23 c49">Chapter 3: COVID-19 Therapies and Clinical Trials</span></h1><sup><a href="#cmnt6" id="cmnt_ref6">[f]</a></sup><p class="c9 c27"><span class="c75 c81 c22 c66 c80"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0 start" start="1"><li class="c28 c26"><h2 id="h.cjp7h4q36i0a" style="display:inline"><span class="c11">Note: </span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c9 c18"><span class="c75 c81 c22 c66 c80">The anti-viral and anti-inflammatory section below written by our critical care group is meant to provide a summary of the literature. This section does not represent the views or recommendations of the BWH Division of Infectious Disease. The separate BWH Infectious Disease guidelines and ID consultation service take precedence over the information from the literature below.</span></li></ol><p class="c9 c27 c56"><span class="c75 c81 c22 c66 c80"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="2"><li class="c54 c26"><h2 id="h.hf0jef6dlsvm" style="display:inline"><span class="c11">Clinical trials </span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c17">Consult Infectious Disease for:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span>P</span><span class="c8">atients with +COVID-19 PCR; and clinical history and any chest imaging suspicious for COVID-19. </span></li><li class="c12 c1"><span class="c8">Re-consult if the patient develops ARDS (mechanically ventilated with P/F ratio &lt; 300) or shock/cytokine syndrome. </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c17">Current trials:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">ID teams are enrolling for clinical trials of Remdesivir and possibly other antiviral agents.</span></li><li class="c12 c1"><span>ID and the PETAL network are coordinating to enroll for clinical trials of host-response modifying therapies (see &nbsp;</span><span class="c16"><a class="c15" href="#h.x05c129ivxrw">&ldquo;Systemic Corticosteroids&rdquo;</a></span><span>&nbsp;and </span><span class="c16"><a class="c15" href="#h.m6l0vgre9d0s">&ldquo;Anti-IL6 agents&rdquo;</a></span><span class="c8">&nbsp;sections of this chapter).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c13 c1"><span class="c17">Monitor for drug-drug interactions:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Patients may arrive at the ICU already enrolled in a COVID-19 clinical trial. &nbsp;Verify that ICU treatment regimen does not add harmful drug interactions with study agents.</span></li></ol><p class="c1 c20"><span class="c8"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="3"><li class="c54 c26"><h2 id="h.8vhrbtln428m" style="display:inline"><span class="c11">Antibiotic stewardship</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c17">Antibiotic choice:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Antibiotics should reflect IDSA guidelines, presumed source, and MDRO risk. For a presumed pulmonary source: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Without risk factors for MRSA or Pseudomonas (i.e. living in community, no prior MDROs): </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span>Ceftriaxone +</span><span class="c22">&nbsp;</span><span class="c8">Azithromycin &nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="2"><li class="c19 c1"><span class="c8">With risk factors for MRSA or Pseudomonas (i.e. chronic hospitalization, prior MDR infections): </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span>Vancomycin </span><span>+</span><span class="c22">&nbsp;</span><span class="c8">Cefepime, and consider Ciprofloxacin if high concern for Pseudomonas</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="3"><li class="c19 c1"><span>See special dispensations for oncology patients in </span><span class="c16"><a class="c15" href="#h.aayfijcxre19">&ldquo;Considerations for Oncology Patients&rdquo; section</a></span><span>&nbsp;within </span><span class="c16"><a class="c15" href="#h.l3i6lcz3jr27">&ldquo;Other Guidance&rdquo; chapter</a></span><span>.</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c17">Formulation:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Give oral antibiotics (Azithromycin, Levofloxacin, Ciprofloxacin) when possible to reduce volume load, unless concerns for poor oral absorption</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c13 c1"><span class="c17">Coinfection:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">If concurrent influenza give Oseltamivir</span></li><li class="c12 c1"><span class="c8">Given lymphopenia consider Pneumocystis and treat accordingly</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="4"><li class="c13 c1"><span class="c17">Discontinuation:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Antibiotics should be discontinued as soon as possible (within 48h) if:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Clinical status is not deteriorating, cultures do not reveal pathogens at 48h, and procalcitonin and WBC are relatively stable from 0 to 48h</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">Clinical judgement should prevail over any specific lab value</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="5"><li class="c13 c1"><span class="c33 c22">Rationale</span><span class="c33">: </span><span>Clinical reports indicate that rates of bacterial superinfection of COVID19 are low (10-20%), but when present increase mortality risk. Anecdotal reports suggest less MRSA superinfection than with influenza. Unnecessary antibiotics carry risks of fluid overload and drug-resistance, as well as the possibility that antibiotics may become a limited resource. (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770904000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770904000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770904000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770905000">&nbsp;2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770905000">Yang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770905000">Lancet Respir Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770905000">, 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016770906000">Lippi and Plebani, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016770906000">Clinica Chimica Acta</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016770906000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016770906000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016770907000">2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770907000">WHO, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770908000">COVID-19 Interim guidance</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770908000">, March 2020</a></span><span>)</span></li></ol><p class="c1 c67"><span class="c17">&nbsp;</span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="4"><li class="c54 c26"><h2 id="h.eudti5z0ojjo" style="display:inline"><span>M</span><span>etered-dose inhalers (MDIs)</span><span>&nbsp;vs. </span><span>nebulizers</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c33">N</span><span class="c17">on-intubated patients: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">For COVID-19 Confirmed or PUI, use MDI (inhalers), not nebulizers, due to the increased aerosol risk. </span></li><li class="c12 c1"><span class="c8">Because MDI supply is limited, only prescribe when needed. &nbsp;</span></li><li class="c12 c1"><span>For non-COVID-19 Confirmed or PUI patient, use nebulizers even if on droplet precautions (</span><span class="c22">e.g.,</span><span class="c8">&nbsp;influenza) because MDI supply is limited. </span></li><li class="c1 c12"><span>After a patient is COVID-neg (and no longer on COVID precautions per infection control): After the patient&rsquo;s current MDI runs out, switch to neb. </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c33">Intubated patients</span><span class="c33">:</span><span class="c17">&nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span>The ventilator circuit is a closed system so nebulizers can be used when required (</span><span class="c22">e.g., </span><span>DuoNeb standing and albuterol PRN). </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c13 c1"><span class="c33">Rationale</span><span class="c33">:</span><span>&nbsp;Nebulization may aerosolize viral particles and contribute to disease transmission. &nbsp;COVID-19 clinical reports do not indicate wheeze as a common symptom, and not all patients require bronchodilators (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770910000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770910000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770911000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770911000">&nbsp;2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770911000">Yang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770911000">Lancet Repir Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770911000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016770911000">&nbsp;2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016770912000">Guan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016770912000">N Engl J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016770912000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016770912000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016770913000">2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770913000">WHO, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770913000">COVID-19 Interim guidance</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770914000">, March 2020</a></span><span class="c8">)</span></li></ol><p class="c1 c20"><span class="c17"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="5"><li class="c54 c26"><h2 id="h.8pktimpr5u6o" style="display:inline"><span class="c11">Airway Clearance &nbsp;</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c17">Management principles:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Reports from Wuhan and Italy indicate that some patients develop very thick secretions causing dangerous mucus plugging. However, nebulizers and airway clearance techniques may aerosolize secretions</span></li><li class="c12 c1"><span>Airway clearance should be used only in </span><span>selected ventilated patients</span><span class="c33 c22">&nbsp;</span><span>(closed circuit)</span><span class="c22">&nbsp;</span><span>with extremely thick secretions to avoid mucus plugging that would require bronchoscopy</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c33">For t</span><span class="c17">hinning secretions:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span>A</span><span>necdotal reports suggest Dornase alfa may be particularly effective in thinning secretions in COVID-19</span><span>&nbsp;</span><span>patients</span><span>.</span><span>&nbsp;</span><span>However, data for Dornase alfa in non-CF patients is poor</span><span>. For now we recommend:</span><sup><a href="#cmnt7" id="cmnt_ref7">[g]</a></sup><sup><a href="#cmnt8" id="cmnt_ref8">[h]</a></sup></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span>Consideration of </span><span class="c8">Dornase alfa 2.5mg nebulizer once daily </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">Can cause bronchoconstriction and mucosal bleeding </span></li><li class="c30 c1"><span class="c8">Pre-treat with albuterol 2.5mg, just prior to delivery</span></li><li class="c30 c1"><span>Avoid in setting of bloody secretions </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="2"><li class="c19 c1"><span>Alternative: Nebulized </span><span class="c8">hypertonic (3-7%) saline once daily</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">Side effects can include bronchoconstriction</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c67 c38"><span class="c8">Start with 3% to assess response and bronchoconstriction</span></li><li class="c1 c38 c67"><span>Pre-treat with albuterol 2.5mg just prior to delivery</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="3"><li class="c19 c1"><span>Avoid N-acetylcysteine due to frequent dosing requirements </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c13 c1"><span class="c33">Airway clearance: &nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span>Continue</span><span>&nbsp;chest PT vests if patient uses at home (</span><span class="c22">e.g.,</span><span>&nbsp;CF patients) with appropriate isolation precautions</span><span class="c8">. Bronchiectasis patients may be considered on a case-by-case basis. </span></li><li class="c12 c1"><span>Avoid oscillating positive expiratory pressure devices (Aerobika or Acapella) and cough assist (MIE). </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-0" start="6"><li class="c54 c26"><h2 id="h.ym3ao1e1uli3" style="display:inline"><span class="c11">Inhaled Pulmonary Vasodilators</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c17">Indications for use:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Inhaled vasodilators should not be routinely used except in two circumstances</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span>As a rescue strategy in already prone ventilated patients (see </span><span class="c16"><a class="c15" href="#h.hu2czim2nti8">&ldquo;Respiratory Support for COVID-19 Patients&rdquo; chapter</a></span><span class="c8">). </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span>There is no evidence of survival benefit of inhaled vasodilators in ARDS, and there are risks of viral aerosolization when connecting the device &nbsp;(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&amp;sa=D&amp;ust=1585016770920000">Fuller et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&amp;sa=D&amp;ust=1585016770920000">Chest</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&amp;sa=D&amp;ust=1585016770920000">, 2015</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770921000">Gebistorf et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770921000">Cochrane Database Syst Rev</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770921000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770921000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770922000">2016</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28806480&amp;sa=D&amp;ust=1585016770922000">Afshari et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28806480&amp;sa=D&amp;ust=1585016770922000">Cochrane Database Syst Rev</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28806480&amp;sa=D&amp;ust=1585016770923000">, 2017</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="2"><li class="c19 c1"><span>To reduce RV afterload in hemodynamically significant RV failure in consultation with cardiology</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c17">Instructions for use:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">If inhaled vasodilators are used, they should reevaluated at 4 hours &nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c42 c0">Inhaled Epoprostenol:</span><span class="c59 c42 c75 c0 c57">&nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c0">S</span><span class="c8 c0">tart continuous nebulization at 0.05mcg/kg/min based on IBW &nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c67 c38"><span class="c0">If no improvement in P/F ratio in 2 hours, wean off by decreasing 0.01mcg/kg/min every </span><span class="c0">hour</span><span class="c8 c0">&nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="2"><li class="c19 c1"><span class="c41">Inhaled Nitric Oxide (iNO):</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span>Strong consideration in refractory ARDS that does not respond to inhaled epoprostenol. </span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c67 c38"><span>Limited </span><span class="c22">in vitro</span><span>&nbsp;data notes that iNO at high doses inhibits replication of SARS-CoV, but this has not been studied </span><span class="c22">in vivo</span><span>. (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&amp;sa=D&amp;ust=1585016770925000">Akerstrom et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&amp;sa=D&amp;ust=1585016770926000">J Virol</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&amp;sa=D&amp;ust=1585016770926000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&amp;sa=D&amp;ust=1585016770926000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&amp;sa=D&amp;ust=1585016770926000">2005</a></span><span>;</span><span>&nbsp;</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770927000">Gebistorf et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770927000">Cochrane Database Syst Rev</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770927000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770928000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016770928000">2016</a></span><span class="c8">)</span></li><li class="c1 c67 c38"><span>iNO may be included in future trial protocols</span><span class="c8">, such as early initiation in milder disease (non-intubated). </span></li></ol><p class="c1 c20 c34"><span class="c8"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="7"><li class="c54 c26"><h2 id="h.x05c129ivxrw" style="display:inline"><span>S</span><span class="c11">ystemic Corticosteroids</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c33">Data on </span><span class="c33">corticosteroids for COVID-19: </span><span class="c24 c22">&nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Most studies show negative effects of corticosteroids on similar viruses</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span>There is no clinical evidence of net benefit from steroids in SARS-CoV, MERS-CoV or influenza infection, and observational data show increased mortality, more secondary infections, impaired viral clearance and more adverse effects in survivors (</span><span class="c22">e.g.,</span><span>&nbsp;psychosis, diabetes, avascular necrosis) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016770930000">Lee et al,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016770930000">&nbsp;J Clin Virol</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016770931000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016770931000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016770931000">2004</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&amp;sa=D&amp;ust=1585016770931000">Stockman et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&amp;sa=D&amp;ust=1585016770932000">PLoS Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&amp;sa=D&amp;ust=1585016770932000">, 2006</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&amp;sa=D&amp;ust=1585016770932000">Arabi</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&amp;sa=D&amp;ust=1585016770933000">&nbsp;et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&amp;sa=D&amp;ust=1585016770933000">Am J Respir Crit Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&amp;sa=D&amp;ust=1585016770933000">, 201</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&amp;sa=D&amp;ust=1585016770933000">8</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770934000">WHO, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770934000">COVID-19 Interim guidance</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770935000">, March 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770935000">Wu et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770935000">JAMA Int Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770936000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770936000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770936000">2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2" start="2"><li class="c12 c1"><span>However, a new retrospective cohort (201 patients, 84 [42%] of whom developed ARDS) demonstrated that among patients with ARDS, methylprednisolone decreased risk of death (HR, 0.38; 95% CI, 0.20-0.72)</span><span>&nbsp;(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770937000">Wu et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770937000">JAMA Int Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770937000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770938000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016770938000">2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c33">Recommendation</span><span class="c8">:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c17">We recommend against using steroids for COVID-19 except as part of a clinical trial</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span>This is in line with </span><span>WHO guidance (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770939000">WHO, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770939000">COVID-19 Interim guidance</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770939000">, March 2020</a></span><span>).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c1 c13"><span>&nbsp;</span><span class="c17">Use corticosteroids if required for other indications:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">&nbsp;Use the lowest dose for the shortest duration:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Asthma or COPD exacerbation</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">40mg prednisone PO or 30mg methylprednisolone IV, once daily x 3-5 days</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="2"><li class="c19 c1"><span class="c8">Shock with history of chronic steroid use &gt; 10mg prednisone daily:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">50mg hydrocortisone IV Q6H until improvement in shock </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3" start="3"><li class="c19 c1"><span class="c8">Multipressor shock without history of chronic steroid use</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">50mg hydrocortisone IV Q6H until improvement in shock </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-0" start="8"><li class="c54 c26"><h2 id="h.m6l0vgre9d0s" style="display:inline"><span class="c11">Anti-IL6 Agents (Tocilizumab, Siltuximab) &nbsp;</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c17">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span>IL-6 activates T cells and macrophages, among other cell types (see </span><span class="c16"><a class="c15" href="#h.7i62kagnynf0">&ldquo;Cytokine Activation Syndrome&rdquo; section</a></span><span>&nbsp;in </span><span class="c16"><a class="c15" href="#h.dpe5gr1hwjp">&ldquo;Shock&rdquo; chapter</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span>IL-6 inhibitors are approved for cytokine activation syndrome complications related to Chimeric Antigen Receptor T cell (CAR-T) therapy (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&amp;sa=D&amp;ust=1585016770941000">Brudno and Kochenderfer, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&amp;sa=D&amp;ust=1585016770941000">Blood Rev</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&amp;sa=D&amp;ust=1585016770941000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&amp;sa=D&amp;ust=1585016770942000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&amp;sa=D&amp;ust=1585016770942000">2019</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016770942000">Rubin et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016770942000">Brain</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016770943000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016770943000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016770943000">20</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016770943000">19</a></span><span class="c8">).</span></li><li class="c19 c1"><span class="c8">IL-6 levels are reported to correlate with severe COVID-19 </span></li><li class="c19 c1"><span class="c8">While patients have peripheral lymphopenia, BAL fluid is often lymphocytic, suggesting that IL-6 inhibition and prevention of T cell activation may be protective.</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c33">Recommendation:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">We do not recommend routine use at this time </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span>There are anecdotal reports of benefit of tocilizumab in COVID-19 patients but no rigorous studies are available (</span><span>Anecdotal reports from Italy</span><sup><a href="#cmnt9" id="cmnt_ref9">[i]</a></sup><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf&amp;sa=D&amp;ust=1585016770945000">National Health Commission &amp; State Administration of Traditional Chinese Medicine, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf&amp;sa=D&amp;ust=1585016770945000">Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia [Trial Version 7]</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://busan.china-consulate.org/chn/zt/4/P020200310548447287942.pdf&amp;sa=D&amp;ust=1585016770945000">, March 2020</a></span><sup><a href="#cmnt10" id="cmnt_ref10">[j]</a></sup><span class="c8">)</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2" start="2"><li class="c12 c1"><span>For severe </span><span>cytokine activation syndrome cases (see </span><span class="c16"><a class="c15" href="#h.l3i6lcz3jr27">&ldquo;Other Guidance&rdquo; chapter</a></span><span class="c8">):</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span>Consult</span><span>&nbsp;Infectious Disease team for enrollment in a clinical trial based on CRP and IL-6 levels.</span><sup><a href="#cmnt11" id="cmnt_ref11">[k]</a></sup></li></ol><ol class="c3 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c1 c67 c38"><span>Exercise caution if </span><span class="c8">secondary infection is clinically suspected, including sepsis, pneumocystis or bacterial pneumonia. </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c13 c1"><span class="c33">Dosing regimens</span><span class="c33">: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span class="c8">Tocilizumab 4-8mg/kg (suggested dose 400mg) IV x1 (anti-IL6R mAb)</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Dose can be repeated 12h later if inadequate response to the first dose. &nbsp;Total dose should be no more than 800mg. Tocilizumab should not be administered more than twice. </span></li><li class="c19 c1"><span class="c8">Common adverse effects include: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">Transaminitis (AST, ALT) &gt; 22%</span></li><li class="c30 c1"><span class="c8">Infusion reaction 4-20%</span></li><li class="c30 c1"><span class="c8">Hypercholesterolemia 20%</span></li><li class="c30 c1"><span class="c8">Upper respiratory tract infection 7%</span></li><li class="c30 c1"><span class="c8">Neutropenia 2-7%</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2" start="2"><li class="c12 c1"><span class="c8">Alternative: Siltuximab 11mg/kg IV x1 (anti-IL6 mAb)</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Common adverse effects include: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c30 c1"><span class="c8">Edema &gt;26%</span></li><li class="c30 c1"><span class="c8">Upper respiratory infection &gt;26%</span></li><li class="c1 c30"><span class="c8">Pruritus / skin rash 28%</span></li><li class="c30 c1"><span class="c8">Hyperuricemia 11%</span></li><li class="c30 c1"><span class="c8">Lower respiratory tract infection 8%</span></li><li class="c30 c1"><span class="c8">Thrombocytopenia 8%</span></li><li class="c30 c1"><span class="c8">Hypotension 4% </span></li></ol><p class="c1 c20"><span class="c8"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="9"><li class="c54 c26"><h2 id="h.wr1agkjgho7b" style="display:inline"><span class="c11">Hydroxychloroquine and Chloroquine</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c9 c18"><span class="c17 c0">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58 c0"><span class="c0">Hydroxychloroquine (HQ) is an anti-malarial 4-aminoquinoline shown to have in vitro (but not yet in-vivo) activity against diverse RNA viruses including SARS-CoV-1 (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&amp;sa=D&amp;ust=1585016770949000">T</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&amp;sa=D&amp;ust=1585016770950000">ouret and de Lamballerie, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&amp;sa=D&amp;ust=1585016770950000">Antivir Res</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32147496&amp;sa=D&amp;ust=1585016770950000">, 2020</a></span><span class="c8 c0">). </span></li><li class="c9 c0 c58"><span class="c0">HQ is thought to act through multiple mechanisms (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171740&amp;sa=D&amp;ust=1585016770950000">Devaux et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171740&amp;sa=D&amp;ust=1585016770951000">Int J Antimicrob Agent</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171740&amp;sa=D&amp;ust=1585016770951000">, 2020</a></span><span class="c8 c0">):</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c5 c0"><span class="c33 c0">Inhibition of viral entry.</span><span class="c0">&nbsp;HQ inhibits synthesis of sialic acids and interferes with protein glycosylation, which may disrupt interactions necessary for viral attachment and entry (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16115318&amp;sa=D&amp;ust=1585016770951000">Vincent et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16115318&amp;sa=D&amp;ust=1585016770951000">Virol J</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16115318&amp;sa=D&amp;ust=1585016770951000">, 2005</a></span><span class="c0">; </span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15766653&amp;sa=D&amp;ust=1585016770952000">Olofsson et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15766653&amp;sa=D&amp;ust=1585016770952000">Lancet Infect Dis,</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15766653&amp;sa=D&amp;ust=1585016770952000">&nbsp;2005</a></span><span class="c8 c0">).</span></li><li class="c5 c0"><span class="c33 c0">Inhibition of viral release into the host cell.</span><span class="c0">&nbsp;HQ blocks endosomal acidification, which activates endosomal proteases. These proteases are required to initiate coronavirus/endosome fusion that releases viral particles into the cell (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15140961&amp;sa=D&amp;ust=1585016770952000">Yang et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15140961&amp;sa=D&amp;ust=1585016770952000">J Virol </a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15140961&amp;sa=D&amp;ust=1585016770953000">2004</a></span><span class="c8 c0">).</span></li><li class="c5 c0"><span class="c33 c0">Reduction of viral infectivity.</span><span class="c0">&nbsp;HQ has been shown to inhibit protein glycosylation and proteolytic maturation of viral proteins. Studies on other RNA viruses have shown a resulting accumulation of non-infective viral particles, or an inability of viral particles to bud out of the host cell (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&amp;sa=D&amp;ust=1585016770953000">Savarino et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&amp;sa=D&amp;ust=1585016770953000">J Acquir Immune Defic Syndr</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&amp;sa=D&amp;ust=1585016770953000">, </a></span><sup><a href="#cmnt12" id="cmnt_ref12">[l]</a></sup><sup><a href="#cmnt13" id="cmnt_ref13">[m]</a></sup><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15076236&amp;sa=D&amp;ust=1585016770953000">2004</a></span><span class="c0">;</span><sup><a href="#cmnt14" id="cmnt_ref14">[n]</a></sup><sup><a href="#cmnt15" id="cmnt_ref15">[o]</a></sup><span class="c0">&nbsp;</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/8083990&amp;sa=D&amp;ust=1585016770954000">Klumperman et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/8083990&amp;sa=D&amp;ust=1585016770954000">J Virol</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/8083990&amp;sa=D&amp;ust=1585016770954000">, 1994</a></span><span class="c8 c0">).</span></li><li class="c5 c0"><span class="c33 c0">Immune modulation.</span><span class="c0">&nbsp;HQ reduces toll-like receptors and cGAS-STING signaling. It has been shown to reduce release of a number of pro-inflammatory cytokines from several immune cell types (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32034323&amp;sa=D&amp;ust=1585016770954000">Schrezenmeier and Dorner, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32034323&amp;sa=D&amp;ust=1585016770955000">Nat Rev Rheum</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32034323&amp;sa=D&amp;ust=1585016770955000">, 2020</a></span><span class="c0">).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c9 c18"><span class="c33 c0">Data:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58"><span class="c0">An </span><span class="c0">expert consensus group out of China </span><span class="c0">suggests that Chloroquine </span><span class="c0">improved lung imaging and shortened disease course (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32075365&amp;sa=D&amp;ust=1585016770955000">Zhonghua et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32075365&amp;sa=D&amp;ust=1585016770956000">CMAPH</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32075365&amp;sa=D&amp;ust=1585016770956000">, 2020</a></span><span class="c0">). Chloroquine will be included in the next treatment guidelines from the National Health Commission, but the specific data on which this is based is not available yet (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&amp;sa=D&amp;ust=1585016770956000">Gao et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&amp;sa=D&amp;ust=1585016770956000">Biosci Trends</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&amp;sa=D&amp;ust=1585016770957000">, 2020</a></span><span class="c0">).</span></li><li class="c9 c58"><span class="c0">Hydroxychloroquine was found to be more potent than chloroquine in inhibiting SARS-CoV-2 in vitro (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32150618&amp;sa=D&amp;ust=1585016770957000">Yao et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32150618&amp;sa=D&amp;ust=1585016770957000">Clin Infect Dis</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32150618&amp;sa=D&amp;ust=1585016770958000">, 2020</a></span><span class="c0">)</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="3"><li class="c9 c18"><span class="c17 c0">Recommendation:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58"><span class="c0">Strong consideration of h</span><span class="c0">ydroxychloroquine in patients who require supplemental oxygen who are not candidates for other clinical trials.</span><sup><a href="#cmnt16" id="cmnt_ref16">[p]</a></sup></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="4"><li class="c9 c18"><span class="c33 c0">Dosing </span><span class="c33 c0 c22">(from published literature)</span><span class="c17 c0">:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58"><span class="c8 c0">Hydroxychloroquine: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c5"><span class="c0">400mg PO BID on the first day, </span><span class="c0">followed by 200mg </span><span class="c8 c0">q12 (q8h if concerns for absorption) for 5-10 days</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2" start="2"><li class="c9 c58"><span class="c8 c0">Chloroquine (not available at BWH):</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c5"><span class="c8 c0">Second line agent (increased toxicity compared to Hydroxychloroquine)</span></li><li class="c5"><span class="c0">500mg Chloroquine phosphate 500mg PO BID for 10 days</span><sup><a href="#cmnt17" id="cmnt_ref17">[q]</a></sup></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4 start" start="1"><li class="c9 c47 c34"><span class="c8 c0">Common adverse reactions include: </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-5 start" start="1"><li class="c9 c38"><span class="c8 c0">Prolonged QT interval and risk of Torsade de pointes</span></li><li class="c9 c38"><span class="c8 c0">Cardiomyopathy</span></li><li class="c9 c38"><span class="c8 c0">Bone marrow suppression</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-4" start="2"><li class="c9 c47 c34"><span class="c8 c0">Contraindicated in epilepsy and porphyria</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="5"><li class="c9 c18"><span class="c17 c0">Monitoring</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58"><span class="c8 c0">If hydroxychloroquine is being administered with azithromycin, there should be vigilant QTc monitoring:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c5"><span class="c8 c0">Obtain baseline ECG and daily ECG</span></li><li class="c5"><span class="c8 c0">Discontinue all other QT prolonging agents</span></li><li class="c5"><span class="c8 c0">Maintain continuous telemetry while under treatment </span></li><li class="c5"><span class="c8 c0">Do not start if QTc &gt;500 or 550 with pacing or BBB. </span></li><li class="c5"><span class="c8 c0">Discontinue if there is an increase in PVCs or non-sustained PMVT. </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2" start="2"><li class="c9 c58"><span class="c0">There is a reported risk of hydroxychloroquine induced cardiomyopathy. Case series and reports have found this to be a long-term (years) and dose-dependent phenomenon. Given the anticipated short duration in COVID-19, it is not an expected risk (</span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15079764&amp;sa=D&amp;ust=1585016770961000">Nord et al, </a></span><span class="c14 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15079764&amp;sa=D&amp;ust=1585016770962000">Semin Arthritis Rheum</a></span><span class="c16 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15079764&amp;sa=D&amp;ust=1585016770962000">, 2004</a></span><span class="c0">). </span><sup><a href="#cmnt18" id="cmnt_ref18">[r]</a></sup></li></ol><p class="c9 c27"><span class="c17 c0"></span></p><p class="c9 c34 c27"><span class="c8 c0"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="10"><li class="c26 c53"><h2 id="h.uebugzw0ifj" style="display:inline"><span>Angiotensin Converting Enzyme Inhibitors (ACE-I) and </span><span class="c11">Angiotensin II Receptor Blockers (ARB)</span></h2></li></ol><ol class="c3 lst-kix_69woh12i7ucg-1 start" start="1"><li class="c9 c18"><span class="c17">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-2 start" start="1"><li class="c2"><span>SARS-CoV-2, the virus that causes </span><span>COVID-19, enters the same cell entry receptor as SARS-CoV: angiotensin converting enzyme II (ACE2) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31971553&amp;sa=D&amp;ust=1585016770963000">Paules et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31971553&amp;sa=D&amp;ust=1585016770963000">, JAMA, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31971553&amp;sa=D&amp;ust=1585016770964000">2020</a></span><span class="c8">). SARS-CoV-2 is thought to have a higher affinity to ACE2 than SARS-CoV. </span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c5"><span>ACE2 is expressed in the heart, lungs, vasculature, and kidneys. &nbsp;ACEi and ARBs in animal models increase the expression of ACE2 (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32139904&amp;sa=D&amp;ust=1585016770964000">Zheng et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32139904&amp;sa=D&amp;ust=1585016770965000">Nat Rev Cardiol</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32139904&amp;sa=D&amp;ust=1585016770965000">, 2020</a></span><span>)</span><span class="c8">, though this has not been confirmed in human studies. This has led to the hypothesis that ACE-I and ARBs, might worsen myocarditis or precipitate ACS. </span></li><li class="c5"><span>It has also been hypothesized that the upregulation of ACE2 is therapeutic in COVID-19 and that ARBs might be protective in during infection (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32129518&amp;sa=D&amp;ust=1585016770965000">Gurwitz D, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32129518&amp;sa=D&amp;ust=1585016770966000">Drug Dev Res</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32129518&amp;sa=D&amp;ust=1585016770966000">, 2020</a></span><span>).</span><sup><a href="#cmnt19" id="cmnt_ref19">[s]</a></sup></li></ol><ol class="c3 lst-kix_69woh12i7ucg-1" start="2"><li class="c9 c18"><span class="c33 c0 c35">Recommendation:</span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-2 start" start="1"><li class="c2"><span class="c0 c35">For </span><span class="c0 c35">outpatients</span><span class="c23 c0 c35">: </span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c5"><span class="c0 c35">We recommend </span><span class="c0 c35">against discontinuing</span><span class="c23 c0 c35">&nbsp;outpatient ACEi/ARBs. </span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-2" start="2"><li class="c2"><span class="c0 c35">For </span><span class="c0 c35">inpatients</span><span class="c23 c0 c35">:</span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c5"><span class="c0 c35">We recommend against routine discontinuation of ACEi/ARBs, unless otherwise indicated (</span><span class="c0 c22 c35">e.g.,</span><span class="c0 c35">&nbsp;acute kidney injury, hypotension, shock, etc). </span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-2" start="3"><li class="c2"><span class="c23 c0 c35">Rationale</span></li></ol><ol class="c3 lst-kix_69woh12i7ucg-3 start" start="1"><li class="c5"><span class="c0 c35">The American College of Cardiology, American Heart Association and Heart Failure Society of America joint statement recommends against discontinuing ACE-I and ARBs in patients with COVID-19 (</span><span class="c16 c0 c35"><a class="c15" href="https://www.google.com/url?q=http://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19&amp;sa=D&amp;ust=1585016770967000">Bozkurt et al,</a></span><span class="c14 c0 c35"><a class="c15" href="https://www.google.com/url?q=http://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19&amp;sa=D&amp;ust=1585016770968000">&nbsp;HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19, </a></span><span class="c16 c0 c35"><a class="c15" href="https://www.google.com/url?q=http://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19&amp;sa=D&amp;ust=1585016770968000">2020</a></span><span class="c23 c0 c35">). This remains an area of investigation and it is unclear how these medications affect patients with COVID-19.</span></li></ol><p class="c9 c32 c27"><span class="c59 c0 c35 c80 c93"></span></p><ol class="c3 lst-kix_73zznxkq85l2-0" start="11"><li class="c28 c26"><h2 id="h.msot2gdaj2bg" style="display:inline"><span>Non-steroidal anti-inflammatory drugs (NSAIDs)</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c9 c18"><span class="c17">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58"><span>SARS-CoV-2 binds to cells via ACE2. ACE2 is upregulated by ibuprofen in animal models, and this might contribute (see </span><span class="c16"><a class="c15" href="#h.uebugzw0ifj">&ldquo;Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)&rdquo; section</a></span><span class="c8">&nbsp;of this chapter).</span></li></ol><p class="c9 c27"><span class="c8"></span></p><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c9 c18"><span class="c17">Recommendation:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c9 c58"><span>C</span><span>onsider</span><span>&nbsp;acetaminophen instead of NSAIDs if possible; risk / benefit should be discussed with patients and treatment tea</span><span class="c8">m. </span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c5"><span>Reports from France indicate possible increase in mortality with ibuprofen in COVID-19 infection, but these reports have not been corroborated (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&amp;sa=D&amp;ust=1585016770970000">Fang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&amp;sa=D&amp;ust=1585016770970000">Lancet Respir Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&amp;sa=D&amp;ust=1585016770970000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&amp;sa=D&amp;ust=1585016770971000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&amp;sa=D&amp;ust=1585016770971000">2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&amp;sa=D&amp;ust=1585016770971000">Day M, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&amp;sa=D&amp;ust=1585016770971000">BMJ</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&amp;sa=D&amp;ust=1585016770972000">, 2020</a></span><span class="c8">). </span></li><li class="c5"><span>WHO clarified on 3/20/20 it does not recommend avoiding NSAIDs as of 3/18/20 (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770972000">WHO, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770973000">COVID-19 Interim guidance</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016770973000">, March 2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-0" start="12"><li class="c54 c26"><h2 id="h.p7atxkt2b3sh" style="display:inline"><span>B</span><span>lood Products</span><span class="c11">&nbsp;</span></h2></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1 start" start="1"><li class="c13 c1"><span class="c17">Recommendation:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2 start" start="1"><li class="c12 c1"><span>R</span><span class="c8">estrictive transfusion strategy (Hct &gt; 21, Hgb &gt; 7) is recommended unless the patient is actively bleeding or there is concern for acute coronary syndrome.</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Parsimony is encouraged given limited supplies (blood drives are limited by social distancing)</span></li><li class="c19 c1"><span>Acute coronary </span><span>syndrome</span><span class="c8">: Hgb &gt; 10</span></li><li class="c19 c1"><span class="c8">Oncology patients: if possible, reduce threshold to Hgb &gt;7</span></li><li class="c19 c1"><span>All others: Hgb &gt; 7</span></li><li class="c19 c1"><span>Massive transfusion protocol, as a very limited resource, will need to be activated only by the ICU attending</span><span>&nbsp;</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-2" start="2"><li class="c12 c1"><span class="c8">Other blood products:</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-3 start" start="1"><li class="c19 c1"><span class="c8">Treat bleeding not numbers</span></li><li class="c19 c1"><span class="c8">FFP or 4 factor-PCC (lower volume) for active bleeding in setting of known or suspected coagulation abnormalities</span></li><li class="c19 c1"><span class="c8">Warfarin reversal: use 4 factor-PCC given longer effect and lower volume</span></li><li class="c19 c1"><span class="c8">Platelets: goal &gt; 30K unless actively bleeding</span></li></ol><ol class="c3 lst-kix_73zznxkq85l2-1" start="2"><li class="c13 c1"><span class="c33 c22">Rationale</span><span>: Volume overload is of particular concern in patients with COVID-19 so transfusions may be harmful. Randomized controlled trials of ICU patients have shown that a conservative transfusion strategy (Hgb &gt; 7) is associated with less pulmonary edema, fewer cardiac events, fewer transfusions (likely fewer transfusion reactions) and no evidence of harm compared to a liberal transfusion strategy. (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&amp;sa=D&amp;ust=1585016770976000">H&eacute;bert et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&amp;sa=D&amp;ust=1585016770976000">N Engl J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&amp;sa=D&amp;ust=1585016770976000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&amp;sa=D&amp;ust=1585016770976000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&amp;sa=D&amp;ust=1585016770977000">1999</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&amp;sa=D&amp;ust=1585016770977000">Holst et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&amp;sa=D&amp;ust=1585016770977000">N Engl J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&amp;sa=D&amp;ust=1585016770977000">, 2014</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16617262&amp;sa=D&amp;ust=1585016770978000">Gajic et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16617262&amp;sa=D&amp;ust=1585016770978000">Crit Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16617262&amp;sa=D&amp;ust=1585016770978000">, 2006</a></span><span>).</span></li></ol><p class="c1 c20"><span class="c8"></span></p><h1 class="c44 c0" id="h.6zfga8b63w2s"><span class="c23 c49">Chapter 4: Cardiac Complications of COVID-19</span></h1><ol class="c3 lst-kix_yfnaf4f33kdr-0 start" start="1"><li class="c28 c26"><h2 id="h.sxzvrsrmkd1g" style="display:inline"><span class="c11">Acute Cardiac Injury</span></h2></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c9 c18"><span class="c17">Definition:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span>Defined in studies as troponin &gt; 99</span><span class="c64">th</span><span>&nbsp;percentile, or abnormal EKG or echocardiographic findings (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770979000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770979000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770979000">, 2020</a></span><span class="c8">). Non-specific. </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c9 c18"><span class="c33">Incidence</span><span class="c8">:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span>Incidence of 7-22% in hospitalized patients with COVID-19 in China (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770980000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770980000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770981000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770981000">&nbsp;2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770981000">Wang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770981000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770982000">, 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016770982000">Chen et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016770982000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016770982000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016770983000">&nbsp;2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c9 c18"><span class="c17">Prognostic implications: </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span>ACI is higher in non-survivors (59%, n=32) than survivors (1%, n=1) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770983000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770983000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770984000">, 2020</a></span><span class="c8">).</span></li><li class="c2"><span>ACI is higher in ICU patients (22%, n=22) compared to non-ICU patients (2%, n=2) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770984000">Wang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770984000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770985000">, 2020</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="4"><li class="c9 c18"><span class="c17">Time course:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Troponin rise and acute cardiac injury tend to be late manifestations. </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span>Troponin increased rapidly from ~14 days from illne</span><span>ss onset, after the onset of respiratory failure (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770986000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770986000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770986000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770986000">&nbsp;2020</a></span><span>). </span><sup><a href="#cmnt20" id="cmnt_ref20">[t]</a></sup><sup><a href="#cmnt21" id="cmnt_ref21">[u]</a></sup><sup><a href="#cmnt22" id="cmnt_ref22">[v]</a></sup><sup><a href="#cmnt23" id="cmnt_ref23">[w]</a></sup></li><li class="c5"><span>Among non-survivors, a steady rise in troponin I levels was observed throughout the disease course from day 4 of illness through day 22 (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770987000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770987000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016770988000">, 2020</a></span><span>).</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="5"><li class="c9 c18"><span class="c17">Mechanism:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span>The mechanism is unknown, though several have been proposed, based on very limited data outside of case series and reports (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770988000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770989000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016770989000">, 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016770989000">Hu et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016770989000">Eur Heart J</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016770990000">, 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&amp;sa=D&amp;ust=1585016770990000">Zeng et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&amp;sa=D&amp;ust=1585016770990000">Preprints</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&amp;sa=D&amp;ust=1585016770990000">, 2020</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span>Possible direct toxicity through viral invasion into cardiac myocytes (</span><span class="c22">i.e.</span><span class="c8">, myocarditis)</span></li><li class="c9 c47 c34"><span class="c8">Acute coronary syndrome and demand ischemia</span></li><li class="c9 c47 c34"><span>Stress or cytokine-mediated cardiomyopathy (</span><span class="c22">i.e., </span><span class="c8">Takotsubo&rsquo;s)</span></li></ol><p class="c9 c34 c27"><span class="c8"></span></p><ol class="c3 lst-kix_yfnaf4f33kdr-0" start="2"><li class="c28 c26"><h2 id="h.es6b8f4xqski" style="display:inline"><span class="c11">Cardiovascular Testing </span></h2></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c9 c18"><span class="c17">Troponin: </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">ICU patients: Check hsTrop daily and SCvO2 daily</span></li><li class="c2"><span class="c8">Inpatients: Check hsTrop every other day </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">If hsTrop &gt; 200 ng/L</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Obtain 12-lead ECG</span></li><li class="c9 c47 c34"><span class="c8">Perform point-of-care US (POCUS) if you are trained to do so </span></li><li class="c9 c47 c34"><span class="c8">If no new ECG or echocardiographic abnormalities, continue to monitor every other day hsTrop</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c9 c18"><span class="c17">Telemetry: </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Telemetry should be used for all critically-ill patients</span></li><li class="c2"><span class="c8">At BWH, COVID-19 floor patients also have telemetry. </span></li><li class="c2"><span>For hospitals, with resource-limitations, telemetry is most important for patients who meet </span><span>AHA </span><span>criteria</span><span>&nbsp;(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28974521&amp;sa=D&amp;ust=1585016770993000">Sandau et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28974521&amp;sa=D&amp;ust=1585016770994000">Circulation, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/28974521&amp;sa=D&amp;ust=1585016770994000">2017</a></span><span>)</span><span class="c8">. </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c9 c18"><span class="c17">ECGs: </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Daily ECGs are reasonable for individuals with severe COVID-19.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">When possible, print ECGs from the in-room monitor to minimize contamination of equipment.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="4"><li class="c9 c18"><span class="c17">TTE:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Do not order routine TTEs on COVID-19 patients.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Cardiology consult or a trained provider should perform POCUS if:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Significant troponin elevation or decline in ScvO2/MvO2</span></li><li class="c9 c47 c34"><span class="c8">Shock</span></li><li class="c9 c47 c34"><span>New</span><span class="c8">&nbsp;heart failure (not pre-existing heart failure) </span></li><li class="c9 c47 c34"><span>New persistent</span><span class="c22">&nbsp;</span><span class="c8">arrhythmia</span></li><li class="c9 c34 c47"><span class="c8">Significant ECG changes</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c2"><span class="c8">If abnormalities are identified on POCUS (e.g. new reduction in LVEF &lt; 50%), a formal TTE should be obtained and cardiology consulted.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Where possible order limited TTEs instead of full TTEs to conserve resources.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="5"><li class="c9 c18"><span class="c17">Stress Testing: </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Stress testing is likely not indicated in individuals with active COVID. </span></li><li class="c2"><span class="c8">Any question of possible stress testing should be directed to cardiology.</span></li></ol><p class="c9 c63 c27"><span class="c8"></span></p><ol class="c3 lst-kix_yfnaf4f33kdr-0" start="3"><li class="c28 c26"><h2 id="h.rm4wr985h2i8" style="display:inline"><span class="c11">Arrhythmias</span></h2></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c9 c18"><span class="c33 c86 c89">&nbsp;</span><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span>C</span><span>ase series report the occurrence of unspecified arrhythmias in 17% of hospitalized patients with COVID-19 (n=23 of 138), with higher rate in ICU patients (44%, n=16) compared to non-ICU patients (7%, n=7) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770998000">Wang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770998000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016770998000">, 2020</a></span><span class="c8">).</span></li><li class="c2"><span class="c8">There are anecdotal reports of VT and VF as a late manifestation of COVID-19. No specific published findings were identified. </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c9 c18"><span class="c17">Workup:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Telemetry, 12-lead EKG, cardiac troponin, NT-proBNP, TFT</span></li><li class="c5"><span class="c8">ScvO2 if central line present (goal SCVO2 &gt; 60%)</span></li><li class="c5"><span class="c8">POCUS to assess LV and RV function</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Obtain formal TTE if abnormalities of any of the above</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c9 c18"><span class="c17">Treatment:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Atrial fibrillation/atrial flutter </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Beta blockade if no evidence of heart failure or shock</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span>If significant heart failure or borderline BPs, use amiodarone. </span><span class="c8">There is no known increased concern for amiodarone lung toxicity</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3" start="2"><li class="c5"><span class="c8">&nbsp;If unstable, synchronized DCCV with 200 Joules biphasic </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c2"><span>Ventricular tachycardia (</span><span>VT</span><span class="c8">) </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Unstable/pulseless: initiate ACLS</span></li><li class="c5"><span class="c8">Stable:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Cardiology consult (may represent evolving myocardial involvement)</span></li><li class="c9 c47 c34"><span class="c8">Amiodarone 150mg IV x 1 or lidocaine 100mg IV x 1 </span></li></ol><p class="c9 c34 c27"><span class="c8"></span></p><ol class="c3 lst-kix_yfnaf4f33kdr-0" start="4"><li class="c28 c26"><h2 id="h.13b1uhteftcc" style="display:inline"><span class="c11">Acute Coronary Syndromes</span></h2></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c9 c18"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">There is no current available data on the incidence of ACS in COVID. However, we presume that due to the presence of ACE2 receptors on the endothelium, and the known increased risk of ACS in influenza that there is a possible increased incidence of ACS among COVID-19 patients.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span>The incidence of ACS is about 6 times as high within seven days of an influenza diagnosis than during control interval - incidence ratio 6.05 (95% CI, 3.86 to 9.50) </span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29365305&amp;sa=D&amp;ust=1585016771001000">Kwong et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29365305&amp;sa=D&amp;ust=1585016771002000">NEJM</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29365305&amp;sa=D&amp;ust=1585016771002000">, 2018</a></span><span>)</span><sup><a href="#cmnt24" id="cmnt_ref24">[x]</a></sup><sup><a href="#cmnt25" id="cmnt_ref25">[y]</a></sup><span class="c8">.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c9 c18"><span class="c17">Workup:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Elevated troponin/ECG changes alone may not be able to discriminate between:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Coronary thrombosis </span></li><li class="c5"><span class="c8">Demand-related ischemia </span></li><li class="c5"><span class="c8">Myocarditis</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c2"><span class="c8">Determination of ACS will rely on all evidence available: </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Symptoms (if able to communicate)</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span class="c8">New dyspnea, chest pain, anginal equivalents</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3" start="2"><li class="c5"><span>Regional</span><span class="c8">&nbsp;ECG changes</span></li><li class="c5"><span>Rate of change</span><span>&nbsp;of Troponin changes (</span><span class="c22">i.e.</span><span class="c8">, acute rise suggests ACS)</span></li><li class="c5"><span>Echo findings (</span><span class="c22">e.g.</span><span class="c8">, new RWMA)</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2" start="3"><li class="c2"><span class="c8">When in doubt, request a cardiology consult.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c9 c18"><span class="c17">Management:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Medical management of ACS should be coordinated with cardiology</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">Treat with full dose aspirin, clopidogrel (if not bleeding), heparin, oxygen (if hypoxemic), statin, nitrates (if hypertensive), and opioids (if persistent pain during medical management).</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Beta blockers should be used with caution given possible concomitant myocarditis/decompensated heart failure.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2" start="2"><li class="c2"><span class="c8">As of the time of this writing, the cath lab will take COVID-19 patients, even if ventilated. </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-3 start" start="1"><li class="c5"><span class="c8">If resources become constrained and door-to-balloon time is no longer adequate, cardiology may decide to use lytic medications for COVID-19 STEMI patients in lieu of PCI.</span></li></ol><p class="c9 c27 c63"><span class="c8"></span></p><ol class="c3 lst-kix_yfnaf4f33kdr-0" start="5"><li class="c28 c26"><h2 id="h.txp16938ptwl" style="display:inline"><span class="c11">Pericarditis and Myocarditis</span></h2></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1 start" start="1"><li class="c9 c18"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span>Myocarditis and pericarditis are potential manifestations of COVID-19 and source of Acute Cardiac Injury, based on case reports/case series (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771004000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771005000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771005000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771005000">&nbsp;2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&amp;sa=D&amp;ust=1585016771005000">Zeng et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&amp;sa=D&amp;ust=1585016771005000">Preprints</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.20944/preprints202003.0180.v1&amp;sa=D&amp;ust=1585016771005000">, 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016771006000">Hu et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016771006000">Eur Heart J</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016771006000">, 2020</a></span><span class="c8">) </span></li><li class="c2"><span class="c8">However, there is currently no evidence of proven pericarditis or myocarditis, either by biopsy or cMRI. </span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="2"><li class="c9 c18"><span class="c17">Diagnosis:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Likely no role for endomyocardial biopsy</span></li><li class="c2"><span class="c8">cMRI should be discussed on a case-by-case basis with a cardiology consult team.</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-1" start="3"><li class="c9 c18"><span class="c17">Management:</span></li></ol><ol class="c3 lst-kix_yfnaf4f33kdr-2 start" start="1"><li class="c2"><span class="c8">Supportive for heart failure and direct viral treatments </span></li><li class="c2"><span>The use of anti-inflammatory medications such as Colchicine and Ibuprofen should also be discussed with the cardiology consult team as this literature is evolving. </span></li></ol><h1 class="c44" id="h.dpe5gr1hwjp"><span>Chapter 5: Shock: Septic, Cardiogenic, and Cytokine Storm</span></h1><ol class="c3 lst-kix_q7k3qhhwoyo7-0 start" start="1"><li class="c28 c26"><h2 id="h.bdbn9kepy2bs" style="display:inline"><span class="c11">Undifferentiated Shock in COVID</span></h2></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1 start" start="1"><li class="c9 c18"><span class="c17">Definition:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>Acute onset of new and sustained hypotension (MAP &lt; 65 or SBP &lt; 90) with signs of hypoperfusion requiring IVF or vasopressors to maintain adequate blood pressure</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="2"><li class="c9 c18"><span class="c17">Time course:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>Patients rarely present in shock on admission</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Natural history seems to favor the development of shock after multiple days of critical illness. </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="3"><li class="c9 c18"><span class="c17">Etiology:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span class="c8">The range of reasons for shock is wide and more variable than for most patients and includes: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Cardiogenic shock</span></li><li class="c5"><span class="c8">Secondary bacterial infection</span></li><li class="c5"><span class="c8">Cytokine storm </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="4"><li class="c9 c18"><span class="c33">Workup for new </span><span class="c33">undifferentiated shock:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span class="c8">Assess for severity of end organ damage:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">UOP, &nbsp;Mental status, Lactate, BUN/creatinine, electrolytes, LFTs</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="2"><li class="c2"><span class="c8">Obtain a FULL infectious workup, which includes all of the following:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span>Labs: </span><span>CBC with differential. </span><span>Note that most COVID patients are lymphopenic (83%). &nbsp;However, new leukocytosis can occur and left-shift can be used as a part of clinical picture</span><span>&nbsp;(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016771010000">Guan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016771010000">N Engl J Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016771010000">, 2020</a></span><span>). </span><span>Two sets of blood cultures, LFTs (for cholangitis/acalculous cholecystitis), urinalysis (with reflex to culture), sputum culture (if safely obtained via inline suctioning, do not perform bronchoscopy or sputum induction), procalcitonin at 0 and 48h (</span><span>do not withhold early antibiotics on the basis of procalcitonin</span><span class="c22">), </span><span>urine Strep and legionella antigens</span></li><li class="c5"><span class="c8">Portable CXR (avoid CT unless absolutely necessary)</span></li><li class="c5"><span class="c8">Full skin exam</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c2"><span class="c8">Assess for cardiogenic shock</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Assess extremities: warm or cool on exam</span></li><li class="c5"><span class="c8">Assess patient volume status: JVP, CVP, edema, CXR</span></li><li class="c5"><span>Assess pulse pressure: If &lt; 25% of the SBP, correlates highly with a reduction in cardiac index to less than 2.2 with a sensitivity of 91% and a specificity of 83% (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&amp;sa=D&amp;ust=1585016771011000">Stevenson and Perloff, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&amp;sa=D&amp;ust=1585016771011000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&amp;sa=D&amp;ust=1585016771011000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&amp;sa=D&amp;ust=1585016771012000">&nbsp;1989</a></span><span class="c8">)</span></li><li class="c5"><span class="c8">Perform POCUS if trained to do so</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span>For TTE protocols see </span><span class="c16"><a class="c15" href="#h.6zfga8b63w2s">&ldquo;Cardiac Complications of COVID-19&rdquo; chapter</a></span><span class="c8">.</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="5"><li class="c5"><span class="c8">Labs: Obtain an SCV02 or MV02 if the patient has central access, troponin x2, NT proBNP, A1c, lipid profile, TSH</span></li><li class="c5"><span class="c8">EKG (and telemetry)</span></li><li class="c5"><span class="c8">Calculate estimated Fick Cardiac Output</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span>CO (Cardiac Output), L/min = VO</span><span class="c70">2</span><span>/ [(SaO</span><span class="c70">2</span><span>&nbsp;- SvO</span><span class="c70">2</span><span class="c8">) x Hb x 13.4)],</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-5 start" start="1"><li class="c9 c47 c92"><span>where VO</span><span class="c70">2</span><span>&nbsp;= 125 mL O</span><span class="c70">2</span><span>/min x </span><span>BSA, where </span><span>BSA = [(Height, cm x Weight, kg)/ 3,600 ]</span><span class="c64">&frac12;</span><span>; i</span><span>n patients aged &ge;70, use 110 mL O</span><span class="c70">2 </span><span>x BSA for VO</span><span class="c65 c70">2</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4" start="2"><li class="c9 c47 c34"><span>MDcalc online calculators: </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.mdcalc.com/cardiac-output-ficks-formula&amp;sa=D&amp;ust=1585016771014000">Fick CO</a></span><span>, </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.mdcalc.com/body-mass-index-bmi-body-surface-area-bsa&amp;sa=D&amp;ust=1585016771015000">BSA</a></span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="4"><li class="c2"><span class="c8">Assess for other causes of shock:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Vasoplegia: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Run medication list for recent cardiosuppressive medications, vasodilatory agents, antihypertensives </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="2"><li class="c5"><span class="c8">Adrenal insufficiency:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Unless high pretest probability of adrenal insufficiency, we recommend against routine cortisone stimulation testing</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="3"><li class="c5"><span class="c8">Obstruction:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span class="c8">PE (given the elevated risk of thrombosis)</span></li><li class="c9 c47 c34"><span class="c8">Tamponade (given elevated risk of pericarditis)</span></li><li class="c9 c47 c34"><span class="c8">Obstruction from PEEP</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="4"><li class="c5"><span>C</span><span>ytokine storm</span><span class="c57">&nbsp;</span><span>(see </span><span class="c16"><a class="c15" href="#h.7i62kagnynf0">&ldquo;Cytokine Activation Syndrome&rdquo; section</a></span><span class="c8">&nbsp;in this chapter below)</span></li><li class="c5"><span class="c8">Allergic reactions to recent medications</span></li><li class="c5"><span class="c8">Neurogenic shock is uncommon in this context</span></li><li class="c5"><span class="c8">Hypovolemia:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Bleeding</span></li><li class="c9 c47 c34"><span class="c8">Insensible losses from fever</span></li><li class="c9 c47 c34"><span class="c8">Diarrhea/vomiting</span></li></ol><p class="c9 c34 c27"><span class="c8"></span></p><ol class="c3 lst-kix_q7k3qhhwoyo7-0" start="2"><li class="c28 c26"><h2 id="h.ebuidko2u3iz" style="display:inline"><span>Differentiating Shock</span></h2></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span class="c42 c84"><a class="c15" href="https://www.google.com/url?q=https://www.khanacademy.org/science/health-and-medicine/circulatory-system-diseases/shock/v/differentiating-shock&amp;sa=D&amp;ust=1585016771018000">This video</a></span><span class="c8">&nbsp;is a helpful tutorial.</span></li></ol><p class="c9 c27"><span class="c24 c22"></span></p><p class="c9 c27"><span class="c24 c22"></span></p><a id="t.360bbd040a7d74c422f46692d8beb3d45d1de991"></a><a id="t.0"></a><table class="c90"><tbody><tr class="c68"><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Type of Shock</span></p></td><td class="c21" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Cardiac Output</span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">SVR</span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">CVP/Wedge</span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">ScvO2, MvO2</span></p></td><td class="c73" colspan="1" rowspan="1"><p class="c1"><span class="c33 c22">Other features</span></p></td></tr><tr class="c68"><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Cardiogenic</span></p></td><td class="c21" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c73" colspan="1" rowspan="1"><p class="c1 c27"><span class="c81 c33 c22 c66 c80 c88"></span></p></td></tr><tr class="c55"><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Distributive (sepsis,cytokine, anaphylaxis)</span></p></td><td class="c21" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c73" colspan="1" rowspan="1"><p class="c1 c27"><span class="c24 c22"></span></p></td></tr><tr class="c68"><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Obstructive</span></p></td><td class="c21" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c73" colspan="1" rowspan="1"><p class="c1 c27"><span class="c24 c22"></span></p></td></tr><tr class="c68"><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Hypovolemic</span></p></td><td class="c21" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 48.00px;"><img alt="" src="media/image2.png" style="width: 26.00px; height: 48.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c73" colspan="1" rowspan="1"><p class="c1 c27"><span class="c24 c22"></span></p></td></tr><tr class="c68"><td class="c46" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Neurogenic</span></p></td><td class="c21" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c61" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c69" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span><span class="c22 c24">/normal</span></p></td><td class="c60" colspan="1" rowspan="1"><p class="c1"><span style="overflow: hidden; display: inline-block; margin: 0.00px 0.00px; border: 0.00px solid #000000; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px); width: 26.00px; height: 52.00px;"><img alt="" src="media/image1.png" style="width: 26.00px; height: 52.00px; margin-left: 0.00px; margin-top: 0.00px; transform: rotate(0.00rad) translateZ(0px); -webkit-transform: rotate(0.00rad) translateZ(0px);" title=""></span></p></td><td class="c73" colspan="1" rowspan="1"><p class="c1"><span class="c24 c22">Decreased HR</span></p></td></tr></tbody></table><p class="c9 c27"><span class="c8"></span></p><p class="c9 c27"><span class="c24 c22"></span></p><ol class="c3 lst-kix_q7k3qhhwoyo7-0" start="3"><li class="c28 c26"><h2 id="h.lydcfzsuv4hc" style="display:inline"><span class="c11">Septic Shock and Secondary Infections </span></h2></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1 start" start="1"><li class="c9 c18"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span class="c8">The reported rates of sepsis and septic shock are not reported consistently in currently available case series</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Secondary bacterial infections are reported:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span>20% of non-survivors (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771035000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771035000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771035000">, 2020</a></span><span class="c8">)</span></li><li class="c9 c47 c34"><span>16% of non-survivors (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771036000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771036000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771036000">, 2020</a></span><span class="c8">)</span></li><li class="c9 c47 c34"><span>12-19% In H1N1 epidemic (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&amp;sa=D&amp;ust=1585016771037000">MacIntyre et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&amp;sa=D&amp;ust=1585016771037000">BMC Infect Dis</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&amp;sa=D&amp;ust=1585016771037000">, 2018</a></span><span class="c8">) </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="2"><li class="c2"><span class="c8">Concurrent Pneumocystis pneumonia has been reported in at least one case (possibly due to lymphopenia)</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="2"><li class="c9 c18"><span class="c17">Antibiosis:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>Early empiric antibiotics should be initiated within 1 hour (see </span><span class="c16"><a class="c15" href="#h.8vhrbtln428m">&ldquo;Antibiotic Stewardship&rdquo; section</a></span><span>&nbsp;within </span><span class="c16"><a class="c15" href="#h.kx686gedgtzg">&ldquo;COVID-19 Therapies and Clinical Trials&rdquo; chapter</a></span><span>)</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="3"><li class="c9 c18"><span class="c17">Conservative Fluid Management:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span class="c8">Goal MAP &gt; 65mmHg</span></li><li class="c2"><span>Start Norepinephrine while determining the etiology of undifferentiated shock</span></li><li class="c2"><span class="c8">We do not recommend conventional 30cc/kg resuscitation</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Give 250-500cc IVF and assess in 15-30 minutes for:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Increase &gt; 2 in CVP</span></li><li class="c9 c47 c34"><span class="c8">Increase in MAP or decrease in pressor requirement</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-5 start" start="1"><li class="c9 c47 c92"><span class="c8">Use isotonic crystalloids; Lactated Ringer&rsquo;s solution is preferred where possible. Avoid hypotonic fluids, starches, or colloids</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="2"><li class="c19 c1"><span class="c8">Repeat 250-500cc IVF boluses; Use dynamic measures of fluid responsiveness</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span>Pulse Pressure Variation: can be calculated in mechanically </span><span class="c8">ventilated patients without arrhythmia; PPV &gt;12% is sensitive and specific for volume responsiveness</span></li><li class="c9 c47 c34"><span class="c8">Straight Leg Raise: raise legs to 45&deg; w/ supine torso for at least one minute. A change in pulse pressure of &gt; 12% has sensitivity of 60% &amp; specificity of 85% for fluid responsiveness in mechanically ventilated patients; less accurate if spontaneously breathing</span></li><li class="c9 c47 c34"><span class="c8">Ultrasound evaluation of IVC collapsibility should only be undertaken by trained personnel to avoid contamination of ultrasound</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="3"><li class="c19 c1"><span>For further guidance, </span><span>Conservative Fluid Management protocols are available from from </span><span>FACCT</span><span>&nbsp;Lite trial </span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771041000">Grissom et al,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771041000">&nbsp;Crit Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771042000">, 2015</a></span><span>)</span><span class="c8">.</span></li><li class="c5"><span class="c22">Rationale</span><span>: COVID-19 clinical reports indicate the majority of patients present with respiratory failure without shock. ARDS is mediated in part by pulmonary capillary leak, and randomized controlled trials of ARDS indicate that a conservative fluid strategy is protective in this setting (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771042000">Grissom et al,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771043000">&nbsp;Crit Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771043000">, 2015</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&amp;sa=D&amp;ust=1585016771043000">Famous et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&amp;sa=D&amp;ust=1585016771043000">Am J Respir Crit Care Med,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&amp;sa=D&amp;ust=1585016771044000">&nbsp;2017</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&amp;sa=D&amp;ust=1585016771044000">Silversides et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&amp;sa=D&amp;ust=1585016771044000">Int Care Med,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&amp;sa=D&amp;ust=1585016771045000">&nbsp;2017</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016771045000">WHO, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016771045000">COVID-19 Interim guidance</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected&amp;sa=D&amp;ust=1585016771046000">, March 2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="4"><li class="c13 c1"><span class="c17">Pressor management</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c7 c1"><span>Unless new evidence emerges, standard choices for distributive shock (</span><span class="c22">i.e.</span><span class="c8">, norepinephrine then vasopressin) are recommended, with high vigilance for the development of cardiogenic shock, addressed in the next section.</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="5"><li class="c13 c1"><span class="c17">Corticosteroids</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c7 c1"><span>See </span><span class="c16"><a class="c15" href="#h.x05c129ivxrw">&ldquo;Systemic Corticosteroids&rdquo; section</a></span><span>&nbsp;within </span><span class="c16"><a class="c15" href="#h.kx686gedgtzg">&ldquo;COVID-19 Therapies and Clinical Trials&rdquo; chapter</a></span><span class="c8">.</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c19 c1"><span>Stress dose hydrocortisone should still be considered in patients on &gt; 2 pressors</span><span class="c22">.</span></li></ol><p class="c9 c63 c27"><span class="c8"></span></p><ol class="c3 lst-kix_q7k3qhhwoyo7-0" start="4"><li class="c28 c26"><h2 id="h.ftupyxepmedz" style="display:inline"><span>&nbsp;Cardiogenic Shock</span></h2></li></ol><p class="c37 c20"><span class="c8"></span></p><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="6"><li class="c9 c18"><span class="c17">Incidence: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>Heart failure or cardiogenic shock was observed in 23% (n=44 of 191) of hospitalized patients in one case series (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771048000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771049000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771049000">, 2020</a></span><span>). Moreover, there were higher rates in non-survivors (52%, n=28) compared to survivors (12%, n=16). &nbsp;</span><span>Among 21 patients admitted to an ICU in Washington State 33% (n=7) developed a new cardiomyopathy (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32191259&amp;sa=D&amp;ust=1585016771049000">Arentz et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32191259&amp;sa=D&amp;ust=1585016771050000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32191259&amp;sa=D&amp;ust=1585016771050000">, 2020</a></span><span>). Notably, these patients tended to be older with more comorbidities and had a high mortality (11 of the 21 died)</span><sup><a href="#cmnt26" id="cmnt_ref26">[z]</a></sup><sup><a href="#cmnt27" id="cmnt_ref27">[aa]</a></sup><span class="c8">.</span></li><li class="c2"><span>Heart failure or myocardial damage contributed to death in 39% (n=29) of deaths in a series of 68 patients in Wuhan. Most (n=22 of 29) had concomitant respiratory failure (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771050000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771051000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771051000">, 2020</a></span><span>).</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="7"><li class="c37 c13"><span class="c17">Diagnosis:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c37 c7"><span>Significant concern for cardiogenic shock if any of the following are present with evidence of hypoperfusion (</span><span class="c22">e.g.</span><span class="c8">, elevated lactate):</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c19 c37"><span class="c8">Elevated NT-proBNP, or</span></li><li class="c19 c37"><span class="c8">CvO2 &lt; 60% (PvO2 &lt; 35 mm Hg), or</span></li><li class="c19 c37"><span class="c8">Echocardiogram with depressed LV and/or RV function</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="8"><li class="c9 c18"><span class="c17">Time course:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>C</span><span>ardiogenic shock may present late in the course of illness even after improvement of respiratory symptoms, and manifest as a precipitous clinical deterioration in the setting of an acute decline in LVEF (see </span><span class="c16"><a class="c15" href="#h.sxzvrsrmkd1g">&ldquo;Acute Cardiac Injury&rdquo; section</a></span><span>&nbsp;in </span><span class="c16"><a class="c15" href="#h.6zfga8b63w2s">&ldquo;Cardiac Complications&rdquo; chapter</a></span><span>). </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="9"><li class="c9 c18"><span class="c17">Etiology:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>See </span><span class="c16"><a class="c15" href="#h.sxzvrsrmkd1g">&ldquo;Acute Cardiac Injury&rdquo; section</a></span><span>&nbsp;in </span><span class="c16"><a class="c15" href="#h.6zfga8b63w2s">&ldquo;Cardiac Complications&rdquo; chapter</a></span><span class="c8">. </span></li><li class="c2"><span class="c8">Mechanism is unknown, potentially direct viral toxicity, ACS, or stress cardiomyopathy.</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="10"><li class="c9 c18"><span class="c17">Workup:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>Rule out ACS and complete the initial work up as described in </span><span class="c16"><a class="c15" href="#h.6zfga8b63w2s">&ldquo;Cardiac Complications&rdquo; chapter</a></span><span>.</span></li><li class="c2"><span>Ongoing monitoring: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span>Labs</span><span class="c8">: Trend troponins to peak, SCvO2 (obtained by upper body CVC) or MvO2 q8-12h or with clinical change, Lactate q4-6h, &nbsp;LFTs daily (for hepatic congestion)</span></li><li class="c5"><span class="c8">Daily EKGs or prn with clinical deterioration</span></li><li class="c5"><span class="c8">Trend troponin to peak</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c2"><span class="c8">All cardiogenic shock cases require cardiovascular consult</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">PA catheters may be placed bedside by experienced providers, with preference for use only in mixed shock or complex cases with cardiology guidance</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="11"><li class="c9 c18"><span class="c17">Medical management:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span class="c8">Close collaboration with the cardiovascular consultation service is recommended</span></li><li class="c2"><span class="c8">Goals: MAPs 65-75, CVP 6-14, PCWP 12-18, PAD 20-25, SVR 800-1000, SCvO2 &gt; 60%, CI &gt; 2.2</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Note: Achieving MAP goal is first priority, then optimize other parameters</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c2"><span class="c8">How to achieve goals:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c5"><span class="c8">Continue titration of norepinephrine gtt for goal MAP 65-75</span></li><li class="c5"><span class="c8">Initiate diuretic therapy for CVP &gt; 14, PCWP &gt;18, PAD &gt; 25</span></li><li class="c5"><span class="c8">Initiate inotropic support: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Dobutamine gtt for SCvO2 &lt; 60%, CI &lt; 2.2 and MAP &gt; 65. &nbsp;Start at 2mcg/kg/min. Up-titrate by 1-2mcg/kg/min every 30-60 minutes for goal parameters. Alternative strategies should be considered once dose exceeds 5mcg/kg/min. &nbsp;Maximum dose is 10mcg/kg/min.</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="4"><li class="c19 c37"><span>Ensure negative inotropes such as beta blockers, calcium channel blockers and antihypertensives are discontinued.</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="12"><li class="c9 c18"><span class="c17">Candidacy for Mechanical Support</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>The benefit of Mechanical Support in COVID-19 is not yet clear. In one study of patients with severe COVID-19, five (83%) of six patients receiving ECMO died (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771057000">Yang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771057000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771057000">, 2020</a></span><span class="c8">). There is concern that the further decrease of lymphocytes from ECMO could contribute to higher mortality. However, this is a very small study and more information is needed.</span></li><li class="c37 c7"><span>Patients who experi</span><span>ence the following should prompt an immediate call to the cardiovascular medicine consult service for consideration of mechanical support:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c19 c37"><span class="c8">Dobutamine gtt at 5mcg/kg/min (or unable to tolerate dobutamine due to tachyarrhythmias) and SCVO2 &lt; 60% or CI &lt; 2.2</span></li><li class="c19 c37"><span>Lactate &gt; 4 after medical therapy </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2" start="3"><li class="c2"><span class="c8">The criteria for ECMO and other mechanical cardiovascular support varies among centers and are difficult to develop under typical circumstances. The unclear trajectory of the COVID-19 pandemic makes these evaluations even more difficult. Please refer to the separate BWH ECMO and Cardiovascular Medicine guidelines which are in development. </span></li></ol><p class="c9 c63 c27"><span class="c8"></span></p><p class="c9 c63"><span>The following does not reflect the recommendation of the BWH ECMO and Cardiovascular services. However, for the purposes of general education, a </span><span class="c57">hypothetical</span><span>&nbsp;set of</span><span class="c42">&nbsp;inclusion criteria</span><span class="c8">&nbsp;for ECMO or MCS could cover: </span></p><ol class="c3 lst-kix_q7k3qhhwoyo7-3" start="3"><li class="c9 c47 c34"><span class="c8">Younger age </span></li><li class="c9 c47 c34"><span class="c8">Expected life expectancy &gt;6 months pre-hospitalization</span></li><li class="c9 c47 c34"><span class="c8">No evidence of solid or liquid malignancy</span></li><li class="c9 c47 c34"><span class="c8">Able to tolerate anticoagulation</span></li><li class="c9 c47 c34"><span class="c8">Platelets &gt;50,000</span></li><li class="c9 c47 c34"><span class="c8">Absence of severe peripheral arterial disease</span></li><li class="c9 c47 c34"><span class="c8">No evidence of irreversible neurological injury</span></li><li class="c9 c47 c34"><span class="c8">Able to perform ADLs at baseline prior to illness</span></li><li class="c9 c47 c34"><span>Cannot have profound respiratory failure (defined as requiring prone ventilation at time of consult for MCS or having PaO2:FiO2 ratio &lt; 150)</span><span>&nbsp;(for MCS other than </span><span>ECMO</span><span>)</span></li></ol><p class="c9 c34 c27"><span class="c8"></span></p><ol class="c3 lst-kix_q7k3qhhwoyo7-0" start="5"><li class="c26 c28"><h2 id="h.7i62kagnynf0" style="display:inline"><span class="c11">&nbsp;Cytokine Activation Syndrome</span></h2></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1 start" start="1"><li class="c9 c18"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>A subgroup of patients with severe COVID-19 may have cytokine storm syndrome and secondary HLH (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&amp;sa=D&amp;ust=1585016771061000">Mehta et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&amp;sa=D&amp;ust=1585016771061000">, Lancet, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&amp;sa=D&amp;ust=1585016771062000">2020</a></span><span>). Patients who had cytokine storm developed rapid progression to ARDS, shock, and multiorgan failure (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016771062000">Chen et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016771062000">, Lancet, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016771063000">2020</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="2"><li class="c9 c18"><span class="c17">Pathophysiology: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>Neutrophil activation likely contributes to the pathogenesis of cytokine storm and ARDS (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771063000">Wu et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771064000">, JAMA Intern Med, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771064000">2020</a></span><span>).</span><span class="c64">&nbsp;</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771064000">Wu et al</a></span><span class="c8">&nbsp;found that COVID-19 confirmed patients with ARDS have higher neutrophil counts, average 7.04 (95% CI: 3.98 to 10.12) vs. those without ARDS, average 3.06 (2.03 to 5.56) </span></li><li class="c2"><span>Similar patterns of cytokine storm and ARDS have been seen with SARS, MERS (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&amp;sa=D&amp;ust=1585016771065000">Kim et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&amp;sa=D&amp;ust=1585016771065000">, J Korean Med Sci, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&amp;sa=D&amp;ust=1585016771065000">2016</a></span><span class="c8">)</span></li><li class="c2"><span>Other studies have suggested that increased proinflammatory cytokines in the serum are associated with pulmonary injury in SARS, MERS, and COVID-19 (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&amp;sa=D&amp;ust=1585016771066000">Wong et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&amp;sa=D&amp;ust=1585016771066000">, Clin Exp Immunol, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&amp;sa=D&amp;ust=1585016771066000">2004</a></span><span class="c8">) </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="3"><li class="c36 c13"><span class="c17">Workup:</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c36 c7"><span>Suspect if clinical deterioration with shock and multiorgan failure</span></li><li class="c36 c7"><span>CBC with diff, PT/INR, PTT, fibrinogen, d-dimer, ferritin, liver function test, triglycerides, c-reactive protein (CRP) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771067000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771068000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771068000">, 2020</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-3 start" start="1"><li class="c19 c36"><span>CRP seems to correlate with disease severity and prognosis of COVID-19 (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771068000">Ruan et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771069000">Intensive Care Med</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771069000">, 2020</a></span><span>;</span><span class="c22">&nbsp;</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125362&amp;sa=D&amp;ust=1585016771069000">Young et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125362&amp;sa=D&amp;ust=1585016771070000">, JAMA, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125362&amp;sa=D&amp;ust=1585016771070000">2020</a></span><span>)</span></li><li class="c19 c36"><span>An HScore (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.mdcalc.com/hscore-reactive-hemophagocytic-syndrome&amp;sa=D&amp;ust=1585016771071000">MDcalc online calculator</a></span><span>) may be helpful in estimating the probability of secondary HLH in these patients</span><span class="c64 c65">&nbsp;</span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-1" start="4"><li class="c9 c18"><span class="c17">Management: </span></li></ol><ol class="c3 lst-kix_q7k3qhhwoyo7-2 start" start="1"><li class="c2"><span>If high suspicion, discuss with ID about the use of IVIG, steroids, cytokine blockade, particularly IL-6 pathway and perhaps IL-1 (see </span><span class="c16"><a class="c15" href="#h.m6l0vgre9d0s">&ldquo;Anti-IL6 Agents&rdquo; section</a></span><span>&nbsp;within </span><span class="c16"><a class="c15" href="#h.kx686gedgtzg">&ldquo;COVID-19 Therapies and Clinical Trials&rdquo; chapter</a></span><span class="c8">). While steroids have been implicated with worse lung injury and outcomes, they may be beneficial in the hyperinflammatory state.</span></li></ol><p class="c9 c27"><span class="c8"></span></p><h1 class="c44" id="h.5s70bzlr4ojz"><span>Chapter 6: Thrombotic and Coagulation Manifestations</span></h1><ol class="c3 lst-kix_h8i9ymdmzkx8-0 start" start="1"><li class="c28 c26"><h2 id="h.9wzf9ick65rt" style="display:inline"><span class="c11">Thrombotic Disease</span></h2></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1 start" start="1"><li class="c9 c18"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>Unclear incidence, though case reports suggest there may be increased venous thromboembolism (VTE) in COVID-19 patients </span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1148/ryct.2020200067&amp;sa=D&amp;ust=1585016771073000">Xie et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1148/ryct.2020200067&amp;sa=D&amp;ust=1585016771073000">Radiol: Cardiothoracic Imaging,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1148/ryct.2020200067&amp;sa=D&amp;ust=1585016771073000">&nbsp;2020</a></span><span class="c8">)</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="2"><li class="c9 c18"><span class="c17">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>The mechanism for VTE are unknown and likely multifactorial:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span class="c8">Systemic inflammatory response as seen in sepsis</span></li><li class="c5"><span class="c8">Stasis/critical illness</span></li><li class="c5"><span class="c8">Possibly direct endothelial damage from viral injury/ACE2 binding</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2" start="2"><li class="c2"><span>Colleagues from Wuhan have reported finding microthrombi in pulmonary vasculature on autopsy (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&amp;sa=D&amp;ust=1585016771075000">Luo et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&amp;sa=D&amp;ust=1585016771075000">Preprints</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&amp;sa=D&amp;ust=1585016771075000">,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.preprints.org/manuscript/202002.0407/v2&amp;sa=D&amp;ust=1585016771075000">&nbsp;2020 preprint</a></span><span class="c8">), which could contribute to local V/Q mismatch or hydrostatic changes causing edema. However these mechanisms remain entirely hypothetical.</span></li><li class="c2"><span>One theory: </span><span class="c0">SARS-CoV Spike protein can be cleaved by FXa and FIIa. Cleavage of the Spike protein activates it which promotes infectivity. By extension, it is hypothesized that anticoagulation might inhibit SARS-CoV-2 replication</span><span>. There is a small case series suggesting dipyridamole may be useful, though anticoagulation and antiplatelet agents require further investigation prior to being used therapeutically </span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1101/2020.02.27.20027557&amp;sa=D&amp;ust=1585016771076000">Liu et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1101/2020.02.27.20027557&amp;sa=D&amp;ust=1585016771076000">medRxiv,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1101/2020.02.27.20027557&amp;sa=D&amp;ust=1585016771077000">&nbsp;2020 preprint</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="3"><li class="c9 c18"><span class="c17">Management:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>Initiate p</span><span class="c8">rophylactic anticoagulation therapy for all COVID-19 patients unless otherwise contraindicated</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span class="c8">If CrCl &gt; 30: Lovenox 40 mg SC daily</span></li><li class="c5"><span class="c8">If CrCl &lt; 30 or AKI: Heparin 5000 units SC TID</span></li><li class="c5"><span class="c8">Hold if Platelets &lt;30,000 or bleeding, start TEDs and SCDs</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2" start="2"><li class="c2"><span>If the patient is on direct oral anticoagulants (DOACs) or Warfarin for Afib or VTE, switch </span><span>to full dose</span><span class="c8">&nbsp;anticoagulation (LMWH or UFH, as indicated based on renal function or clinical scenario).</span></li><li class="c2"><span class="c8">While therapeutic anticoagulation has been used empirically in some severe COVID-19 patients in Wuhan given the microthrombi in pulmonary vasculature (see &ldquo;Pathophysiology&rdquo; above), our interpretation of the data is that the risks outweigh the benefits at this time, unless documented DVT or PE.</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="4"><li class="c9 c18"><span class="c17">Prognosis:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>Higher D-dimer and FDP levels track with multi-organ dysfunction syndrome and poorer prognosis </span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771079000">Wang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771079000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771079000">, 2020</a></span><span>; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771079000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771080000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771080000">, 2020</a></span><span class="c8">).</span></li></ol><p class="c9 c27"><span class="c8"></span></p><ol class="c3 lst-kix_h8i9ymdmzkx8-0" start="2"><li class="c28 c26"><h2 id="h.vpg0k312hzmd" style="display:inline"><span class="c11">Disseminated Intravascular Coagulation (DIC)</span></h2></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1 start" start="1"><li class="c9 c18"><span class="c17">Incidence/pathophysiology:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>Limited data: 16 of 183 hospitalized patients in Wuhan had DIC (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771081000">Tang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771081000">J Thromb Haemost,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771082000">&nbsp;2020</a></span><sup><a href="#cmnt28" id="cmnt_ref28">[ab]</a></sup><sup><a href="#cmnt29" id="cmnt_ref29">[ac]</a></sup><span class="c8">).</span></li><li class="c2"><span>Laboratory changes in coagulation parameters and FDP track with multi-organ dysfunction (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771082000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771082000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771083000">, 2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="2"><li class="c9 c18"><span class="c17">Time course:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>Median time to onset of DIC was 4 days into hospital admission (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771083000">Tang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771083000">J Thromb Haemost,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771084000">&nbsp;2020</a></span><sup><a href="#cmnt30" id="cmnt_ref30">[ad]</a></sup><sup><a href="#cmnt31" id="cmnt_ref31">[ae]</a></sup><span>).</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="3"><li class="c9 c18"><span class="c17">Workup:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>I</span><span class="c8">dentify and treat underlying condition</span></li><li class="c2"><span>ISTH DIC score (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.mdcalc.com/isth-criteria-disseminated-intravascular-coagulation-dic&amp;sa=D&amp;ust=1585016771085000">MDcalc online calculator</a></span><span>)</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span class="c8">If score &lt; 5, no DIC; recalculate in 1-2 days</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="4"><li class="c9 c18"><span class="c17">Management:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span class="c8">If bleeding, give blood products:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span class="c8">For elevated PT/PTT and bleeding, use FFP or 4F-PCC (KCentra is less volume, but must discuss dose with HAT/pharmacy)</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2" start="2"><li class="c2"><span class="c8">If not bleeding, supportive care:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span>If fibrinogen &lt; 150: </span><span>FFP, cryoprecipitate or fibrinogen concentrate (RiaSTAP)</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-4 start" start="1"><li class="c9 c47 c34"><span class="c8">RiaSTAP is less volume, but dose must be discussed with HAT/pharmacy</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3" start="2"><li class="c5"><span class="c8">Transfuse platelets if &lt; 30K</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2" start="3"><li class="c2"><span>Hold anticoagulation </span><sup><a href="#cmnt32" id="cmnt_ref32">[af]</a></sup><sup><a href="#cmnt33" id="cmnt_ref33">[ag]</a></sup><span class="c8">for active bleeding. </span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span class="c8">Consider holding anticoagulation if patient requires blood products for supportive care, though clinician should weigh risks and benefits.</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2" start="4"><li class="c2"><span class="c8">Start anticoagulation only if:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-3 start" start="1"><li class="c5"><span>Overt thromboembolism or organ failure due to clot (</span><span class="c22">i.e.</span><span class="c8">, purpura fulminans)</span></li><li class="c5"><span>There has been no mortality benefit of therapeutic anticoagulation in DIC (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&amp;sa=D&amp;ust=1585016771087000">Levi et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&amp;sa=D&amp;ust=1585016771088000">Blood,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&amp;sa=D&amp;ust=1585016771088000">&nbsp;2018</a></span><span>)</span><sup><a href="#cmnt34" id="cmnt_ref34">[ah]</a></sup><sup><a href="#cmnt35" id="cmnt_ref35">[ai]</a></sup><span class="c8">.</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-1" start="5"><li class="c9 c18"><span class="c17">Prognosis:</span></li></ol><ol class="c3 lst-kix_h8i9ymdmzkx8-2 start" start="1"><li class="c2"><span>DIC is associated with worse survival in COVID-19 patients. Out of 183 COVID-19 patients in Wuhan, 71% of non-survivors had DIC (ISTH score &ge; 5; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.mdcalc.com/isth-criteria-disseminated-intravascular-coagulation-dic&amp;sa=D&amp;ust=1585016771089000">MDcalc online calculator</a></span><span>) compared to 0.6% of survivors (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771089000">Tang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771089000">J Thromb Haemost,</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771090000">&nbsp;2020</a></span><sup><a href="#cmnt36" id="cmnt_ref36">[aj]</a></sup><sup><a href="#cmnt37" id="cmnt_ref37">[ak]</a></sup><span class="c8">).</span></li></ol><p class="c9 c27 c78"><span class="c29 c45"></span></p><h1 class="c44" id="h.9jn4ulxubc3h"><span class="c23 c49">Chapter 7: Renal Manifestations </span></h1><ol class="c3 lst-kix_b0ja666m9l9x-0 start" start="1"><li class="c52"><h2 id="h.fj20lj7bpd6o" style="display:inline"><span class="c11">Acute Kidney Injury</span></h2></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-1 start" start="1"><li class="c36 c13"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c36 c7"><span>I</span><span>ncidence of AKI in COVID-19 varies widely, but estimates range from 2.1% to 29%.</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-1" start="2"><li class="c36 c13"><span class="c17">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c36 c7"><span>Likely that the most common pathophysiology will be </span><span>acute tubular necrosis (ATN) driven by shock (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145717&amp;sa=D&amp;ust=1585016771091000">Xianghong et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145717&amp;sa=D&amp;ust=1585016771092000">, Natl Med J China, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145717&amp;sa=D&amp;ust=1585016771092000">2020</a></span><span class="c8">) and in some cases cytokine storm.</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span>Areas for future research: Some have hypothesized that there could direct cellular injury by the virus via angiotensin converting enzyme II (</span><span>ACE2). COVID-19 uses ACE2 for cell entry. ACE2 is expressed in proximal renal tubules more than glomeruli (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&amp;sa=D&amp;ust=1585016771092000">Fan et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&amp;sa=D&amp;ust=1585016771093000">, medRxiv, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&amp;sa=D&amp;ust=1585016771093000">2020</a></span><span class="c8">); but it remains likely that shock (and in some cases cytokine storm) are the main causes of ATN. </span></li></ol><p class="c36 c20 c32"><span class="c8"></span></p><ol class="c3 lst-kix_b0ja666m9l9x-1" start="3"><li class="c36 c13"><span class="c33">Workup:</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c36 c7"><span class="c8">Monitor Creatinine at least daily</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span>Studies find variable onset of AKI, from 7 days (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771094000">Cheng et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771094000">medRxiv</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771094000">, 2020 preprint</a></span><span>) to 15 days after illness onset (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771095000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771095000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771095000">, 2020</a></span><span>).</span><span class="c64">&nbsp;</span><span>Onset of AKI more rapid and severe in patients with underlying CKD</span><span class="c64">&nbsp;</span><span>(</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771096000">Cheng et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771096000">medRxiv</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771096000">, 2020 preprint</a></span><span>)</span><span class="c64">&nbsp;</span><span class="c8">&nbsp;</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2" start="2"><li class="c36 c7"><span>If evidence of rising BUN and/or creatinine, order urinalysis</span><span class="c17">&nbsp;</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span class="c8">Patients may present with proteinuria (44%), hematuria (26.9%)</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-1" start="4"><li class="c36 c13"><span class="c17">Management: </span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c36 c7"><span class="c8">Consult ICU nephrology early at the first sign of renal injury for all COVID-19 confirmed patients </span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span>Do not wait until need for RRT (renal replacement therapy)/dialysis for consultation. </span></li><li class="c19 c36"><span class="c8">At this time, all confirmed COVID-19 patients should be covered by ICU nephrology, not general nephrology</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-4 start" start="1"><li class="c36 c30"><span class="c8">ICU</span></li><li class="c36 c30"><span class="c8">RRT Triage</span></li><li class="c36 c30"><span>Floor</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2" start="2"><li class="c36 c7"><span class="c8">Managing AKI:</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span class="c8">Minimize nephrotoxic agents</span></li><li class="c19 c36"><span>Give judicious fluids for suspected prerenal insults, but discuss with renal if any ambiguity (see </span><span class="c16"><a class="c15" href="#h.dpe5gr1hwjp">&ldquo;Shock&rdquo; chapter</a></span><span>&nbsp;for conservative fluid recommendations)</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-1" start="5"><li class="c13 c36"><span class="c17">Renal Replacement Therapy (RRT):</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c36 c7"><span>Estimates for RRT range from </span><span>1 to 5%</span><span class="c8">&nbsp;of hospitalized patients. Among critically ill patients, need for CRRT ranges from 5 to 23% </span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span>Few studies have reported outcomes of RRT. One case series reported that out of 191 patients, 10 received CRRT, and all 10 died (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771100000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771100000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771100000">, 2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2" start="2"><li class="c36 c7"><span>Renal will be coordinating RRT continuation and initiation </span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-3 start" start="1"><li class="c19 c36"><span>Indications for dialysis in COVID-19 patients are the same as the indications for all patients.</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2" start="3"><li class="c36 c7"><span class="c8">ICU nephrology will determine the need, timing, and modality of renal replacement on a case-by-case basis.</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-1" start="6"><li class="c36 c13"><span class="c33">Prognosis:</span></li></ol><ol class="c3 lst-kix_b0ja666m9l9x-2 start" start="1"><li class="c36 c7"><span>Increased serum creatine, BUN, AKI, proteinuria, or hematuria are each </span><span>independent risk factors for in-hospital death (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771102000">Cheng et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771102000">medRxiv</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771102000">, 2020 preprint</a></span><span>)</span><span class="c8">&nbsp;</span></li><li class="c36 c7"><span>In two other studies, non-survivors had higher BUN and creatinine and higher rates of AKI (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771103000">Wang et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771103000">JAMA</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771103000">, 2020</a></span><span class="c22">; </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771103000">Yang et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771104000">, Lancet Respir Med, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771104000">2020</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32105632&amp;sa=D&amp;ust=1585016771104000">)</a></span><span class="c8">.</span></li><li class="c36 c7"><span>Another study found that higher BUN and creatinine are associated with progression to ARDS, and higher BUN (though not creatinine) is associated with death (HR 1.06-1.20) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771105000">Wu et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771105000">, JAMA Intern Med, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771105000">2020</a></span><span>).</span></li><li class="c36 c7"><span>In comparison</span><span>, AKI was found in 6.7% of SARS patients. AKI correlated with poor prognosis and </span><span>91.7% of patients with AKI died</span><span class="c33">&nbsp;</span><span>(vs 8.8% without AKI, p &lt; 0.0001) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&amp;sa=D&amp;ust=1585016771106000">Chu et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&amp;sa=D&amp;ust=1585016771106000">, Kidney Int</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&amp;sa=D&amp;ust=1585016771107000">,</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&amp;sa=D&amp;ust=1585016771107000">&nbsp;</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&amp;sa=D&amp;ust=1585016771107000">2005</a></span><span>).</span></li></ol><h1 class="c39" id="h.l3i6lcz3jr27"><span>Chapter 8: Other Guidance</span></h1><ol class="c3 lst-kix_xgq4y4xln1s-0 start" start="1"><li class="c9 c26 c0 c82"><h2 id="h.fg1hqkm6u1r8" style="display:inline"><span class="c11">Liver Disease</span></h2></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c9 c18 c0"><span class="c17">Incidence:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2 c0"><span>Up to 53% of patients had abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145190&amp;sa=D&amp;ust=1585016771108000">Zhang et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145190&amp;sa=D&amp;ust=1585016771108000">, Lancet Gastroenterol Hepatol, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145190&amp;sa=D&amp;ust=1585016771108000">2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="2"><li class="c9 c18 c0"><span class="c17">Pathophysiology:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2 c0"><span class="c8">Possible mechanisms of liver injury include: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5 c0"><span class="c8">Direct viral infection of liver cells (2-10% of patients have diarrhea; COVID-19 found in stool samples)</span></li><li class="c5 c0"><span class="c8">Drug hepatotoxicity </span></li><li class="c5 c0"><span class="c8">Cytokine storm</span></li><li class="c5 c0"><span class="c8">Shock</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="3"><li class="c9 c18 c0"><span class="c17">Time course:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2 c0"><span>In general, liver injury in mild COVID-19 disease is transient and self-resolving. However,</span><span class="c22">&nbsp;</span><span class="c8">liver injury correlates with severity</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5 c0"><span>ALT &gt; 40 is associated with higher odds of in-hospital death (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771110000">Zhou et al, </a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771110000">Lancet</a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171076&amp;sa=D&amp;ust=1585016771110000">, 2020</a></span><span class="c8">).</span></li><li class="c5 c0"><span>AST is associated with progression to ARDS but not death; total bilirubin is associated with both progression to ARDS and death (</span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771110000">Wu et al</a></span><span class="c14"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771110000">, JAMA Intern Med, </a></span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771111000">2020</a></span><span class="c8">).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="4"><li class="c9 c18 c0"><span class="c17">Monitoring: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2 c0"><span class="c8">Monitor LFTs every third day</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">If on hepatotoxic medications, monitor more frequently in conjunction with pharmacy.</span></li><li class="c5"><span>If starting L</span><span class="c83">opinavir/</span><span>R</span><span class="c83">itonavir and </span><span>C</span><span class="c8">hloroquine, monitor LFTs daily.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="2"><li class="c2"><span>Workup for other etiologies of liver injury with RUQUS, doppler ultrasound, hepatitis serologies, etc., as clinically indicated.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="5"><li class="c9 c18"><span class="c17">Management:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Consult GI/Hepatology if concern for acute liver failure (severe liver injury with elevated bilirubin, encephalopathy, and INR &gt;1.5).</span></li><li class="c2"><span class="c8">Run medication list for all possible offending agents and discontinue where possible.</span></li><li class="c2"><span>N-Acetyl-Cysteine is not recommended at this time due to significant volume load. </span><span class="c83">Chinese studies refer to giving &ldquo;liver protective drugs&rdquo; in case of severe liver injury but </span><span class="c8">we recommend against this for now.</span></li><li class="c2"><span>There are no current </span><span class="c83">guidelines for treatment of COVID-19 patients with underlying cirrhosis, but societies such as AASLD are working on registries of these patients.</span></li></ol><p class="c9 c27 c78"><span class="c8"></span></p><ol class="c3 lst-kix_xgq4y4xln1s-0" start="2"><li class="c28 c26"><h2 id="h.aayfijcxre19" style="display:inline"><span>Considerations for Oncology Patients &nbsp;</span></h2></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c9 c18"><span class="c17">Data:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">As of March 16, 2020, there are no available published data specific to COVID-19 management in oncologic or immunosuppressed patients.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="2"><li class="c9 c18"><span class="c17">Oncology Consultation/Coverage: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">For established DFCI patients, oncology consultation and guidance is provided by each patient&rsquo;s primary oncologist (or coverage). </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Contact primary oncologist via page, not the general pager.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="3"><li class="c9 c18"><span class="c17">Prognosis: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Many patients have reasonable or even good prognosis with current therapies. Do not assume a prognosis, involve outpatient attending.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="4"><li class="c9 c18"><span class="c17">Meds: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Check in Epic medications tab and in &ldquo;Research: Active&rdquo; tab.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="5"><li class="c9 c18"><span class="c17">Workup: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Labs: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Weekly glucan/galactomannan in neutropenic/transplant patients.</span></li><li class="c5"><span class="c8">Specific patient populations may require additional monitoring (such as CMV, EBV monitoring in transplant patients &ndash; ask outpatient team).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="2"><li class="c2"><span class="c8">Exam: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Examine catheters (port, CVC, others) daily. </span></li><li class="c5"><span class="c8">Avoid rectal exams in neutropenic patients, but examine the perirectal area if symptoms or persistent fevers. </span></li><li class="c5"><span class="c8">Do not give per rectum therapies to neutropenic patients.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="6"><li class="c9 c18"><span class="c17">Pain management: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Patients with cancer-related pain may have high opiate needs at baseline. Opiates should not be stopped but type may need to be adjusted in the setting of respiratory failure, renal injury, or liver injury.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Pain / Palliative Care service can help guide dose titrations in these situations.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="7"><li class="c9 c18"><span class="c17">Goals of Care: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Involve primary team whenever possible (recognizing that in critical/emergent situations may not be possible).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="8"><li class="c9 c18"><span class="c17">Anticoagulation:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Thrombosis prophylaxis should be initiated for all patients unless otherwise contraindicated, given that both COVID-19 infection and malignancy increase thrombotic risk, particularly with solid tumors.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span>See </span><span class="c16"><a class="c15" href="#h.9wzf9ick65rt">&ldquo;Thrombotic Disease&rdquo; section</a></span><span>&nbsp;within </span><span class="c16"><a class="c15" href="#h.5s70bzlr4ojz">&ldquo;Thrombotic and Coagulation Manifestations&rdquo; chapter</a></span><span class="c8">&nbsp;for guidelines on both prophylactic and therapeutic anticoagulation.</span></li><li class="c5"><span class="c8">Remember to hold if platelet count &lt; 30K.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="9"><li class="c9 c18"><span class="c17">Patients with Heme Malignancy and Stem Cell Transplant:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Daily exam: Findings are more subtle or absent in neutropenic and immune suppressed patients. Examine catheters daily. Avoid rectal exam.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="10"><li class="c9 c18"><span class="c17">Febrile Neutropenia:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Definition:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">ANC &lt; 500 cells/mm3 AND T &ge; 101F or T &ge; 100.5 for 1hr</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="2"><li class="c2"><span class="c8">Workup: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Blood cultures from peripheral (ideally two sets), and each lumen of central line (label clearly); UA/sed with urine culture (UA may not be as informative with neutropenia); glucan and galactomannan (if not checked recently), sputum if able; CXR</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Continue DAILY blood cultures while febrile.</span></li><li class="c9 c47 c34"><span class="c8">Monitor serum galactomannan and 1-3-beta glucan once weekly.</span></li><li class="c9 c47 c34"><span class="c8">Any positive glucan or galactomannan prompts ID consult.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="3"><li class="c2"><span class="c8">Initial Empiric Antibiotics:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">GNRs: Ceftazidime OR Cefepime </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Alternatives: &nbsp;Piperacillin-tazobactam (2nd line) or meropenem (3rd line).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3" start="2"><li class="c5"><span class="c8">GPCs: add Vancomycin if hemodynamically unstable, or if MRSA pneumonia or catheter-associated infection is suspected. Check dosing with pharmacy if able.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="4"><li class="c2"><span class="c8">Removal of lines:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Catheter removal should be discussed if associated infection is suspected - involve primary oncologist and/or ID team to weigh risks and benefits, given that not all lines require removal.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="5"><li class="c2"><span class="c8">Persistent Neutropenic Fever:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">If fever persists x3 days despite antibiotics </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Micafungin 100mg IV daily </span></li><li class="c9 c47 c34"><span class="c8">Consideration of further imaging even if patient appears stable (discuss with oncology / ID).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="6"><li class="c2"><span class="c8">Antiinfective course:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Anti-Infectives should be continued until the patient has met all of these criteria: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c9 c47 c34"><span class="c8">clinically improved, and </span></li><li class="c9 c47 c34"><span class="c8">has been afebrile for 48h, and </span></li><li class="c9 c47 c34"><span class="c8">has been non-neutropenic for 48h.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="11"><li class="c9 c18"><span class="c17">Transfusions: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span>Blood bank reviews orders and will release appropriate products (</span><span class="c22">i.e.</span><span class="c8">, irradiated, leukoreduced, etc).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">RBC transfusion if Hgb &lt; 7 or Hct &lt; 21.</span></li><li class="c5"><span class="c8">Platelet transfusion if Platelets &lt; 10K. Higher transfusion goals if needed for procedures or if active bleeding:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c9 c47 c34"><span>Platelet count &gt; 20K if mild bleeding (</span><span class="c22">i.e.</span><span class="c8">, epistaxis, line oozing) or if patient has rigors.</span></li><li class="c9 c47 c34"><span class="c8">Platelet count &gt; 50K if more serious bleeding; may be higher for CNS bleeding or neurosurgery required.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3" start="3"><li class="c5"><span class="c8">Cryoprecipitate transfusion if fibrinogen &lt; 100.</span></li><li class="c5"><span class="c8">FFP transfusion if procedure needed (INR of FFP = ~1.4).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="12"><li class="c9 c18"><span class="c17">Patients with Solid Tumors:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">Patients with solid tumors are at very high risk of thrombosis but at lower risk of infection than most heme malignancy patients.</span></li><li class="c2"><span class="c8">Immune Checkpoint Inhibitors (ICIs) do not significantly immunosuppress patients when used alone.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">Most common are CTLA-4 inhibitor (ipilimumab) and PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, durvalumab, atezolizumab and avelumab).</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2" start="3"><li class="c2"><span class="c8">Immune toxicity: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3 start" start="1"><li class="c5"><span class="c8">If patient develops organ dysfunction, it may be due to immune toxicity- consult the service team of the involved organ system and inform primary oncologist.</span></li><li class="c5"><span class="c8">Common immune toxicities include pneumonitis / respiratory failure (may be difficult to distinguish between COVID19 disease or may be aggravated by COVID19 infection), colitis, endocrine dysfunction (thyroid, pituitary / hypothalamic, adrenal), nephritis. Less common hepatitis, meningitis, dermatitis.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-4 start" start="1"><li class="c9 c47 c34"><span class="c8">Check TSH, ACTH, cortisol, T-spot, HIV, HBV, HCV serologies if concerned.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-3" start="3"><li class="c5"><span class="c8">Immune toxicities are usually treated with high dose steroids - risks and benefits must be weighed immediately with primary oncologist and ID consult teams if immune toxicity is suspected concurrent with COVID19 infection.</span></li><li class="c5"><span>BWH/DFCI iTox guidelines can be found </span><span class="c16"><a class="c15" href="https://www.google.com/url?q=http://dfcionline.org/clinical/clinicalresources/immunotherapy-toxicity/&amp;sa=D&amp;ust=1585016771121000">here</a></span><span class="c8">&nbsp;on BWH/DFCI intranet.</span></li></ol><p class="c9 c27"><span class="c8"></span></p><ol class="c3 lst-kix_xgq4y4xln1s-0" start="3"><li class="c28 c26"><h2 id="h.t1khoickfgoo" style="display:inline"><span class="c11">Goals of Care</span></h2></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c13 c1"><span class="c33">Assess understanding and sign Health Care Proxy form on admission:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c2"><span class="c8">In conscious patients, review or sign Health Care Proxy form.</span></li><li class="c7 c1"><span>Make sure families are aware that p</span><span>atients with significant comorbid illnesses or who have poor baseline functional or health status decompensate rapidly and have very high mortality due to COVID-19 (see </span><span class="c16"><a class="c15" href="#h.d36vdx67mxka">&ldquo;Non-ICU Management, Triage, Transfers&rdquo; chapter</a></span><span>). </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="2"><li class="c13 c1"><span class="c17">Goals of Care should be documented and focus on:</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c7 c1"><span class="c8">A patient&rsquo;s desired quality of life</span></li><li class="c7 c1"><span class="c8">Tolerance for/desire for invasive measures</span></li><li class="c7 c1"><span class="c8">Understanding of disease process </span></li></ol><p class="c1 c20 c32"><span class="c59 c45 c75"></span></p><ol class="c3 lst-kix_xgq4y4xln1s-0" start="4"><li class="c26 c54"><h2 id="h.ipfys4gecnv0" style="display:inline"><span class="c11">Management of Cardiac Arrest</span></h2></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c13 c1"><span class="c17">Early goals of care conversations are imperative.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c7 c1"><span>The aim is to avoid unnecessary codes in patients without a reversible underlying condition.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="2"><li class="c13 c1"><span class="c17">Health care workers should be protected in code situations: </span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-2 start" start="1"><li class="c7 c1"><span class="c8">PPE should be worn by all healthcare workers, even if donning prolongs time the patient spends in a low-flow state during cardiac arrest.</span></li><li class="c1 c7"><span class="c8">Codes should be run with an automated compression device where available and minimal personnel.</span></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1" start="3"><li class="c13 c1"><span class="c17">Full code guidelines are forthcoming and will be included here when available.</span></li></ol><p class="c1 c20"><span class="c8"></span></p><ol class="c3 lst-kix_xgq4y4xln1s-0" start="5"><li class="c54 c26"><h2 id="h.6ogwg6sl9a40" style="display:inline"><span class="c11">The Role of Palliative Care</span></h2></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c13 c1"><span>This section in in progress</span><sup><a href="#cmnt38" id="cmnt_ref38">[al]</a></sup></li></ol><p class="c9 c27 c56"><span class="c8"></span></p><ol class="c3 lst-kix_xgq4y4xln1s-0" start="6"><li class="c54 c26"><h2 id="h.foc01qidskrl" style="display:inline"><span class="c11">Ethical Considerations and Resource Allocation</span></h2></li></ol><ol class="c3 lst-kix_xgq4y4xln1s-1 start" start="1"><li class="c9 c18"><span>This section </span><span>is</span><sup><a href="#cmnt39" id="cmnt_ref39">[am]</a></sup><span>&nbsp;in progress</span></li></ol><p class="c36 c20 c56"><span class="c23 c86"></span></p><hr style="page-break-before:always;display:none;"><p class="c36 c20"><span class="c23 c86"></span></p><p class="c36 c20"><span class="c23 c86"></span></p><p class="c36 c67 c56"><span class="c86">&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></p><p class="c9 c0"><span class="c59 c42 c33 c66 c77">Afterword</span></p><p class="c9 c0"><span class="c8">We built the first iteration of these guidelines &ldquo;from the bottom up&rdquo; in less than a week with the input of over 50 people. With the help of our readers, we expect to correct and revise as we as a society learn about COVID-19. </span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span class="c8">We hope that this pandemic brings with it a new era of collaborativity and speed in Evidence Based Medicine. We welcome all help, and will be restructuring this to be more navigable and collaborative in the coming days.</span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span>Currently we are looking for ongoing section editors, please email </span><span class="c16"><a class="c15" href="mailto:BWHCOVIDGuidelines@gmail.com">BWHCOVIDGuidelines@gmail.com</a></span><span class="c8">&nbsp;if you are interested.</span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span class="c8">(signed)</span></p><p class="c9 c0"><span class="c8">&nbsp;</span></p><p class="c9 c0"><span class="c8">BWH intensivists, fellows, respiratory therapists and pharmacists</span></p><hr style="page-break-before:always;display:none;"><h1 class="c44 c79" id="h.fu2z89vxpri3"><span class="c23 c49"></span></h1><h1 class="c44" id="h.24n5wzicja05"><span>REFERENCES &nbsp;</span></h1><p class="c9 c27"><span class="c23 c10 c0"></span></p><ol class="c3 lst-kix_d9wep1z810b6-0 start" start="1"><li class="c9 c26"><span class="c10 c0">Afshari A, Bastholm bille A, Allingstrup M. Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS). </span><span class="c10 c0 c22">Cochrane Database Syst Rev</span><span class="c10 c0">. 2017;7:CD007733. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1002/14651858.CD007733.pub3&amp;sa=D&amp;ust=1585016771129000">10.1002/14651858.CD007733.pub3</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483148/&amp;sa=D&amp;ust=1585016771129000">28806480</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Akerstr&ouml;m S, Mousavi-jazi M, Klingstr&ouml;m J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. </span><span class="c10 c0 c22">J Virol</span><span class="c10 c0">. 2005;79(3):1966-9. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1128/JVI.79.3.1966-1969.2005&amp;sa=D&amp;ust=1585016771130000">10.1128/JVI.79.3.1966-1969.2005</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15650225&amp;sa=D&amp;ust=1585016771130000">15650225</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">American College of Cardiology. Cardiologist&rsquo;s Insights From Treating COVID-19 Patients in China. Mar 12, 2020. &nbsp;</span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.acc.org/latest-in-cardiology/articles/2020/03/12/17/02/cardiologists-insights-from-treating-covid-19-patients-in-china&amp;sa=D&amp;ust=1585016771131000">https://www.acc.org/latest-in-cardiology/articles/2020/03/12/17/02/cardiologists-insights-from-treating-covid-19-patients-in-china</a></span><span class="c10 c0">&nbsp;</span></li><li class="c9 c26"><span class="c10 c0">Arabi YM, Mandourah Y, Al-hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. </span><span class="c10 c0 c22">Am J Respir Crit Care Med</span><span class="c10 c0">. 2018;197(6):757-767. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1164/rccm.201706-1172OC&amp;sa=D&amp;ust=1585016771132000">10.1164/rccm.201706-1172OC</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29161116&amp;sa=D&amp;ust=1585016771132000">29161116</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Mar 17, 2020. </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.acc.org/sitecore/content/Sites/ACC/Home/Latest-in-Cardiology/Articles/2020/03/17/08/59/HFSA-ACC-AHA-Statement-Addresses-Concerns-Re-Using-RAAS-Antagonists-in-COVID-19&amp;sa=D&amp;ust=1585016771133000">https://www.acc.org/sitecore/content/Sites/ACC/Home/Latest-in-Cardiology/Articles/2020/03/17/08/59/HFSA-ACC-AHA-Statement-Addresses-Concerns-Re-Using-RAAS-Antagonists-in-COVID-19</a></span><span class="c23 c10 c0">&nbsp;</span></li><li class="c9 c26"><span class="c10 c0">Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. </span><span class="c10 c0 c22">Blood Rev</span><span class="c10 c0">. 2019;34:45-55. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/j.blre.2018.11.002&amp;sa=D&amp;ust=1585016771133000">10.1016/j.blre.2018.11.002</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30528964&amp;sa=D&amp;ust=1585016771134000">30528964</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Tsch&ouml;pe C, Cooper LT, Torre-amione G, Van linthout S. Management of Myocarditis-Related Cardiomyopathy in Adults. </span><span class="c10 c0 c22">Circ Res</span><span class="c10 c0">. 2019;124(11):1568-1583.</span><span class="c10 c0">&nbsp;DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://doi.org/10.1161/CIRCRESAHA.118.313578&amp;sa=D&amp;ust=1585016771135000">10.1161/CIRCRESAHA.118.313578</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/31120823&amp;sa=D&amp;ust=1585016771135000">31120823</a></span><span class="c10 c0">.</span><sup><a href="#cmnt40" id="cmnt_ref40">[an]</a></sup></li><li class="c9 c26"><span class="c10 c0">Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. </span><span class="c10 c0 c22">Lancet</span><span class="c10 c0">. 2020;395(10223):507-513. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/S0140-6736(20)30211-7&amp;sa=D&amp;ust=1585016771136000">10.1016/S0140-6736(20)30211-7</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32007143&amp;sa=D&amp;ust=1585016771136000">32007143</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Cheng Y, Luo R, Wang K, et al. Kidney Impairment Is Associated with In-Hospital Death of COVID-19 Patients. </span><span class="c10 c0 c22">medRxiv</span><span class="c10 c0">. 2020. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.18.20023242&amp;sa=D&amp;ust=1585016771137000">10.1101/2020.02.18.20023242</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. </span><span class="c10 c0 c22">Kidney Int</span><span class="c10 c0">. 2005;67(2):698-705. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1111/j.1523-1755.2005.67130.x&amp;sa=D&amp;ust=1585016771137000">10.1111/j.1523-1755.2005.67130.x</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15673319&amp;sa=D&amp;ust=1585016771138000">15673319</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Day, M. COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. </span><span class="c10 c0 c22">BMJ</span><span class="c10 c0">. 2020;368:m1086. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1136/bmj.m1086&amp;sa=D&amp;ust=1585016771138000">10.1136/bmj.m1086</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32184201&amp;sa=D&amp;ust=1585016771139000">32184201</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. </span><span class="c10 c0 c22">Crit Care</span><span class="c10 c0">. 2016;20:75. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/%252010.1186/s13054-016-1230-8&amp;sa=D&amp;ust=1585016771139000">10.1186/s13054-016-1230-8</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27036638&amp;sa=D&amp;ust=1585016771140000">27036638</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. </span><span class="c10 c0 c22">Am J Respir Crit Care Med.</span><span class="c10 c0">&nbsp;2017;195(3):331-338. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1164/rccm.201603-0645OC&amp;sa=D&amp;ust=1585016771140000">10.1164/rccm.201603-0645OC</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27513822&amp;sa=D&amp;ust=1585016771141000">27513822</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Fan C, Li K, Ding Y, Lu WL, Wang J. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-NCoV Infection. </span><span class="c10 c0 c22">medRxiv</span><span class="c10 c0">. 2020. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1101/2020.02.12.20022418&amp;sa=D&amp;ust=1585016771141000">10.1101/2020.02.12.20022418</a></span><span class="c23 c10 c0">. </span></li><li class="c9 c26"><span class="c10 c0">Fang, L, Karakiulakis G, Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? </span><span class="c10 c0 c22">Lancet Respir Med</span><span class="c10 c0">. 2020. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/S2213-2600(20)30116-8&amp;sa=D&amp;ust=1585016771141000">10.1016/S2213-2600(20)30116-8</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32171062&amp;sa=D&amp;ust=1585016771142000">32171062</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Fuller et al. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. </span><span class="c10 c0 c22">Chest</span><span class="c10 c0">. 2015; 147(6): 1510-1522. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://dx.doi.org/10.1378/chest.14-3161&amp;sa=D&amp;ust=1585016771142000">10.1378/chest.14-3161</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? </span><span class="c10 c0 c22">Crit Care Med</span><span class="c10 c0">. 2006;34(5 Suppl):S170-3. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1097/01.CCM.0000214288.88308.26&amp;sa=D&amp;ust=1585016771142000">10.1097/01.CCM.0000214288.88308.26</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25742022&amp;sa=D&amp;ust=1585016771143000">25742022</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. </span><span class="c10 c0 c22">Biosci Trends</span><span class="c10 c0">. 2020. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.5582/bst.2020.01047&amp;sa=D&amp;ust=1585016771143000">10.5582/bst.2020.01047</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32074550&amp;sa=D&amp;ust=1585016771143000">32074550</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. </span><span class="c10 c0 c22">Cochrane Database Syst Rev</span><span class="c10 c0">. 2016;(6):CD002787. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1002/14651858.CD002787.pub3&amp;sa=D&amp;ust=1585016771144000">10.1002/14651858.CD002787.pub3</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27347773&amp;sa=D&amp;ust=1585016771144000">27347773</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. </span><span class="c10 c0 c22">Crit Care Med</span><span class="c10 c0">. 2015;43(2):288-95. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1097/CCM.0000000000000715&amp;sa=D&amp;ust=1585016771144000">10.1097/CCM.0000000000000715</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25599463&amp;sa=D&amp;ust=1585016771145000">25599463</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. </span><span class="c10 c0 c22">N Engl J Med</span><span class="c10 c0">. 2020. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa2002032&amp;sa=D&amp;ust=1585016771145000">10.1056/NEJMoa2002032</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32109013&amp;sa=D&amp;ust=1585016771146000">32109013</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Gu&eacute;rin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. </span><span class="c10 c0 c22">N Engl J Med</span><span class="c10 c0">. 2013;368(23):2159-68. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa1214103&amp;sa=D&amp;ust=1585016771146000">10.1056/NEJMoa1214103</a></span><span class="c0 c10">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23688302&amp;sa=D&amp;ust=1585016771147000">23688302</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">H&eacute;bert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. </span><span class="c10 c0 c22">N Engl J Med</span><span class="c10 c0">. 1999;340(6):409-17. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJM199902113400601&amp;sa=D&amp;ust=1585016771147000">10.1056/NEJM199902113400601</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/9971864&amp;sa=D&amp;ust=1585016771148000">9971864</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock.</span><span class="c10 c0 c22">&nbsp;N Engl J Med</span><span class="c10 c0">. 2014;371(15):1381-91. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1056/NEJMoa1406617&amp;sa=D&amp;ust=1585016771148000">10.1056/NEJMoa1406617</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/25270275&amp;sa=D&amp;ust=1585016771149000">25270275</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. </span><span class="c10 c0 c22">Eur Heart J</span><span class="c10 c0">. 2020. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1093/eurheartj/ehaa190&amp;sa=D&amp;ust=1585016771149000">10.1093/eurheartj/ehaa190</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32176300&amp;sa=D&amp;ust=1585016771150000">32176300</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy CPAP different masks. </span><span class="c10 c0 c22">Eur Respir J</span><span class="c10 c0">. 2019;53(4). DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1183/13993003.02339-2018&amp;sa=D&amp;ust=1585016771150000">10.1183/13993003.02339-2018</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30705129&amp;sa=D&amp;ust=1585016771151000">30705129</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Kallet RH, Matthay MA. Hyperoxic acute lung injury. </span><span class="c10 c0 c22">Respir Care</span><span class="c10 c0">. 2013;58(1):123-41. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.4187/respcare.01963&amp;sa=D&amp;ust=1585016771151000">10.4187/respcare.01963</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/23271823&amp;sa=D&amp;ust=1585016771152000">23271823</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Kim ES, Choe PG, Park WB, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. </span><span class="c10 c0 c22">J Korean Med Sci</span><span class="c10 c0">. 2016;31(11):1717-1725. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.3346/jkms.2016.31.11.1717&amp;sa=D&amp;ust=1585016771152000">10.3346/jkms.2016.31.11.1717</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27709848&amp;sa=D&amp;ust=1585016771153000">27709848</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Lee N, Allen chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. </span><span class="c10 c0 c22">J Clin Virol</span><span class="c10 c0">. 2004;31(4):304-9. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/j.jcv.2004.07.006&amp;sa=D&amp;ust=1585016771153000">10.1016/j.jcv.2004.07.006</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016771154000">15494274</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Levi M, Scully M. How I treat disseminated intravascular coagulation. </span><span class="c10 c0 c22">Blood</span><span class="c10 c0">. 2018;131(8):845-854. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/29255070&amp;sa=D&amp;ust=1585016771154000">10.1182/blood-2017-10-804096</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/29255070&amp;sa=D&amp;ust=1585016771155000">29255070</a></span><span class="c10">.</span></li><li class="c9 c26"><span class="c10 c0">Lippi G and Plebani M. Procalcitonin in patients with severe coronavirus disease 2019: A meta-analysis. </span><span class="c10 c0 c22">Clin Chim Acta</span><span class="c10 c0">. 2020;505:190-191. DOI: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016771155000">10.1016/j.cca.2020.03.004</a></span><span class="c10">. PMID: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32145275&amp;sa=D&amp;ust=1585016771155000">32145275</a></span><span class="c10">.</span></li><li class="c9 c26"><span class="c10 c0">Liu X, Li Z, Liu S, Chen Z, Zhao Z, Huang Y, Zhang Q, Wang J, Shi Y, Xu Y, Sun J, Xian H, Fang R, Fan Bai F, Changxing Ou, Bei Xiong, Andrew M Lew, Jun Cui, Hui Huang, Jincun Zhao, Xuechuan Hong, &nbsp;H-BL. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. </span><span class="c10 c0 c22">medRxiv</span><span class="c10 c0">. 2020. </span><span class="c10 c0 c87">DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1&amp;sa=D&amp;ust=1585016771156000">10.1101/2020.02.27.20027557</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Luo, W., Yu, H., Gou, J., et al. Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19). </span><span class="c10 c0 c22">Preprints</span><span class="c10 c0">. 2020. </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.preprints.org/manuscript/202002.0407/v1&amp;sa=D&amp;ust=1585016771157000">2020020407</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">MacIntyre CR, Chughtai AA, Barnes M et al (2018) The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09.</span><span class="c10">&nbsp;</span><span class="c10 c22">BMC Infect Dis</span><span class="c10">.</span><span class="c10">&nbsp;2018 Dec 7;18(1):637. DOI: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/30526505&amp;sa=D&amp;ust=1585016771158000">10.1186/s12879-018-3548-0</a></span><span class="c10">. PMID: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30526505&amp;sa=D&amp;ust=1585016771158000">30526505</a></span><span class="c10">.</span></li><li class="c9 c26"><span class="c10 c0">Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. </span><span class="c10 c0 c22">Lancet</span><span class="c10 c0">. 2020;0(0). DOI:</span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32192578&amp;sa=D&amp;ust=1585016771159000">10.1016/S0140-6736(20)30628-0</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32192578&amp;sa=D&amp;ust=1585016771159000">32192578</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10">Nates JL</span><span class="c10">, </span><span class="c10">Nunnally M</span><span class="c10">, </span><span class="c10">Kleinpell R</span><span class="c10">, </span><span class="c10">Blosser S</span><span class="c10">, </span><span class="c10">Goldner J</span><span class="c10">, </span><span class="c10">Birriel B</span><span class="c10">, </span><span class="c10">Fowler CS</span><span class="c10">, </span><span class="c10">Byrum D</span><span class="c10">, </span><span class="c10">Miles WS</span><span class="c10">, </span><span class="c10">Bailey H</span><span class="c10">, </span><span class="c10">Sprung CL</span><span class="c10">. ICU Admission, Discharge, and Triage Guidelines: A Framework to Enhance Clinical Operations, Development of Institutional Policies, and Further Research. </span><span class="c10 c22">Crit Care Med.</span><span class="c10">&nbsp;2016 Aug;44(8):1553-602. DOI: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/27428118&amp;sa=D&amp;ust=1585016771161000">10.1097/CCM.0000000000001856</a></span><span class="c10">. PMID: </span><span class="c16 c10"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27428118&amp;sa=D&amp;ust=1585016771161000">27428118</a></span><span class="c10">.</span></li><li class="c9 c26"><span class="c10 c0">Penn Medicine Treatment Guidelines for SARS-CoV-2 Infection. Mar 14 2020. Accessed Mar 18 2020. </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.uphs.upenn.edu/antibiotics/COVID19.html&amp;sa=D&amp;ust=1585016771162000">http://www.uphs.upenn.edu/antibiotics/COVID19.html</a></span><span class="c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Ruan et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. </span><span class="c10 c0 c22">Intensive Care Med</span><span class="c10 c0">. 2020 Mar 3. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771163000">10.1007/s00134-020-05991-x</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32125452&amp;sa=D&amp;ust=1585016771163000">32125452</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Rubin DB, Danish HH, Ali AB, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. </span><span class="c10 c0 c22">Brain</span><span class="c10 c0">. 2019;142(5):1334-1348. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016771164000">10.1093/brain/awz053</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/30891590&amp;sa=D&amp;ust=1585016771164000">30891590</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Shahpori R, Stelfox HT, Doig CJ, Boiteau PJ, Zygun DA. Sequential Organ Failure Assessment in H1N1 pandemic planning. </span><span class="c10 c0 c22">Crit Care Med</span><span class="c10 c0">. 2011 Apr;39(4):827-32. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/pubmed/21263327&amp;sa=D&amp;ust=1585016771165000">10.1097/CCM.0b013e318206d548</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/21263327&amp;sa=D&amp;ust=1585016771165000">21263327</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. </span><span class="c10 c0 c22">Intensive Care Med</span><span class="c10 c0">. 2017;43(2):155-170. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1007/s00134-016-4573-3&amp;sa=D&amp;ust=1585016771166000">10.1007/s00134-016-4573-3</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/27734109&amp;sa=D&amp;ust=1585016771166000">27734109</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. </span><span class="c10 c0 c22">PLoS Med.</span><span class="c10 c0">&nbsp;2006;3:e343. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1371/journal.pmed.0030343&amp;sa=D&amp;ust=1585016771167000">10.1371/journal.pmed.0030343</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/16968120&amp;sa=D&amp;ust=1585016771167000">16968120</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. </span><span class="c10 c0 c22">JAMA</span><span class="c10 c0">. 1989;261(6):884-8. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1001/jama.1989.03420060100040&amp;sa=D&amp;ust=1585016771168000">10.1001/jama.1989.03420060100040</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/2913385&amp;sa=D&amp;ust=1585016771168000">2913385</a></span><span class="c10 c0">. </span></li><li class="c9 c26"><span class="c10 c0">Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. </span><span class="c10 c0 c22">J Thromb Haemost</span><span class="c10 c0">. 2020 Feb. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1111/jth.14768&amp;sa=D&amp;ust=1585016771169000">10.1111/jth.14768</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32073213&amp;sa=D&amp;ust=1585016771169000">32073213</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. </span><span class="c10 c0 c22">PLoS One.</span><span class="c10 c0">&nbsp;2012;7(4). DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1371/journal.pone.0035797&amp;sa=D&amp;ust=1585016771170000">10.1371/journal.pone.0035797</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/22563403&amp;sa=D&amp;ust=1585016771170000">22563403</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus&ndash;Infected Pneumonia in Wuhan, China. </span><span class="c10 c0 c22">JAMA</span><span class="c10 c0">. 2020 Feb. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1001/jama.2020.1585&amp;sa=D&amp;ust=1585016771171000">10.1001/jama.2020.1585</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32031570&amp;sa=D&amp;ust=1585016771171000">32031570</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. </span><span class="c10 c0 c22">J Clin Virol</span><span class="c10 c0">. 2004;31(4):304-9. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1016/j.jcv.2004.07.006&amp;sa=D&amp;ust=1585016771172000">10.1016/j.jcv.2004.07.006</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15494274&amp;sa=D&amp;ust=1585016771172000">15494274</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://dx.doi.org/10.1111/j.1365-2249.2004.02415.x&amp;sa=D&amp;ust=1585016771173000">10.1111/j.1365-2249.2004.02415.x</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/15030519&amp;sa=D&amp;ust=1585016771173000">15030519</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c10 c0">World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. WHO. 2020;(January):12. </span><sup><a href="#cmnt41" id="cmnt_ref41">[ao]</a></sup></li><li class="c9 c26"><span class="c10 c0">Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. </span><span class="c10 c0 c22">JAMA Intern Med</span><span class="c10 c0">. 2020 Mar. DOI: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://doi.org/10.1001/jamainternmed.2020.0994&amp;sa=D&amp;ust=1585016771174000">10.1001/jamainternmed.2020.0994</a></span><span class="c10 c0">. PMID: </span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=http://www.ncbi.nlm.nih.gov/pubmed/32167524&amp;sa=D&amp;ust=1585016771174000">32167524</a></span><span class="c23 c10 c0">.</span></li><li class="c9 c26"><span class="c23 c10 c0">Xianghong Y, Renhua S, Dechang C. Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored. Natl Med J China. 2020;100(00):E017-E017. doi:10.3760/cma.j.cn112137-20200229-00520</span></li><li class="c9 c26"><span class="c23 c10 c0">Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiol Cardiothorac Imaging. 2020;2(2).</span></li><li class="c9 c26"><span class="c10 c0">Yang et al. COVID-19 control in China during mass population movements at New Year.</span><span class="c10">&nbsp;Lancet, Feb 2020; </span><span class="c10"><a class="c15" href="https://www.google.com/url?q=https://doi.org/10.1016/S0140-6736(20)30421-9&amp;sa=D&amp;ust=1585016771175000">https://doi.org/10.1016/S0140-6736(20)30421-9</a></span></li><li class="c9 c26"><span class="c23 c10 c0">Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;0(0). doi:10.1016/S2213-2600(20)30079-5</span></li><li class="c9 c26"><span class="c23 c10 c0">Yao et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, March 2020</span></li><li class="c9 c26"><span class="c23 c10 c0">Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA, March 2020; doi:10.1001/jama.2020.3204</span></li><li class="c9 c26"><span class="c10 c0 c23">Zeng, et al. First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights. Preprints 2020; doi: 10.20944/preprints202003.0180.v1</span></li><li class="c9 c26"><span class="c23 c10 c0">Zeng, J., Huang, J. &amp; Pan, L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People&rsquo;s Hospital. Intensive Care Med, 2020; https://doi.org/10.1007/s00134-020-05993-9</span></li><li class="c9 c26"><span class="c23 c10 c0">Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, March 2020; doi:10.1016/S2468-1253(20)30057-1</span></li><li class="c9 c26"><span class="c23 c10 c0">Zheng, Y et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 2020; doi.org/10.1038/s41569-020-0360-5</span></li><li class="c9 c26"><span class="c23 c10 c0">Zhonghua et al. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. CMAPH, Feb 2020;43(0):E019. doi: 10.3760/cma.j.issn.1001-0939.2020.0019.</span></li><li class="c9 c26"><span class="c23 c10 c0">Zhonghua Xin Xue Guan Bing Za Zhi. &nbsp;Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]. March 2020;48(0):E008. doi: 10.3760/cma.j.cn112148-20200225-00123. &nbsp;</span></li><li class="c9 c26"><span class="c23 c10 c0">Zhou F, et al. Lancet 2020; DOI:https://doi.org/10.1016/S0140-6736(20)30566-3. Hamming I, et al. J Pathol 2004; 203(2): 631-7.</span></li><li class="c9 c26"><span class="c23 c10 c0">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. March 2020. doi:10.1016/S0140-6736(20)30566-3</span></li><li class="c9 c26"><span class="c23 c10 c0">Zhou &nbsp;P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7</span></li><li class="c9 c26"><span class="c10 c0">Zuo M-Z, Huang Y-G, Ma W-H, et al. Expert Recommendations for Tracheal Intubation in Critically ill Patients with Novel Coronavirus Disease 2019. Chin Med Sci J. February 2020.</span><span class="c10 c0">&nbsp;</span><span class="c16 c10 c0"><a class="c15" href="https://www.google.com/url?q=https://doi.org/10.24920/003724&amp;sa=D&amp;ust=1585016771178000">doi:10.24920/003724</a></span></li></ol><p class="c9 c27 c56"><span class="c85 c96 c66 c80 c97"></span></p><hr style="page-break-before:always;display:none;"><h1 class="c44 c79" id="h.t36cynad724o"><span class="c23 c49"></span></h1><h1 class="c44" id="h.9um4ryva0zlb"><span class="c23 c49">ADDENDUM: COVID ICU Bundle Checklist &nbsp;</span></h1><p class="c0 c9"><span>Rationale: Use of a daily checklist ensures that routine quality measures are in place for each patient. &nbsp;Review Bundle Checklist at the end of each patient&rsquo;s presentation, every day. &nbsp;</span><span class="c42">Each section should be performed unless there is a contraindication or barrier to implementation</span><span class="c8">. If a contraindication is present, discuss how barriers may be overcome. </span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span class="c33">Ventilator</span><span class="c8">&nbsp;</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Spontaneous Awakening Trial (SAT)</span></p><p class="c9 c0"><span class="c8">= turn off sedation </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Spontaneous Breathing Trial (SBT)</span></p><p class="c9 c0"><span class="c8">= Place patient on Pressure Support 5/5</span></p><p class="c9 c0"><span class="c8">- Perform SAT &amp; SBT concurrently if able</span></p><p class="c9 c0"><span class="c8">- Contraindications to SAT/SBT include FiO2 &gt; 50%, PEEP &gt; 8, O2 sat &lt; 90%, pH &lt; 7.30, SBP &lt; 90 or MAP &lt; 60, paralysis, intracranial pressure &gt;15, concern for significant bleeding</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; If ARDS: goal Vt 4-6 cc/kg of ideal body weight (calculated by height), plateau pressure &lt; 30</span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Head of bed at &gt;30 degrees </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Oral care is ordered </span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c17">Sedation / Delirium</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Ask: Is patient delirious (CAM+)? </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Review med list for any deliriogenic medications and discontinue/change where possible</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Define RASS goal</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Record QTc daily, consider changing medications if QTc &gt; 500 </span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c17">Restraints</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Ask: Are restraints needed? </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Sign necessary restraint orders</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Discuss barriers to removing restraint orders </span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c33">Mobility</span><span class="c8">&nbsp;</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Consult PT for early mobility</span></p><p class="c9 c0"><span class="c8">- Contraindications include: deep sedation, paralysis</span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span class="c17">Pressure Ulcers</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Ask: Are pressure ulcers present? Is a wound care consult needed? </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Discuss whether any changes are needed to ulcer management plan</span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c17">DVT prophylaxis</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Review patient&rsquo;s current DVT prophylaxis orders and adjust if needed </span></p><p class="c9 c0"><span class="c8">- Contraindications to LMWH DVT ppx include AKI (switch to UFH TID), clinically significant bleeding (hold pharmacologic), platelet count &lt; 30K (hold pharmacologic)</span></p><p class="c9 c0"><span class="c8">- Add sequential compression boots if holding pharmacologic prophylaxis</span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c17">GI / Nutrition </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Famotidine 20mg IV BID in intubated patients; Pantoprazole 20-40mg IV daily if history of GERD or GI bleed</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Review nutrition, consult nutrition if not already done. &nbsp;While awaiting nutrition input, start enteral nutrition: </span></p><p class="c9 c0"><span class="c8">- In most patients, Osmolite 1.5 @10mL/hr, advance by 20mL Q6h to goal 50mL/hr</span></p><p class="c9 c0"><span class="c8">- If renal failure and high K or phos: Nepro @ 10mL/hr, advance by 10mL Q6h to goal 40mL/hr</span></p><p class="c9 c0"><span class="c8">- MVI with minerals daily </span></p><p class="c9 c0"><span class="c8">- thiamine 100mg daily x3 days</span></p><p class="c9 c0"><span class="c8">- folate 1mg daily x 3 days</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Ask: Is bowel regimen adequate? Make changes if necessary. </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Review glucose range over past 48h and insulin regimen, adjust regimen if needed. </span></p><p class="c9 c0"><span class="c8">- Goal glucose range is 70-180</span></p><p class="c9 c0 c27"><span class="c75 c66 c80 c85"></span></p><p class="c9 c0"><span class="c17">Tubes / Lines / Drains</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; List all tubes / lines / drains and discuss if any can be removed or should be changed</span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c17">Patient / Family Communication </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Discuss if patient has healthcare making capacity - if not, activate healthcare proxy </span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Update families by phone </span></p><p class="c9 c0"><span class="c8">- Suggest RN update at least daily </span></p><p class="c9 c0"><span class="c8">- MD update Q3 days, with any significant clinical change, or per family request</span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c33">Disposition</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Discuss anticipated dispo, barriers to dispo</span></p><p class="c9 c0 c27"><span class="c17"></span></p><p class="c9 c0"><span class="c17">Code Status</span></p><p class="c9 c0"><span class="c8">&#x1f5c6; Review current code status, discuss if goals of care are realistic with prognosis - if not, discuss with patient / family</span></p><p class="c9 c0 c27"><span class="c8"></span></p><p class="c9 c0"><span class="c8">Abbreviations: </span></p><p class="c9 c0"><span class="c8">SAT = Spontaneous Awakening Trial </span></p><p class="c9 c0"><span class="c8">SBT = Spontaneous Breathing Trial </span></p><p class="c9 c0"><span class="c8">CAM = Confusion Assessment Method</span></p><p class="c9 c0"><span class="c8">RASS = Richmond Agitation and Sedation Scale</span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><p class="c1 c20"><span class="c8"></span></p><div><p class="c50 c27"><span class="c8"></span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref1" id="cmnt1">[a]</a><span class="c8">Having trouble finding this exact quote in the resource cited</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref2" id="cmnt2">[b]</a><span class="c8">add ref to bibliography J Crit Care. 2012 Oct;27(5):434-9.</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref3" id="cmnt3">[c]</a><span class="c8">Am J Respir Crit Care Med. 2012;185:1307&ndash;1315.</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref4" id="cmnt4">[d]</a><span class="c8">insert ref into bibliograph N Engl J Med. 2020 Mar 12;382(11):999-1008.</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref5" id="cmnt5">[e]</a><span class="c8">Link ECMO guidelines when available</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref6" id="cmnt6">[f]</a><span class="c8">Also may want to link http://handbook.partners.org/content/pdf/BWHCovid19Treatment.pdf in the document just not sure where the best place would be</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref7" id="cmnt7">[g]</a><span class="c8">need becky and kevin to decide</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref8" id="cmnt8">[h]</a><span class="c8">my comment to Becky was &quot;No strong objections to the use of Dornase in COVID. I had just mentioned in the document that the data for dornase for management of secretions in non-CF patients is very poor. The other factors I was considering were drug cost ($450 a dose) as well as drug availability, neither of which would be a consideration in a trial setting. </span></p><p class="c1 c27"><span class="c8"></span></p><p class="c1"><span class="c8">I know there have been some reports of its benefit in COVID, but obviously that is limited in number so not sure if would make first line therapy. </span></p><p class="c1 c27"><span class="c8"></span></p><p class="c1"><span class="c8">But if the PETAL group is interested in doing a study on dornase, I am definitely in support of that&quot;</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref9" id="cmnt9">[i]</a><span class="c8">Do we have a link for this?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref10" id="cmnt10">[j]</a><span class="c8">May need to be added to References section</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref11" id="cmnt11">[k]</a><span class="c8">There are no trials currently onging (that I am aware of not sure if PETAL network is) involving Toci at BWH. Would change to &quot;to be used in conjunction with infectious disease consultation in severe COVID-19 disease and suspicision of CRS&quot;</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref12" id="cmnt12">[l]</a><span class="c8">Can someone confirm that this is the right reference here? (Changed from &quot;Savarino et al, J AIDS, 1996&quot; which I was unable to find)</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref13" id="cmnt13">[m]</a><span class="c8">(also probably needs to be added to References section)</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref14" id="cmnt14">[n]</a><span class="c8">Can someone confirm that this is the right reference here? (Changed from &quot;Savarino et al, J AIDS, 1996&quot; which I was unable to find)</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref15" id="cmnt15">[o]</a><span class="c8">(also probably needs to be added to References section)</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref16" id="cmnt16">[p]</a><span class="c8">per the treatment guidelines this also may be used in patients not requiring supplemental oxygen but have a risk factor for progression to severe disease . Would consider adding &quot;or in those not on supplemental oxygen but at risk for progression to severe disease&quot;</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref17" id="cmnt17">[q]</a><span class="c8">Chloroquine on longterm manufacturer backorder</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref18" id="cmnt18">[r]</a><span class="c8">all new</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref19" id="cmnt19">[s]</a><span class="c8">lots of changes here</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref20" id="cmnt20">[t]</a><span class="c8">Would like to include a clip of the timecourse here... trop rise starts late? or thats when the problems manifest?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref21" id="cmnt21">[u]</a><span class="c8">Paper doesn&#39;t mention specifically if that&#39;s when the problems start, but it does say that in 23/50 (46%) non survivors had trop rises &gt;28 and whereas only 1/95 (1%) survivors had such a trop rise.</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref22" id="cmnt22">[v]</a><span class="c8">Hi guys, glad to join!</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref23" id="cmnt23">[w]</a><span class="c8">If you look at the Zhou paper from the Lancet there is a beautiful figure showing the timeline of events. It&#39;s Figure 2 - and if we have space might be nice to include.</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref24" id="cmnt24">[x]</a><span class="c8">Here are the data by virus, but thought this was less important: Incidence ratios within 7 days of detection by virus: influenza B: 10.11(95% CI, 4.37-23.38); influenza A 5.17 (95% CI, 3.02 to 8.84), RSV 3.51 (95% CI, 1.11 to 11.12), and other viruses 2.77 (95% CI, 1.23 to 6.24).</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref25" id="cmnt25">[y]</a><span class="c8">Not sure this is what you meant but in case you want to keep it, here is the citation.</span></p><p class="c1 c27"><span class="c8"></span></p><p class="c1"><span class="c8">Kwong J, Schwartz K, Campitelli M, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018;378:345-53. DOI: 10.1056/NEJMoa1702090</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref26" id="cmnt26">[z]</a><span class="c8">New addition with citation</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref27" id="cmnt27">[aa]</a><span class="c8">Also did a little reformatting</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref28" id="cmnt28">[ab]</a><span class="c8">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref29" id="cmnt29">[ac]</a><span class="c8">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref30" id="cmnt30">[ad]</a><span class="c8">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref31" id="cmnt31">[ae]</a><span class="c8">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref32" id="cmnt32">[af]</a><span class="c8">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref33" id="cmnt33">[ag]</a><span class="c8">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref34" id="cmnt34">[ah]</a><span class="c8">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref35" id="cmnt35">[ai]</a><span class="c8">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref36" id="cmnt36">[aj]</a><span class="c8">Matt: can clarify threshold to hold AC? should know this but i dont</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref37" id="cmnt37">[ak]</a><span class="c8">No well-defined threshold from what I understand. &nbsp;Usually we hold for active bleeding or if requiring substantial blood products - kind of a gray area/clinical decision. &nbsp;At least that is my usual ICU practice. &nbsp;you?</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref38" id="cmnt38">[al]</a><span class="c8">Mike is doing this section</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref39" id="cmnt39">[am]</a><span class="c8">Will is adding generic language here, not BWH specific</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref40" id="cmnt40">[an]</a><span class="c8">Out of alphabetical order</span></p></div><div class="c25"><p class="c1"><a href="#cmnt_ref41" id="cmnt41">[ao]</a><span class="c8">Update to march one</span></p></div></body></html>